

12



Europäisches Patentamt
European Patent Office
Office européen des brevets



Publication number: **0 269 859 B2**

(12)

NEW EUROPEAN PATENT SPECIFICATION

- (43) Date of publication of the new patent specification: **18.10.95**
- (51) Int. Cl.⁸: **C07D 487/04, A61K 31/53, //(C07D487/04,251:00,231:00)**
- (21) Application number: **87115806.9**
- (22) Date of filing: **28.10.87**

(54) **Pyrazolotriazine compounds.**

- (30) Priority: **31.10.86 JP 261008/86**
26.03.87 JP 73911/87
18.05.87 JP 120688/87
25.06.87 JP 159437/87
- (43) Date of publication of application: **08.06.88 Bulletin 88/23**
- (45) Publication of the grant of the patent: **06.10.93 Bulletin 93/40**
- (45) Mention of the opposition decision: **18.10.95 Bulletin 95/42**
- (84) Designated Contracting States: **CH DE ES FR GB IT LI NL SE**
- (66) References cited:
US-A- 3 865 824
US-A- 3 910 907
US-A- 3 995 039
- J. HET. CHEM., 22, 1985, pp. 601-634**
- (73) Proprietor: **OTSUKA PHARMACEUTICAL CO., LTD.**
9, Kandatsukasa-ch 2-chome
Chiyoda-ku
T kyo 101 (JP)

- (72) Inventor: **Fujii, Setsuro 703, Alg de Blanche**
Ebiya-cho, Gokomachi-dori
Sanji-sagaru Nakagyo-ku
Kyoto-shi
Kyoto-fu (JP)
Inventor: **Kawamura, Hiroyuki**
No. 7-23, Chuo 4-chome
Otsu-shi
Shiga-ken (JP)
Inventor: **Kiyokawa, Hiroshi**
No. 227-6, Sugahara-cho
Nara-shi
Nara-ken (JP)
Inventor: **Yamada, Satoshi**
No. 6-12, Imakatata 2-chome
Otsu-shi
Shiga-ken (JP)
- (74) Representative: **von Kreisler, Alek,**
Dipl.-Chem. et al
Patentanwälte
von Kreisler-Selting-Werner
Postfach 10 22 41
D-50462 Köln (DE)

EP 0 269 859 B2

Description


This invention relates to novel pyrazolotriazine compounds.

It is known to us allopurinol, i.e. 4-hydroxy-pyrazolo[3,4-d]pyrimidine as a xanthine oxidase inhibitor.

The object of the present invention is to provide a new class of compounds having xanthine oxidase inhibiting activity.

This object has been solved by the novel pyrazolotriazine compounds mentioned below.

Thus, provided is a pyrazolotriazine compound of the formula:




wherein


R¹ is hydroxy or an C₁₋₆ alkanoyloxy,

R² is hydrogen atom,


R³ is (1) an unsaturated heterocyclic group selected from pyrrolyl, pyridyl, thienyl, thiopyranyl, indolyl, benzothienyl, 2,3-dihydrobenzothienyl, thiochromanyl, dibenzothienyl, which may optionally have one or two substituents selected from a halogen atom, nitro, and phenylthio, (2) naphthyl, and (3) a phenyl which may optionally have one to three substituents selected from the group consisting of (i) an C₁₋₆ alkyl, (ii) phenyl, (iii) an C₁₋₆ alkoxy, (iv) cyano, (v) nitro, (vi) an C₁₋₆ alkoxy, (vii) a phenyl-C₁₋₆ alkoxy, (viii) a phenylthio-C₁₋₆ alkyl, (ix) phenoxy, (x) a group of the formula:



wherein R is an C₁₋₆ alkyl, a halogen-substituted C₁₋₆ alkyl, a phenyl which may optionally have one to three substituents selected from a halogen atom, an C₁₋₆ alkyl and an C₁₋₆ alkoxy, or pyridyl, and t is an integer of 0, 1 or 2, (xi) a halogen atom, (xii) a phenyl-C₁₋₆ alkyl, (xiii) carboxy, (xiv) an C₁₋₆ alkanoyl, (xv) a benzoyl which may optionally have one to three substituents selected from a halogen atom, a phenyl-C₁₋₆ alkoxy and hydroxy on the phenyl ring, (xvi) amino, (xvii) hydroxy, (xviii) an C₁₋₆ alkanoyloxy, (xix) a group of the formula:




wherein R⁴ and R⁵ are the same or different and are each hydrogen atom, a C₃₋₈ cycloalkyl, an C₁₋₆ alkyl which may optionally have a substituent selected from hydroxy, furyl, thienyl, tetrahydrofuranyl and phenyl, a phenyl which may optionally have one to three substituents selected from an C₁₋₆ alkyl, a hydroxy-substituted C₁₋₆ alkyl, an C₁₋₆ alkanoyl, cyano, carboxy, an C₁₋₆ alkoxy, an C₁₋₆ alkoxy, and a halogen atom, or a heterocyclic group selected from pyridyl, pyrimidinyl, thiazolyl, isoxazolyl, and pyrazolyl, said heterocyclic group being optionally substituted by an C₁₋₆ alkyl, amino, or an C₁₋₆ alkanoyl-amino, or R⁴ and R⁵ may join together with the adjacent nitrogen atom to form a saturated 5- or 6-membered heterocyclic group which may optionally be intervened with oxygen atom, or (xx) a group of the formula:



wherein A is an C₁₋₆ alkylene.

Further provided are a process for preparing a pyrazolotriazine compound of the formula (1):




wherein


R¹ is hydroxy or an C₁₋₆ alkanoyloxy,

R² is hydrogen atom,

R³ is (1) an unsaturated heterocyclic group selected from pyrrolyl, pyridyl, thienyl, thiopyranyl, indolyl, benzothienyl, 2,3-dihydrobenzothienyl, thiochromanyl, dibenzothienyl, which may optionally have one or two substituents selected from a halogen atom, nitro, and phenylthio, (2) naphthyl, and (3) a phenyl which may optionally have one to three substituents selected from the group consisting of (i) an C₁₋₆ alkyl, (ii) phenyl, (iii) an C₁₋₆ alkoxy, (iv) cyano, (v) nitro, (vi) an C₁₋₆ alkoxy, (vii) a phenyl-C₁₋₆ alkoxy, (viii) a phenylthio-C₁₋₆ alkyl, (ix) phenoxy, (x) a group of the formula:




wherein R is an C₁₋₆ alkyl, a halogen-substituted C₁₋₆ alkyl, a phenyl which may optionally have one to three substituents selected from a halogen atom, an C₁₋₆ alkyl and an C₁₋₆ alkoxy, or pyridyl, and t is an integer of 0, 1 or 2, (xi) a halogen atom, (xii) a phenyl-C₁₋₆ alkyl, (xiii) carboxy, (xiv) an C₁₋₆ alkanoyl, (xv) a benzoyl which may optionally have one to three substituents selected from a halogen atom, a phenyl-C₁₋₆ alkoxy and hydroxy on the phenyl ring, (xvi) amino, (xvii) hydroxy, (xviii) an C₁₋₆ alkanoyloxy, (xix) a group of the formula:




wherein R⁴ and R⁵ are the same or different and are each hydrogen atom, a C₃₋₈ cycloalkyl, an C₁₋₆ alkyl which may optionally have a substituent selected from hydroxy, furyl, thienyl, tetrahydrofuranyl and phenyl, a phenyl which may optionally have one to three substituents selected from an C₁₋₆ alkyl, a hydroxy-substituted C₁₋₆ alkyl, an C₁₋₆ alkanoyl, cyano, carboxy, an C₁₋₆ alkoxy, hydroxy, an C₁₋₆ alkoxy, and a halogen atom, or a heterocyclic group selected from pyridyl, pyrimidinyl, thiazolyl, isoxazolyl, and pyrazolyl, said heterocyclic group being optionally substituted by an C₁₋₆ alkyl, amino, or an C₁₋₆ alkanoyl-amino, or R⁴ and R⁵ may join together with the adjacent nitrogen atom to form a saturated 5- or 6-membered heterocyclic group which may optionally be intervened with oxygen atom, or (xx) a group of the

formula:




10 wherein A is an C₁₋₆ alkylene,
which comprises

(a) reacting a compound of the formula:




25 wherein R³ is as defined above with an alkyl orthoformate to give a compound of the formula:




(1-a)

wherein R³ is as defined above, or
(b) acylating a compound of the formula:



50 wherein R² and R³ are as defined above to give a compound of the formula:

55




(1-e)

wherein R² and R³ are as defined above and R^{1a} is a C₁₋₆ alkanoyl,


a pharmaceutical composition for the prophylaxis and treatment of gout, which comprises an active ingredient a prophylactically and therapeutically effective amount of a pyrazolotriazine compound of the formula (1) as set forth above in admixture with a pharmaceutically acceptable carrier or diluent,

and the use of a prophylactically and therapeutically effective amount of a pyrazolotriazine compound of the formula (1) as set forth above for the preparation of a medicament for the prophylaxis and treatment of gout.


Preferred embodiments of the present invention are pyrazolo triazine compounds wherein R¹ is hydroxy, R³ is (1) an unsaturated heterocyclic group selected from pyrrolyl, pyridyl, thienyl, thiopyranyl, indolyl, benzothienyl, 2,3-dihydrobenzothienyl, thiochromanyl, or dibenzothienyl, which may optionally have one or two substituents selected from a halogen atom, nitro, and phenylthio, (2) naphthyl, and (3) a phenyl which may optionally have one to three substituents selected from the group consisting of (i) a C₁₋₆ alkyl, (ii) phenyl, (iii) a C₁₋₆ alkoxy, (iv) cyano, (v) nitro, (vi) a C₁₋₆ alkoxy, (vii) a phenyl(C₁₋₆)alkoxy, (viii) a phenylthio(C₁₋₆)alkyl, (ix) phenoxy, (x) a group of the formula:




wherein R is a C₁₋₆ alkyl, a halogen-substituted C₁₋₆ alkyl, a phenyl which may optionally have one to three substituents selected from a halogen atom, a C₁₋₆ alkyl and a C₁₋₆ alkoxy, or pyridyl, and l is an integer of 0, 1 or 2, (xi) a halogen atom, (xii) a phenyl(C₁₋₆)alkyl, (xiii) carboxy, (xiv) a C₁₋₆ alkanoyl, (xv) a benzoyl which may optionally have one to three substituents selected from a halogen atom, a phenyl(C₁₋₆)alkoxy and hydroxy on the phenyl ring, (xvi) amino, (xvii) hydroxy, (xviii) a C₁₋₆ alkanoyloxy, (xix) a group of the formula:




wherein R⁴ and R⁵ are the same or different and are each hydrogen atom, a cycloalkyl, a C₁₋₆ alkyl which may optionally have a substituent selected from hydroxy, furyl, thienyl, tetrahydrofuranyl and phenyl, a phenyl which may optionally have one to three substituents selected from a C₁₋₆ alkyl, a hydroxy-substituted C₁₋₆ alkyl, a C₁₋₆ alkanoyl, cyano, carboxy, a C₁₋₆ alkoxy, a C₁₋₆ alkoxy, and a halogen atom, or a heterocyclic group selected from pyridyl, pyrimidinyl, thiazolyl, isoxazolyl, and pyrazolyl, said heterocyclic group being optionally substituted by a C₁₋₆ alkyl, amino, or a C₁₋₆ alkanoylamino, or R⁴ and R⁵ may join together with the adjacent nitrogen atom to form a heterocyclic group selected from the group consisting of pyrrolidinyl, piperidinyl, tetrahydro-1,2-oxazinyl, tetrahydro-1,3-oxazinyl, and morpholino, or (xx) a group of the formula:




- 10 wherein A is a C₁₋₄ alkylene,
 or wherein R¹ is hydroxy,
 or wherein R¹ is a C₁₋₆ alkanoyloxy,
 or wherein R³ is a phenyl which has at least one substituent of a group of the formula:




- 20 (wherein R is a C₁₋₆ alkyl, a halogen-substituted C₁₋₆ alkyl, a phenyl which may optionally have one to three substituents selected from a halogen atom, a C₁₋₆ alkyl and a C₁₋₆ alkoxy, or pyridyl, and t is an integer of 0, 1 or 2) and may optionally have further one or two substituents selected from the group consisting of (i) a C₁₋₆ alkyl, (ii) phenyl, (iii) a C₁₋₆ alkoxycarbonyl, (iv) cyano, (v) nitro, (vi) a C₁₋₆ alkoxy,
 25 (vii) a phenyl(C₁₋₆)alkoxy, (viii) a phenylthio(C₁₋₆)alkyl, (ix) phenoxy, (x) a halogen atom, (xi) a phenyl-(C₁₋₆)alkyl, (xii) carboxy, (xiii) a C₁₋₆ alkanoyl, (xiv) a benzoyl which may optionally have one to three substituents selected from a halogen atom, a phenyl(C₁₋₆)alkoxy and hydroxy on the phenyl ring, (xv) amino, (xvi) hydroxy, (xvii) a C₁₋₆ alkanoyloxy, (xviii) a group of the formula:



- 35 wherein R⁴ and R⁵ are the same or different and are each hydrogen atom, a cycloalkyl, a C₁₋₆ alkyl which may optionally have a substituent selected from hydroxy, furyl, thienyl, tetrahydrofuranyl and phenyl, a phenyl which may optionally have one to three substituents selected from a C₁₋₆ alkyl, a hydroxy-substituted C₁₋₆ alkyl, a C₁₋₆ alkanoyl, cyano, carboxy, a C₁₋₆ alkoxycarbonyl, hydroxy, a C₁₋₆ alkoxy,
 40 and a halogen atom, or a heterocyclic group selected from pyridyl, pyrimidinyl, thiazolyl, isoxazolyl, and pyrazolyl, said heterocyclic group being optionally substituted by a C₁₋₆ alkyl, amino, or a C₁₋₆ alkanoylamino, or R⁴ and R⁵ may join together with the adjacent nitrogen atom to form a heterocyclic group selected from the group consisting of pyrrolidinyl, piperidinyl, tetrahydro-1,2-oxazinyl, tetrahydro-1,3-oxazinyl, and morpholino, or (xx) a group of the formula:




- 50
- wherein A is a C₁₋₄ alkylene,
 55 or wherein R³ is a phenyl which has at least one substituent of the formula



5


(wherein R^4 and R^5 are the same or different and are each hydrogen atom, a cycloalkyl, a C_{1-6} alkyl which may optionally have a substituent selected from hydroxy, furyl, thienyl, tetrahydrofuranyl and phenyl, a phenyl which may optionally have one to three substituents selected from a C_{1-6} alkyl, a hydroxy-substituted C_{1-6} alkyl, a C_{1-6} alkanoyl, cyano, carboxy, a C_{1-6} alkoxy, a C_{1-6} alkoxy, and a halogen atom, or a heterocyclic group selected from pyridyl, pyrimidinyl, thiazolyl, isoxazolyl, and pyrazolyl, said heterocyclic group being optionally substituted by a C_{1-6} alkyl, amino, or a C_{1-6} alkanoylamino, or R^4 and R^5 may join together with the adjacent nitrogen atom to form a heterocyclic group selected from the group consisting of pyrrolidinyl, piperidinyl, tetrahyro-1,2-oxazinyl, tetrahydro-1,3-oxazinyl, and morpholino) and may optionally have further one or two substituents selected from the group consisting of (i) a C_{1-6} alkyl, (ii) phenyl, (iii) a C_{1-6} alkoxy, (iv) cyano, (v) nitro, (vi) a C_{1-6} alkoxy, (vii) a phenyl(C_{1-6})alkoxy, (viii) a phenylthio(C_{1-6})alkyl, (ix) phenoxy, (x) a group of the formula:

20




wherein R is a C_{1-6} alkyl, a halogen-substituted C_{1-6} alkyl, a phenyl which may optionally have one to three substituents selected from a halogen atom, a C_{1-6} alkyl and a C_{1-6} alkoxy, or pyridyl, and t is an integer of 0, 1 or 2, (xi) a halogen atom, (xii) a phenyl(C_{1-6})alkyl, (xiii) carboxy, (xiv) a C_{1-6} alkanoyl, (xv) a benzoyl which may optionally have one to three substituents selected from a halogen atom, a phenyl(C_{1-6})alkoxy and hydroxy on the phenyl ring, (xvi) amino, (xvii) hydroxy, (xviii) a C_{1-6} alkanoyloxy, and (xix) a group of the formula:

35




wherein A is a C_{1-4} alkylene, or wherein R^3 is a phenyl which has any one of substituents selected from the group consisting of (i) a C_{1-6} alkyl, (ii) phenyl, (iii) a C_{1-6} alkoxy, (iv) cyano, (v) nitro, (vi) a C_{1-6} alkoxy, (vii) a phenyl(C_{1-6})alkoxy, (viii) a phenylthio(C_{1-6})alkyl, (ix) phenoxy, (x) a halogen atom, (xi) a phenyl(C_{1-6})alkyl, (xii) carboxy, (xiii) a C_{1-6} alkanoyl, (xiv) a benzoyl which may optionally have one to three substituents selected from a halogen atom, a phenyl(C_{1-6})alkoxy and hydroxy on the phenyl ring, (xv) amino, (xvi) hydroxy, (xvii) a C_{1-6} alkanoyloxy, and (xviii) a group of the formula:

50




55

wherein A is a C_{1-4} alkylene, and may optionally have further one or two substituents selected from a group the formula:




wherein R is a C₁₋₆ alkyl, a halogen-substituted C₁₋₆ alkyl, a phenyl which may optionally have one to three substituents selected from a halogen atom, a C₁₋₆ alkyl and a C₁₋₆ alkoxy, or pyridyl, and t is an integer of 0, 1 or 2, and a group of the formula:




wherein R⁴ and R⁵ are the same or different and are each hydrogen atom, a cycloalkyl, a C₁₋₆ alkyl which may optionally have a substituent selected from hydroxy, furyl, thienyl, tetrahydrofuranyl and phenyl, a phenyl which may optionally have one to three substituents selected from a C₁₋₆ alkyl, a hydroxy-substituted C₁₋₆ alkyl, a C₁₋₆ alkanoyl, cyano, carboxy, a C₁₋₆ alkoxycarbonyl, hydroxy, a C₁₋₆ alkoxy, and a halogen atom, or a heterocyclic group selected from pyridyl, pyrimidinyl, thiazolyl, isoxazolyl, and pyrazolyl, said heterocyclic group being optionally substituted by a C₁₋₆ alkyl, amino, or a C₁₋₆ alkanoylamino, or R⁴ and R⁵ may join together with the adjacent nitrogen atom to form a heterocyclic group selected from the group consisting of pyrrolidinyl, piperidinyl, tetrahydro-1,2-oxazinyl, tetrahydro-1,3-oxazinyl, and morpholino,
or wherein R³ is a phenyl which is substituted by a group of the formula:



wherein R is a C₁₋₆ alkyl, a halogen-substituted C₁₋₆ alkyl, a phenyl which may optionally have one to three substituents selected from a halogen atom, a C₁₋₆ alkyl and a C₁₋₆ alkoxy, or pyridyl, and t is an integer of 0, 1 or 2 and may optionally have other one or two substituents selected from the group consisting of a C₁₋₆ alkyl, a C₁₋₆ alkoxy, a halogen atom, and a C₁₋₆ alkylthio,
or wherein R³ is a phenyl having one to three substituents selected from the group consisting of a C₁₋₆ alkyl, a C₁₋₆ alkoxy, nitro, a halogen atom, a phenyl(C₁₋₆)alkoxy, and a benzoyl having optionally one to three substituents selected from a halogen atom, a phenyl(C₁₋₆)alkoxy and hydroxy,
or wherein R³ is a phenyl which is substituted by a group of the formula:




(wherein R⁴ is hydrogen atom and R⁵ is a thienyl(C₁₋₆)alkyl, or a phenyl which may optionally have one to three substituents selected from a C₁₋₆ alkyl, a hydroxy-substituted C₁₋₆ alkyl, a C₁₋₆ alkoxycarbonyl, hydroxy, a C₁₋₆ alkoxy, and a halogen atom; or R⁴ and R⁵ are the same and are each a C₁₋₆ alkyl) and has optionally further a substituent selected from a C₁₋₆ alkyl or a halogen atom,
or wherein R³ is a phenyl which is substituted by a group of the formula:



5

wherein R is a C₁₋₆ alkyl or phenyl, and t is an integer of 0, 1 or 2,
or wherein R³ is a phenyl which is substituted by a group of the formula:

10



15

wherein R is a halogen-substituted C₁₋₆ alkyl, a phenyl which may optionally have one to three substituents selected from a halogen atom, a C₁₋₆ alkyl and a C₁₋₆ alkoxy, or pyridyl, and t is an integer of 0, 1 or 2, or wherein R³ is a phenyl having one to three substituents selected from the group consisting of a C₁₋₆ alkyl, a C₁₋₆ alkoxy, a halogen atom, and a C₁₋₆ alkylthio.

20 The pyrazolotriazine compounds of the formula (1) have a xanthine oxidase inhibitory activity and are useful as a medicine for the prophylaxis and treatment of gout.

In the above formula (1), the groups include specifically the following groups.

The "lower alkyl" includes alkyl groups having 1 to 6 carbon atoms, for example, methyl, ethyl, propyl, isopropyl, butyl, t-butyl, pentyl, hexyl.

25 The "halogen atom" includes, for example, fluorine, chlorine, bromine, and iodine.

The "lower alkoxy" includes alkoxy groups having 1 to 6 carbon atoms, for example, methoxy, ethoxy, propoxy, isopropoxy, butoxy, t-butoxy, pentyloxy, hexyloxy.

The "lower alkanoyl", "lower alkanoyloxy" and "lower alkanoylamino" include as the lower alkanoyl moiety alkanoyl groups having 1 to 6 carbon atoms, for example, formyl, acetyl, propionyl, butyryl, isobutyryl, valeryl, isovaleryl, pivaloyl, hexanoyl.

30 The "unsaturated heterocyclic group containing nitrogen or sulfur atom as the hetero atom" includes monocyclic or condensed heterocyclic groups containing nitrogen or sulfur atom, for example, pyrrolyl, pyridyl, thienyl, thiopyranyl, indolyl, benzothienyl, 2,3-dihydrobenzothienyl, thiochromanyl, dibenzothienyl. The heterocyclic group may optionally have one or two substituents selected from a halogen atom, nitro and phenylthio. Suitable examples of the heterocyclic group are, for example, 2-pyrrolyl, 3-pyrrolyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-thienyl, 3-thienyl, 2-thiopyranyl, 3-thiopyranyl, 4-thiopyranyl, 5-chloro-2-thienyl, 5-bromo-2-thienyl, 4-bromo-2-thienyl, 2-bromo-3-thienyl, 2,5-dichloro-3-thienyl, 2,5-dibromo-3-thienyl, 4,5-dibromo-2-thienyl, 4,5-dibromo-3-thienyl, 2-chloro-5-pyridyl, 2,3-dibromo-5-pyridyl, 5-nitro-2-thienyl, 4-nitro-2-thienyl, 3-nitro-2-thienyl, 2-nitro-3-thienyl, 2-nitro-4-pyridyl, 6-nitro-2-pyridyl, 3-phenylthio-2-thienyl, 5-phenylthio-2-thienyl, 5-phenylthio-3-thienyl, 4-phenylthio-2-pyridyl, 5-phenylthio-2-pyridyl, 1-indolyl, 2-indolyl, 3-indolyl, 4-indolyl, 5-indolyl, 6-indolyl, 7-indolyl, 1-benzothiophen-2-yl, 1-benzothiophen-3-yl, 1-benzothiophen-4-yl, 1-benzothiophen-5-yl, 1-benzothiophen-6-yl, 1-benzothiophen-7-yl, 2,3-dihydro-1-benzothiophen-4-yl, 2,3-dihydro-1-benzothiophen-5-yl, 2,3-dihydro-1-benzothiophen-6-yl, 2,3-dihydro-1-benzothiophen-7-yl, thiochroman-5-yl, thiochroman-6-yl, thiochroman-7-yl, thiochroman-8-yl, dibenzothiophen-1-yl, dibenzothiophen-2-yl, dibenzothiophen-3-yl, dibenzothiophen-4-yl.

45 The "naphthyl" includes, for example, 1-naphthyl, 2-naphthyl, etc.

The "lower alkoxy carbonyl" includes alkoxy carbonyl groups having 1 to 6 carbon atoms in the alkoxy moiety, for example, methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, isopropoxycarbonyl, butoxycarbonyl, t-butoxycarbonyl, pentyloxy carbonyl, hexyloxy carbonyl.

50 The "phenyl-lower alkoxy" includes phenylalkoxy groups having 1 to 6 carbon atoms in the alkoxy moiety, for example, benzyloxy, 1-phenylethoxy, 2-phenylethoxy, 3-phenylpropoxy, 2-phenyl-1-methylethoxy, 4-phenylbutoxy, 2-phenyl-1,1-dimethylethoxy, 5-phenylpentyloxy, 6-phenylhexyloxy.

The "phenylthio-lower alkyl" includes phenylthioalkyl groups having 1 to 6 carbon atoms in the alkyl moiety, for example, phenylthiomethyl, 1-phenylthioethyl, 2-phenylthioethyl, 3-phenylthiopropyl, 2-phenylthio-1-methylethyl, 4-phenylthiobutyl, 2-phenylthio-1,1-dimethylethyl, 5-phenylthiopentyl, 6-phenylthiohexyl.

55 The "halogen-substituted lower alkyl" includes halogen-substituted alkyl groups having 1 to 6 carbon atoms in the alkyl moiety, for example, chloromethyl, bromomethyl, 1-chloroethyl, 2-chloroethyl, 2-bromoethyl, 3-chloropropyl, 2-chloro-1-methylethyl, 2-bromobutyl, 4-bromobutyl, 2-chloro-1,1-dimethylethyl,

5-chloropentyl, 6-bromohexyl.

The "phenyl which may optionally have one to three substituents selected from a halogen atom, a lower alkyl and a lower alkoxy" includes phenyl groups which may optionally have one to three substituents selected from a halogen atom, an alkyl having 1 to 6 carbon atoms and an alkoxy having 1 to 6 carbon atoms, for example, phenyl, 2-chlorophenyl, 3-chlorophenyl, 4-chlorophenyl, 2-bromophenyl, 3-bromophenyl, 4-bromophenyl, 4-fluorophenyl, 4-iodophenyl, 2,4-dibromophenyl, 2,6-dibromophenyl, 2,4,6-tribromophenyl, 2-methylphenyl, 3-methylphenyl, 4-methylphenyl, 2-ethylphenyl, 4-ethylphenyl, 3-propylphenyl, 4-(t-butyl)phenyl, 4-pentylphenyl, 4-hexylphenyl, 2,4-dimethylphenyl, 2,6-dimethylphenyl, 2-methyl-4-ethylphenyl, 2,4,6-trimethylphenyl, 2-methoxyphenyl, 3-methoxyphenyl, 4-methoxyphenyl, 2-ethoxyphenyl, 4-ethoxyphenyl, 3-propoxyphenyl, 4-(t-butoxy)phenyl, 4-pentyloxyphenyl, 4-hexyloxyphenyl, 2,6-dimethoxyphenyl, 2-methoxy-4-ethoxyphenyl, 2,4,6-trimethoxyphenyl, 2-chloro-4-methylphenyl, 2,6-dibromo-4-methylphenyl, 2-chloro-4-methoxyphenyl, 2,6-dichloro-4-methoxyphenyl, 2-bromo-4-methoxyphenyl, 2,6-dibromo-4-methoxyphenyl, 2,6-dibromo-4-ethoxyphenyl.

The "phenyl-lower alkyl" includes phenylalkyl groups having 1 to 6 carbon atoms in the alkyl moiety, for example, benzyl, 1-phenylethyl, 2-phenylethyl, 3-phenylpropyl, 2-phenyl-1-methylethyl, 4-phenylbutyl, 2-phenyl-1,1-dimethylethyl, 5-phenylpentyl, 6-phenylhexyl.

The "benzoyl which may optionally have one to three substituents selected from a halogen atom, a phenyl-lower alkoxy and hydroxy on the phenyl ring" includes benzoyl groups which may optionally have one to three substituents selected from a halogen atom, a phenylalkoxy having 1 to 6 carbon atoms in the alkoxy moiety and hydroxy, for example, benzoyl, 3-bromobenzoyl, 4-benzyloxybenzoyl, 4-hydroxybenzoyl, 3,5-dibromobenzoyl, 3-bromo-4-benzyloxybenzoyl, 3-chloro-4-hydroxybenzoyl, 3,5-dibromo-4-benzyloxybenzoyl, 3,5-dibromo-4-(1-phenethyloxy)benzoyl, 3,5-dibromo-4-(2-phenethyloxy)benzoyl, 3,5-dibromo-4-(3-phenylpropoxy)benzoyl, 3,5-dibromo-4-(4-phenylbutoxy)benzoyl, 3,5-dibromo-4-(5-phenylpentyloxy)benzoyl, 3,5-dibromo-4-(6-phenylhexyloxy)benzoyl, 3,5-dichloro-4-benzyloxybenzoyl, 3,5-dichloro-4-hydroxybenzoyl, 3,4-dichloro-5-hydroxybenzoyl.

The "cycloalkyl" includes cycloalkyl groups having 3 to 8 carbon atoms, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, etc.

The "furyl" includes, for example, 2-furyl, 3-furyl.

The "thienyl" includes, for example, 2-thienyl, 3-thienyl.

The "tetrahydrofuranyl" includes, for example, 2-tetrahydrofuranyl, 3-tetrahydrofuranyl.

The "hydroxy-substituted lower alkyl" includes hydroxy-substituted alkyl groups having 1 to 6 carbon atoms in the alkyl moiety, for example, hydroxymethyl, 1-hydroxyethyl, 2-hydroxyethyl, 3-hydroxypropyl, 4-hydroxybutyl, 5-hydroxypentyl, 6-hydroxyhexyl.

The "lower alkyl which may optionally have a substituent selected from hydroxy, furyl, thienyl, tetrahydrofuranyl and phenyl" includes alkyl groups having 1 to 6 carbon atoms which may optionally have a substituent selected from hydroxy, furyl, thienyl, tetrahydrofuranyl and phenyl, for example, 2-furfuryl, 3-furylmethyl, 1-(2-furyl)ethyl, 2-(3-furyl)ethyl, 3-(2-furyl)propyl, 4-(3-furyl)butyl, 3-(2-furyl)pentyl, 6-(2-furyl)hexyl, 2-thienylmethyl, 3-thienylmethyl, 1-(2-thienyl)ethyl, 2-(3-thienyl)ethyl, 3-(2-thienyl)propyl, 4-(3-thienyl)butyl, 5-(2-thienyl)pentyl, 6-(2-thienyl)hexyl, 2-tetrahydrofuranylmethyl, 3-tetrahydrofuranylmethyl, 1-(2-tetrahydrofuranyl)ethyl, 2-(3-tetrahydrofuranyl)ethyl, 3-(2-tetrahydrofuranyl)propyl, 4-(3-tetrahydrofuranyl)butyl, 5-(2-tetrahydrofuranyl)pentyl, 6-(2-tetrahydrofuranyl)hexyl.

The "phenyl which may optionally have one to three substituents selected from a lower alkyl, a hydroxy-substituted lower alkyl, a lower alkanoyl, cyano, carboxy, a lower alkoxy, a lower alkoxy, and a halogen atom" includes phenyl groups which may optionally have one to three substituents selected from an alkyl having 1 to 6 carbon atoms, a hydroxyalkyl having 1 to 6 carbon atoms, an alkanoyl having 1 to 6 carbon atoms, cyano, carboxy, an alkoxy having 1 to 6 carbon atoms, and a halogen, for example, phenyl, 2-methylphenyl, 3-methylphenyl, 4-methylphenyl, 2-ethylphenyl, 3-ethylphenyl, 4-ethylphenyl, 2-isopropylphenyl, 3-isopropylphenyl, 4-isopropylphenyl, 3-propylphenyl, 4-butylphenyl, 2-(t-butyl)phenyl, 3-(t-butyl)phenyl, 4-(t-butyl)phenyl, 4-pentylphenyl, 4-hexylphenyl, 4-hydroxymethylphenyl, 2-(1-hydroxyethyl)phenyl, 3-(1-hydroxyethyl)phenyl, 4-(1-hydroxyethyl)phenyl, 2-(2-hydroxyethyl)phenyl, 4-(2-hydroxyethyl)phenyl, 3-(3-hydroxypropyl)phenyl, 4-(4-hydroxybutyl)phenyl, 4-(5-hydroxypentyl)phenyl, 4-(6-hydroxyhexyl)phenyl, 2-acetylphenyl, 3-acetylphenyl, 4-acetylphenyl, 3-propionylphenyl, 4-butyrylphenyl, 3-valerylphenyl, 4-hexanoylphenyl, 2-cyanophenyl, 3-cyanophenyl, 4-cyanophenyl, 2-carboxyphenyl, 3-carboxyphenyl, 4-carboxyphenyl, 2-methoxycarbonylphenyl, 3-methoxycarbonylphenyl, 4-methoxycarbonylphenyl, 2-ethoxycarbonylphenyl, 4-propoxycarbonylphenyl, 4-(t-butoxycarbonyl)phenyl, 4-pentyloxycarbonylphenyl, 4-hexyloxycarbonylphenyl, 2-hydroxyphenyl, 3-hydroxyphenyl, 4-hydroxyphenyl, 2-methoxyphenyl, 3-methoxyphenyl, 4-methoxyphenyl, 2,4-dimethoxyphenyl, 2,4,6-trimethoxyphenyl, 3,4,5-trimethoxyphenyl, 4-ethoxyphenyl, 4-t-


butoxyphenyl, 4-hexyloxyphenyl, 2-chlorophenyl, 3-chlorophenyl, 4-chlorophenyl, 2,4-dichlorophenyl, 3,5-dichlorophenyl, 2,4,6-trichlorophenyl, 3,4,5-trichlorophenyl, 4-bromophenyl, 4-fluorophenyl, 4-iodophenyl, 2-hydroxy-4-carboxyphenyl, 3-hydroxy-4-carboxyphenyl, 4-hydroxy-3-carboxyphenyl, 2-hydroxy-4-methoxycarbonylphenyl, 3-hydroxy-4-methoxycarbonylphenyl, 4-hydroxy-3-methoxycarbonylphenyl, 2-methoxy-4-methoxycarbonylphenyl, 3-methoxy-4-methoxycarbonylphenyl, 4-methoxy-3-methoxycarbonylphenyl.

The "heterocyclic group selected from pyridyl, pyrimidinyl, thiazolyl, isoxazolyl, and pyrazolyl, said heterocyclic group being optionally substituted by a lower alkyl, amino, or a lower alkanoylamino" includes heterocyclic groups selected from pyridyl, pyrimidinyl, thiazolyl, isoxazolyl, and pyrazolyl which may optionally substituted by an alkyl having 1 to 6 carbon atoms, amino, or an alkanoylamino having 1 to 6 carbon atoms in the alkanoyl moiety, for example, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-pyrimidinyl, 4-pyrimidinyl, 5-pyrimidinyl, 2-thiazolyl, 4-thiazolyl, 5-thiazolyl, 3-isoxazolyl, 4-isoxazolyl, 5-isoxazolyl, 1-pyrazolyl, 3-pyrazolyl, 4-pyrazolyl, 2-methyl-4-pyridyl, 4-methyl-3-pyridyl, 3-amino-5-pyridyl, 4-amino-2-pyridyl, 2-acetylamino-4-pyridyl, 3-propanoylamino-5-pyridyl, 2-methyl-4-pyrimidinyl, 4-methyl-6-pyrimidinyl, 5-ethyl-2-pyrimidinyl, 2-amino-5-pyrimidinyl, 2-amino-4-pyrimidinyl, 4-acetylamino-2-pyrimidinyl, 4-acetylamino-6-pyrimidinyl, 4-propanoylamino-2-pyrimidinyl, 2-methyl-4-thiazolyl, 2-ethyl-5-thiazolyl, 4-methyl-2-thiazolyl, 2-amino-4-thiazolyl, 4-amino-5-thiazolyl, 2-acetylamino-4-thiazolyl, 5-acetylamino-2-thiazolyl, 5-methyl-3-isoxazolyl, 4-methyl-3-isoxazolyl, 4-methyl-5-isoxazolyl, 5-ethyl-3-isoxazolyl, 5-propyl-4-isoxazolyl, 4-isopropyl-3-isoxazolyl, 5-butyl-3-isoxazolyl, 5-pentyl-4-isoxazolyl, 5-hexyl-3-isoxazolyl, 3-amino-4-isoxazolyl, 4-amino-5-isoxazolyl, 3-acetylamino-4-isoxazolyl, 5-acetylamino-3-isoxazolyl, 1-methyl-3-pyrazolyl, 3-methyl-5-pyrazolyl, 4-ethyl-1-pyrazolyl, 5-amino-1-pyrazolyl, 4-amino-1-pyrazolyl, 3-amino-1-pyrazolyl, 5-amino-3-pyrazolyl, 5-acetylamino-1-pyrazolyl, 4-acetylamino-1-pyrazolyl, 3-acetylamino-1-pyrazolyl, 5-acetylamino-3-pyrazolyl, 5-propanoylamino-1-pyrazolyl, 4-butyrylamino-1-pyrazolyl, 5-isobutyrylamino-1-pyrazolyl, 5-valerylamino-1-pyrazolyl, 5-hexanoylamino-1-pyrazolyl.

The "saturated 5- or 6-membered heterocyclic group which may optionally be intervened with oxygen atom formed by joining of R⁴ and R⁵ together with the adjacent nitrogen atom" includes, for example, pyrrolidinyl, piperidinyl, tetrahydro-1,2-oxazinyl, tetrahydro-1,3-oxazinyl, morpholino.

The "lower alkylene" includes alkylene groups having 1 to 6 carbon atoms, for example methylene, ethylene, trimethylene, dimethylmethylene, tetramethylene, pentamethylene, hexamethylene.


The "group of the formula:



(wherein A is as defined above)" includes, for example, phenylmethylenedioxymethyl, phenylethylenedioxymethyl, phenylpropylenedioxymethyl.

The compounds of this invention can be prepared by various processes, for example, by the following reaction schemes.


Reaction Scheme-1



wherein R³ is as defined above.

The compounds (1-a) of this invention can be prepared by reacting a compound (2) with an alkyl orthoformate (e.g. methyl orthoformate, ethyl orthoformate, etc.). The reaction can be carried out in a solvent which does not affect the reaction, but since the alkyl orthoformate can also act as a solvent, use of a specific solvent is not necessarily essential. The reaction is usually carried out by using 15 moles of the alkyl orthoformate per 1 mole of the compound (2) at a temperature of 80 to 120 °C for 2 to 15 hours.

Reaction Scheme-2



wherein R³ is as defined above, R^{1a} is a lower alkanoyl, and R^{2a} is hydrogen atom.

The above process comprises acylating the 4-hydroxy group of the compound (1-d) to obtain the compound (1-e). The reaction can be carried out by a conventional acylating reaction, for example, an acid halide method and an acid anhydride method, a mixed acid anhydride method, an N,N'-dicyclohexylcarbodiimide method (DCC method), particularly preferably by an acid anhydride method or an acid halide method.

The acid anhydride method can be carried out by reacting the compound (1-d) with an acid anhydride in a suitable solvent. The acid anhydride includes an anhydride of an acid corresponding to the acyl group to be introduced into the 4-hydroxy group of the compound (1-d). Suitable examples of the acid anhydride are acetic anhydride, propionic anhydride, butyric anhydride. These acid anhydrides are used in an amount of at least 1 mole, preferably about 1 to 3 moles, per 1 mole of the compound (1-d). The solvent includes various inert solvents, such as pyridine, halogenated hydrocarbons (e.g. chloroform, dichloromethane), ethers (dioxane, tetrahydrofuran (THF)), aromatic hydrocarbons (e.g. benzene, toluene), N,N-dimethylformamide (DMF), dimethylsulfoxide (DMSO) and acetonitrile. The reaction is usually carried out at a temperature from -30 °C to 100 °C, preferably from room temperature to 80 °C, for 20 minutes to 20 hours. Besides, the reaction proceeds preferably in the presence of a basic compound. The basic compound includes, for example, organic basic compounds such as tertiary amines (e.g. pyridine, triethylamine, N,N-dimethylaniline), and inorganic basic compounds such as sodium hydrogen carbonate, potassium carbonate and sodium acetate.

The acid halide method is carried out by reacting the compound (1-d) with an acid halide corresponding to the acyl group to be introduced (e.g. acid chloride, acid bromide) in the presence of a basic compound in a suitable solvent. The solvent and basic compound include the same solvents and basic compounds as mentioned as to the above acid anhydride method. The reaction is usually carried out at a temperature from -30 °C to 80 °C, preferably from 0 °C to room temperature, for 5 minutes to 10 hours.

The compounds of this invention can be prepared by the above-mentioned processes of Reaction Schemes-1 to -4, and further, the compounds having a substituent(s) on the phenyl ring or the unsaturated heterocyclic ring having nitrogen or sulfur atom at 8-position of the compounds can also be prepared by introduction of the substituent(s) or exchange of the substituent(s) as mentioned below. In the following explanation, only the substituent(s) to be introduced or exchanged is mentioned, but the compounds may have any various substituents on the phenyl ring or the unsaturated heterocyclic ring as defined in the claims.

Exchange Reaction-1

In case of the compound having a lower alkyl group on the phenyl ring, the lower alkyl group can be converted into a carboxy group by oxidizing it with an oxidizing agent such as potassium permanganate and chromic acid. The exchange reaction can be carried out in a solvent (e.g. water) under ice cooling for 5 to

24 hours. The oxidizing agent is preferably used in an amount of 1 to 2 moles to 1 mole of the compound having a lower alkyl group.

Exchange Reaction-2

5

In case of the compound having a carboxy group on the phenyl ring, the carboxy group can be converted into a corresponding ester group by a conventional esterification reaction. The exchange reaction can be carried out by reacting the compound having a carboxy group with a lower alcohol (e.g. methanol, ethanol) in the presence of a catalyst (e.g. sulfuric acid, hydrogen chloride) at a boiling point of the solvent
10 for 24 hours. The lower alcohol is preferably used in an amount of 100 to 500 moles to 1 mole of the compound having a carboxy group.

Exchange Reaction-3

15

In case of the compound having a phenyl group substituted by a lower alkyl group containing methylene group, the methylene group can be converted into a carbonyl group by a conventional oxidation reaction. The exchange reaction can advantageously be carried out by using an oxidizing agent such as selenium dioxide, chromic acid, and the like in a solvent (e.g. acetic acid, a mixture of acetic acid and water) at a room temperature for 10 to 18 hours. The oxidizing agent is used in an amount of 5 moles
20 to 1 mole of the compound containing methylene group.

Exchange Reaction-4

25

In case of the compound having a lower alkylenedioxy group (i.e. the carbonyl group being protected with a lower alkylene) on the phenyl ring, the lower alkylenedioxy group can be converted into a carboxy group by subjecting it to a conventional removal of a protecting group. The exchange reaction can advantageously be carried out by reacting one mole of the compound having a lower alkylenedioxy group with 10 moles of a mineral acid (e.g. hydrochloric acid, sulfuric acid) in a solvent at a temperature of 40 to 60 °C for 1 to 3 hours. The solvent used in the above exchange reaction includes a mixture of a lower
30 alcohol (e.g. methanol, ethanol) and water.

Exchange Reaction-5

35

In case of the compound having a phenyl ring or an unsaturated heterocyclic group having nitrogen or sulfur atom as the hetero atom (hereinafter, referred to merely as unsaturated heterocyclic group) of this invention, nitro group can be introduced onto the phenyl ring or the unsaturated heterocyclic group by a conventional nitration reaction. The reaction can advantageously be carried out under the conditions as used in a conventional nitration reaction, for example, by treating with conc. nitric acid, fuming sulfuric acid, or a mixture of conc. nitric acid - conc. sulfuric acid in a solvent (e.g. acetic acid) at a temperature from
40 room temperature to 60 °C for one hour. In case of introduction of nitro group onto the above unsaturated heterocyclic group, the reaction is preferably carried out at room temperature.

Exchange Reaction-6

45

In case of the compound having a nitro group on the phenyl ring, the nitro group can be converted into an amino group by a conventional catalytic reduction. The exchange reaction can advantageously be carried out, for example, by subjecting the compound to a hydrogenation with palladiumcarbon in a mixed solvent of methanol-water at room temperature for 14 hours.

Exchange Reaction-7

50

In case of the compound having an alkoxy group having optionally a phenyl substituent on the phenyl ring, the alkoxy group can be converted into a hydroxy group by reacting it with an aluminum halide. The exchange reaction can be carried out by using an aluminum halide (e.g. aluminum chloride, aluminum bromide) of 6 moles to 1 mole of the compound having an alkoxy group in a solvent such as an aromatic compound (e.g. nitrobenzene, chlorobenzene). The reaction is advantageously carried out at a temperature of from room temperature to 60 °C for 1 to 5 hours.

When the alkoxy group is benzyloxy group, the reaction is preferably carried out at room temperature for

one hour.

Exchange Reaction-8

- 5 In case of the compound having hydroxy group on the phenyl ring, the hydroxy group can be converted into an acyloxy group by reacting it with a lower fatty acid anhydride or lower fatty acid halide in such a manner as the acylation reaction in the above Reaction Scheme-4. The exchange reaction can be carried out by reacting one mole of the compound having hydroxy group on the phenyl ring with at least one mole, preferably 1.1 to 1.5 mole, of the lower fatty acid anhydride or lower fatty acid halide. The reaction is
10 advantageously carried out at room temperature for 45 minutes.

Exchange Reaction-9

- 15 In case of the compound having a lower alkylthio group on the phenyl ring, the lower alkylthio group can be converted into a lower alkylsulfinyl group by oxidizing it with an oxidizing agent such as periodate and hydrogen peroxide. The exchange reaction can be carried out by using a periodate (e.g. sodium periodate, potassium periodate, etc.) of 2 moles to 1 mole of the compound having a lower alkylthio group in a solvent such as a mixture of a lower alcohol (e.g. methanol, ethanol) with water (40 : 1). The reaction is
20 advantageously carried out at room temperature for 40 hours. Besides, the reaction can also be carried out under the same conditions as in the above Exchange Reaction-3 except that the above-mentioned solvent is used.

Moreover, in case of the compound having a phenylthio group on the phenyl ring, the phenylthio group can be converted into a phenylsulfinyl group in the same manner as described above.

Exchange Reaction-10


- 25 In case of the compound having a lower alkylthio group or lower alkylsulfinyl group on the phenyl ring, the lower alkylthio or alkylsulfinyl group can be converted into a lower alkylsulfonyl group by oxidizing it with hydrogen peroxide. The exchange reaction can be carried out by reacting one mole of the compound
30 having a lower alkylthio or lower alkylsulfinyl group on the phenyl ring with 30 moles of hydrogen peroxide in a solvent (e.g. acetic acid). The reaction is advantageously carried out at a temperature of 70 to 80 °C for about one hour.

Exchange Reaction-11

- 35 Introduction of phenylthio group onto an unsaturated heterocyclic group can be done by reacting a compound having an unsaturated heterocyclic group with a halogenothiobenzene. The reaction can be carried out by reacting one mole of the compound having an unsaturated heterocyclic group with about 1.2 mole of a halogenothiobenzene which is prepared by reacting mercaptobenzene and an N-halogenated
40 succinimide (e.g. N-chlorosuccinimide, N-bromosuccinimide, etc.), in an aprotic solvent (e.g. N,N-dimethylformamide, N,N-dimethylacetamide, etc.). The reaction is advantageously carried out at a temperature from 0 °C to room temperature for 2 hours.


Exchange Reaction-12

- 45 Introduction of the group:



- 50 (wherein R⁴ and R⁵ are as defined above) onto the phenyl ring can be done by introducing sulfonic group onto the phenyl ring by reacting a compound having a phenyl group with a halogenosulfonic acid and subjecting the resultant to a conventional amido bond forming reaction. The halogenosulfonic acid used in the above reaction includes chlorosulfonic acid and bromosulfonic acid. The above reaction can advantageously be carried out by reacting one mole of a compound having a phenyl group with 20 to 25 moles of a

halogenosulfonic acid at 80 °C for 1 to 3 hours, by which chlorosulfonyl group is introduced onto the phenyl ring, and then reacting the resultant with an amine of the formula:



- (wherein R⁴ and R⁵ are as defined above) without using a solvent or in the presence of an organic basic compound (e.g. pyridine, triethylamine) at a temperature of 50 to 100 °C for 2 to 15 hours

Exchange Reaction-13


- Introduction of a halogen atom onto the phenyl ring can be done by a conventional halogenation reaction. The halogenation reaction can be done by reacting one mole of a compound having a phenyl group with 5 moles of a halogen molecule in a solvent such as an aromatic compound (e.g. nitrobenzene, chlorobenzene, bromobenzene). The reaction is advantageously carried out in the presence or absence of a catalyst (e.g. aluminum chloride) at a temperature of 50 to 60 °C for 4 hours.

- Besides, when a compound having a phenylthio group on the phenyl ring is subjected to the above-mentioned halogenation reaction at room temperature for 12 hours, the compound having a phenylthio group on the phenyl ring can be converted into a compound having a halogen-substituted phenylthio group on the phenyl ring.

- Moreover, when a compound having an unsaturated heterocyclic group is subjected to the above-mentioned halogenation reaction at room temperature for one hour, a halogen atom can be introduced onto the unsaturated heterocyclic group of the compound having an unsaturated heterocyclic group.

The starting compounds of the formulae (2) and (3) in the Reaction Scheme-1 hereinabove can be prepared by processes of the following reaction schemes.

Reaction Scheme-3



- wherein R³ is as defined above.


The above process comprises reacting an acetonitrile compound (4) with a formate to obtain a compound (5) and then reacting the compound (5) with a semicarbazide mineral acid salt (e.g. semicarbazide hydrochloride, semicarbazide sulfate) to obtain the compound (2).

- The reaction of the compound (4) and a formate can be carried out in a solvent which does not affect on the reaction, such as aromatic hydrocarbons (e.g. benzene, toluene, xylene), N,N-dimethylformamide and dimethylsulfoxide. The formate includes methyl formate, ethyl formate, etc. and is used in an amount of at least 1 mole, preferably 1.05 to 1.25 mole, per 1 mol⁻ of the compound (4). The reaction is preferably carried out by reacting firstly under ice cooling for 5 to 20 minutes and then at room temperature for 4 to 12 hours. Besides, the reaction is preferably done in the presence of a sodium alkoxide (e.g. sodium methoxide, etc.) in at least equimolar amount to that of the formate. After the reaction, water is added to the reaction mixture, and the aqueous layer is separated and regulated to pH 3 to 4 with a mineral acid (e.g. hydrochloric acid) to precipitate the compound (5).


To the compound (5) thus obtained is added dropwise at least equimolar amount, preferably 1 to 1.2 mole, of a semicarbazide mineral acid salt under ice cooling, and the mixture is reacted at room temperature for 4 to 15 hours to give the compound (2). The reaction is carried out in a solvent which does not affect on the reaction, for example, a lower alcohol (e.g. methanol, ethanol), or a mixture of the lower alcohol with water in a mixed ratio of 1 : 1 to 10 : 1.

The starting compound (4) in the above Reaction Scheme-3 can be prepared by processes as shown in the following Reaction Schemes-4 to -9.


Reaction Scheme-4




wherein X is as defined above, R^7 is a lower alkyl, a halogen-substituted lower alkyl, or a phenyl which may optionally have one to three substituents selected from a halogen atom, a lower alkyl and a lower alkoxy, R^8 is a substituent selected from the group consisting of (i) a lower alkyl, (ii) phenyl, (iii) a lower alkoxycarbonyl, (iv) cyano, (v) nitro, (vi) a lower alkoxy, (vii) a phenyl-lower alkoxy, (viii) a phenylthio-lower alkyl, (ix) phenoxy, (x) a group of the formula:



(wherein R and l are as defined above), (xi) a halogen atom, (xii) a phenyl-lower alkyl, (xiii) carboxy, (xiv) a lower alkanoyl, (xv) a benzoyl which may optionally have one to three substituents selected from a halogen atom, a phenyl-lower alkoxy and hydroxy on the phenyl ring, (xvi) amino, (xvii) hydroxy, (xviii) a lower alkanoyloxy, (xix) a group of the formula:



(wherein R^4 and R^5 are as defined above), (xx) a group of the formula:



(wherein A is as defined above), or (xxi) hydrogen atom, and m is an integer of 1 or 2.


The compound (11) can be obtained by reacting the compound (9) with the compound (10) in the presence of a basic compound in an inert solvent. The inert solvent includes any solvent which does not affect on the reaction, for example, water, lower alcohols (e.g. methanol, ethanol, propanol), aprotic polar solvents such as N,N-dimethylformamide, N,N-dimethylacetamide, hexamethylphosphoric triamide, and a

mixture of these solvents. The basic compound includes, for example, alkali metal hydroxides (e.g. sodium hydroxide, potassium hydroxide), alkali metal carbonates (e.g. sodium carbonate, potassium carbonate, alkali metal hydrogen carbonates (e.g. sodium hydrogen carbonate, potassium hydrogen carbonate), alkali metal alkoxides (e.g. sodium methoxide, sodium ethoxide), which may be used alone or in combination of two or more thereof.

The compound (10) is usually used in at least equimolar amount, preferably in an excess amount, to that of the compound (9). The basic compound is used in an amount of at least two moles, preferably in an excess amount, to 1 mole of the compound (9) in order to form a salt of the compound (9) and the compound (10). The reaction is usually carried out at a temperature from room temperature to 180 °C for 30 minutes to 24 hours, by which the desired compound can be obtained in approximately quantitative yield.

The compound (11) wherein R⁸ is nitro can be converted into a compound (11) wherein R⁸ is amino by subjecting it to a conventional reducing reaction for converting nitro group into amino group. The compound having amino group thus obtained can also be converted into a compound wherein R⁸ is hydroxy group by subjecting it to Sandmeyer type reaction,

Reaction Scheme-5




wherein R⁵, R⁷, R⁸ and m are as defined above

The ester compound (12) can be prepared by subjecting the compound (11) to a conventional esterification reaction

The esterification reaction is carried out, for example, by reacting the compound (11) with an alcohol of the formula: R⁶-OH (wherein R⁶ is as defined above) in the presence of a catalyst which is usually used in an esterification reaction. Suitable examples of the catalyst are inorganic acids (e.g. hydrochloric acid, conc. sulfuric acid, phosphoric acid, polyphosphoric acid, trifluoroboron, perchlorinate), organic acids (e.g. trifluoroacetic acid, trichloromethanesulfonic acid, naphthalenesulfonic acid, p-toluenesulfonic acid, benzenesulfonic acid, ethanesulfonic acid), acid anhydrides (e.g. trichloromethanesulfonic anhydride, trifluoromethanesulfonic anhydride) and thionyl chloride. Cationic exchange resins (acid type) can also be used. The above esterification reaction can be carried out in a solvent or without using any solvent. The solvent includes any solvent which is usually used in the esterification reaction, for example, aromatic hydrocarbons (e.g. benzene, toluene, xylene), halogenated hydrocarbons (e.g. dichloromethane, dichloroethane, chloroform) and ethers (e.g. diethyl ether, tetrahydrofuran, dioxane). The acid is usually used in an amount of 1 to 100 moles, preferably 10 to 30 moles, per 1 mole of the compound (11). The reaction is usually carried out at a temperature of -20 °C to 200 °C, preferably 0 to 150 °C.

The compound (12) can also be obtained by reacting an alkali metal salt (e.g. sodium salt, potassium salt) of the compound (11) with a halide compound of the formula: R⁶-X (wherein R⁶ and X are as defined above); by reacting the compound (11) with a diazoalkane (e.g. diazomethane, diazoethane, diazopropane); by converting the compound (11) into a reactive derivative at the carboxy group thereof and then reacting it with an alcohol of the formula: R⁶-OH (wherein R⁶ is as defined above). These reactions can be carried out in usual manner.

Reaction Scheme- 6




wherein R^6 and R^7 are as defined above, and R^9 is a lower alkyl.

15 The compound (14) can be prepared by alkylating the compound (13). The reaction can be carried out by a conventional alkylation reaction which is usually used in the alkylation of a phenolic hydroxy group, for example, by reacting the compound (13) with a di(lower)alkyl sulfate (e.g. dimethyl sulfate, diethyl sulfate), a lower alkyl halide (e.g. methyl iodide, methyl bromide, ethyl iodide, ethyl bromide, propyl iodide) and a diazo(lower)alkane (e.g. diazomethane, diazoethane).

20 In case of the above reaction using a di-(lower)alkyl sulfate, the reaction is usually carried out by reacting the compound (13) with an equimolar amount of the di-(lower)alkyl sulfate in an inert solvent (e.g. a lower alcohol such as methanol, ethanol, acetone) at a temperature from 50°C to a boiling point of the solvent for 3 to 10 hours, preferably for 6 hours. The reaction is preferably carried out in the presence of a basic compound in order to promote the reaction rate by forming a salt of the compound (13) and further to neutralize the mono(lower)alkyl sulfate produced by the reaction. The basic compound includes the basic compounds mentioned in the above Reaction Scheme-8 and is used in an equimolar amount, preferably in excess amount, to that of the compound (13).

Reaction Scheme- 7



wherein R^6 , R^7 , R^8 , X and m are as defined above.


55 The compound (12) can be converted into the compound (15) by subjecting it to a conventional reducing reaction with a metal halide reducing agent (e.g. lithium aluminum hydride, aluminum hydride, diisopropylaluminum hydride, lithium borohydride, sodium borohydride-aluminum chloride, diborane). The reducing reaction can be carried out in a solvent such as ethers (e.g. diethyl ether, tetrahydrofuran, dioxane, diglyme), aliphatic hydrocarbons (e.g. hexane, heptane) and aromatic hydrocarbons (e.g. benzene, toluene). The hydrogenation reducing agent is used in an amount of at least 0.5 mole, preferably 0.6 to 1.2 mole, per

1 mole of the compound (12). The reaction is usually carried out at a temperature from ice cooling to 100°C, preferably 0 to 50°C, for 30 minutes to 10 hours.

The compound (16) can be obtained by reacting the compound (15) with a halogenating agent in a suitable solvent or without using any solvent. The solvent includes ethers (e.g. diethyl ether, tetrahydrofuran, dioxane), halogenated hydrocarbons (e.g. methylene chloride, chloroform, dichloroethane) and aromatic hydrocarbons (e.g. benzene, toluene). The halogenating agent includes thionyl halides (e.g. thionyl chloride, thionyl bromide), hydrogen halides (e.g. hydrogen chloride, hydrogen bromide, hydrogen iodide) and phosphorus halides (e.g. phosphorus trichloride, phosphorus tribromide), which is used in an amount of at least 1 mole, preferably 1 - 1.3 mole, per 1 mole of the compound (15). The reaction is usually carried out at a temperature from ice cooling to 100°C, preferably 0 to 50°C, for 30 minutes to 5 hours.

The compound (17) can be obtained by reacting the compound (16) with a cyanide compound in a suitable solvent. The solvent includes lower alcohols (e.g. methanol, ethanol, propanol), aprotic polar solvents (e.g. N,N-dimethylformamide, dimethylsulfoxide, hexamethylphosphoric triamide), or a mixture of these solvents with water. The cyanide compound includes, for example, potassium cyanide, sodium cyanide, silver cyanide, copper cyanide and calcium cyanide, which is used in an amount of at least 1 mole, preferably 1 to 1.3 mole, per 1 mole of the compound (16). The above reaction is usually carried out at a temperature from room temperature to 150°C, preferably from room temperature to 100°C, for 1 to 20 hours.


Reaction Scheme- 8



wherein R^7 , R^8 and m are as defined above, X' is hydrogen atom or a halogen atom, and X'' is a halogen atom.

The above process comprises replacing the halogen atom (X'') in the compound (18) with a group: $-\text{SR}^7$ to obtain the compound (20). The reaction is carried out by preparing a Grignard reagent by adding an excess amount of magnesium to the compound (18) in an ether (e.g. diethyl ether, tetrahydrofuran) and reacting the produced Grignard reagent with a disulfide compound (19). The reaction for forming Grignard reagent is preferably carried out in the presence of a catalytic amount of an iodine compound (e.g. iodine, methyl iodide). The reaction of the Grignard reagent with the compound (19) is usually carried out at a temperature from room temperature to a boiling point of the solvent for 1 to 10 hours, wherein the compound (19) is used in an amount of at least 1 mole, preferably 1 to 1.2 mole, per 1 mole of the compound (18).

Reaction Scheme- 9



wherein R^7 , R^8 , X , X' and m are as defined above.

The above conversion of the compound (20) to the compound (21) can be carried out by subjecting the compound (20) to a halogenomethylation by a conventional halogenomethylation reaction. The reaction is carried out by reacting the compound (20) with a halogenomethylating agent in an inert solvent in the presence of a catalyst. The inert solvent includes halogenated hydrocarbons (e.g. methylene chloride, chloroform, dichloroethane, carbon tetrachloride) and carbon disulfide. The catalyst includes, for example, Lewis acids (e.g. aluminum chloride, iron chloride, zinc chloride, antimony pentachloride, tin tetrachloride, boron trifluoride), protonic acids (e.g. hydrogen fluoride, conc. sulfuric acid). The halogenomethylating agent includes, for example, chloromethyl methyl ether, bromomethyl methyl ether, dichloromethyl ether and dibromomethyl ether. The catalyst is used in an amount of 1 to 3 moles, preferably 2 moles, per 1 mole of the compound (20). The halogenomethylating agent is used in an amount of 1 to 3 moles, preferably 2 moles, per 1 mole of the compound (20). The above reaction is usually carried out at room temperature or an elevated temperature for 1 to 5 hours.

In the above reaction, the position of substitution of the halogenomethyl group varies depending on the kinds and numbers of the substituents of the compound (21), the electronic density and the steric hindrance of the replaceable carbon atom(s) on the benzene ring, and when the products are obtained in a mixture of two or more different compounds, they can be isolated and purified by a conventional purification method, such as distillation and column chromatography.


The reaction of converting the compound (21) into the compound (22) is carried out in the same manner as in the conversion of the compound (16) into the compound (17) in the above Reaction Scheme-11.

In case of the compound (4) wherein R^3 is a phenyl having one to three groups of $-S-R'$ (wherein R' is a lower alkyl, a halogen-substituted lower alkyl, or a phenyl which may have one to three substituents selected from a halogen atom, a lower alkyl and a lower alkoxy on the phenyl ring), the compound can be converted into a compound (4) wherein R^3 is a phenyl having one to three groups of $-SO-R'$ (wherein R' is as defined above) by oxidizing it in the same manner as in the above Conversion Reaction-9. In the reaction, when hydrogen peroxide is used as the oxidizing agent, it is used in an amount of 1 to 3 moles, preferably 1.5 to 2.5 moles, per 1 mole of the compound (4), and the reaction is carried out at room temperature for 4 to 24 hours, preferably 10 hours.

The compound (4) wherein R^3 is a phenyl having one to three groups of $-SO-R'$ (wherein R' is as defined above) obtained above can be converted into a compound (5) wherein R^3 is a phenyl having one to three groups of $-SO-R'$ (wherein R' is as defined above) by the same method as used in the conversion of the compound (4) into the compound (5) in the above Reaction Scheme-3. Moreover, the compound can be converted into the corresponding compound (2) by the same methods as in Reaction Scheme-3.

Besides, other inventors have reported that a diphenyl thioether compound useful as an intermediate for the preparation of the pyrazolotriazine compounds of the invention can also be prepared by the process as shown in the following Reaction Scheme-10:

Reaction Scheme- 10



wherein R''' is a lower alkyl or a lower alkoxy, and R'''' is a lower alkyl or a phenyl which may optionally be substituted by a lower alkyl.

The above reaction can be carried out by reacting 1 mole of the benzaldehyde compound (23) with at least 1 mole, preferably 1 to 3 moles, of thiophenol in an inert solvent at a temperature of 100 to 200 °C, preferably 130 to 160 °C, for 1 to 100 hours, preferably for 2 to 70 hours. The inert solvent includes any solvent which does not affect on the reaction, for example, N,N-dimethyl-formamide, dimethylsulfoxide, acetonitrile, N,N-dimethylacetamide, hexamethylphosphoric triamide, preferably N,N-dimethylformamide and hexamethylphosphoric triamide, which may be used alone or in combination of two or more thereof. The reaction is preferably carried out in the presence of a basic compound, for example, inorganic basic compounds such as alkali metal hydroxides (e.g. sodium hydroxide, potassium hydroxide), alkali metal or alkaline earth metal carbonates (e.g. sodium carbonate, potassium carbonate, calcium carbonate), or organic basic compounds such as pyridine, triethylamine, preferably pyridine and calcium carbonate, which may be used alone or in combination of two or more thereof, and further preferably carried out in an inert gas such as nitrogen gas, argon gas.

The compounds (1) which contain a basic group can easily be converted into a salt thereof by treating them with a pharmaceutically acceptable acid, and the compounds (1) which contain an acidic group can easily be converted into a salt thereof by treating them with a pharmaceutically acceptable base. The acid includes inorganic acids (e.g. hydrochloric acid, sulfuric acid, phosphoric acid, hydrobromic acid) and organic acids (e.g. oxalic acid, maleic acid, fumaric acid, malic acid, tartaric acid, citric acid, lactic acid, benzoic acid, acetic acid, p-toluenesulfonic acid, methanesulfonic acid, ethanesulfonic acid, propionic acid). The base includes alkali metal or alkaline earth metal hydroxides (e.g. sodium hydroxide, potassium hydroxide, calcium hydroxide) and alkali metal carbonates or hydrogen carbonates (e.g. sodium carbonate, sodium hydrogen carbonate, potassium hydrogen carbonate).

The salts of the compounds include also the intramolecular salts.

The compounds thus obtained can easily be isolated by conventional methods, such as extraction with solvents, dilution method, recrystallization, column chromatography and preparative thin layer chromatography.

The compounds (1) of this invention include also the optical isomers, which can easily be separated by a conventional optical resolution method, for example, by using an optical resolving agent.

The compounds of the present invention are usually used in the form of a usual pharmaceutical preparation. The pharmaceutical preparation can be prepared in admixture with conventional pharmaceutically acceptable diluents or carriers, such as fillers, bulking agents, binding agents, wetting agents, disintegrators, surfactants, lubricating agents, and the like. The pharmaceutical preparation includes various preparations suitable for treatment of the diseases, for example, tablets, pills, powders, solutions, suspensions, emulsions, granules, capsules, suppositories and injections (solutions, suspensions). In the preparation of tablets, there may be used any conventional carriers, for example, excipients (e.g. lactose, white sugar, sodium chloride, glucose, urea, starches, calcium carbonate, kaolin, crystalline cellulose, silicate), binding agents (e.g. water, ethanol, propanol, simple syrup, glucose solution, starch solution, gelatin solution, carboxymethyl cellulose, shellac, methyl cellulose, potassium phosphate, polyvinylpyrrolidone), disintegrators (e.g. dry starch, sodium alginate, agar powder, laminaran powder, sodium hydrogen carbonate, calcium carbonate, polyoxyethylene sorbitan fatty acid esters, sodium laurylsulfate, stearic monoglyceride, starches, lactose), disintegration inhibitors (e.g. white sugar, stearin, cacao butter, hydrogenated oils), absorption promoters (e.g. quaternary ammonium salts, sodium laurylsulfate), wetting agents (e.g. glycerin, starches), adsorbents (e.g. starches, lactose, kaolin, bentonite, colloidal silicates) and lubricants (e.g. purified talc, stearates, boric acid powder, polyethylene glycol). The tablets may also be coated with conventional coating agents, for example, may be in the form of a sugar coated tablet, a gelatin-coated tablets, an enteric coating tablet, a film coating tablet, or a double or multiple layers tablet. In the preparation of pills, there may be used conventional carriers, such as excipients (e.g. glucose, lactose, starches, cacao butter, hydrogenated vegetable oils, kaolin, talc), binding agents (e.g. gum arabic powder, tragacanth powder, gelatin, ethanol) and disintegrators (e.g. laminaran, agar). In the preparation of suppositories, there may be used conventional carriers, such as polyethylene glycol, cacao butter, higher alcohols, higher alcohol esters, gelatin and semi-synthesized glycerides. In the preparation of injections, the solutions, emulsions or suspensions of the compounds are sterilized and are preferably made isotonic with the body liquid. These solutions, emulsions and suspensions are prepared by admixing the active compound with a conventional diluent, such as water, aqueous lactic acid solution, ethyl alcohol, propylene glycol, ethoxylated isostearyl alcohol, polyoxylated isostearyl alcohol and polyoxyethylene sorbitan fatty acid esters. The preparations may also be incorporated with sodium chloride, glucose or glycerin in an amount sufficient to make them isotonic with the body liquid. The preparations may also be incorporated with conventional solubilizers, buffering agents, anesthetizing agents, and further, with coloring agents, preservatives, perfumes, flavors, sweetening agents, and other medicaments. The preparations in the form of a paste,

cream or gel may be prepared by using as a diluent white vaseline, paraffin, glycerin, cellulose derivatives, polyethylene glycol, silicon or bentonite.

The active compounds (1) or salts thereof may be contained in any amount in the preparations, and are usually contained in an amount of 1 to 70 % by weight based on the whole weight of the preparations.

5 The pharmaceutical preparations of the present invention can be administered in any methods. Suitable method for administration may be selected in accordance with the preparation form, age and sex of the patients and degree of severity of the diseases. For instance, tablets, pills, solutions, suspensions, emulsions, granules and capsules are administered in oral route. In case of injection, it is administered intravenously alone or together with an auxiliary liquid (e.g. glucose, amino acid solution). The injections
10 may also be administered in intramuscular, intracutaneous, subcutaneous, or intraperitoneal route. Suppositories are administered in intrarectal route.

The dosage of the pharmaceutical preparations of the present invention may vary according to administration methods, age and sex of the patients and severity of the diseases, but is usually in the range of 1 to 100 mg, preferably 5 to 20 mg, of the active compound (1) or a salt thereof per 1 kg of body weight
15 of the patient per day. The preparation is usually administered by dividing into 2 to 4 times per day.

The present invention is illustrated by the following Reference Examples, Examples, Preparations, and Experiments.

Reference Example 1

20 (1) A mixture of 4-chloro-3-nitrobenzoic acid (241.88 g), sodium hydrogen carbonate (100.80 g) and 50 % aqueous methanol (90 ml) is stirred under nitrogen at room temperature, and thereto is added in order thiophenol (128.35 ml) and a solution of sodium hydroxide (49.6 g) in 50 % aqueous methanol (200 ml).
25 After the addition is completed, the mixture is refluxed under nitrogen atmosphere for one hour. After the reaction is completed, the reaction mixture is cooled with ice water and then adjusted to pH 2-3 with conc. hydrochloric acid. The resulting yellow precipitate is separated by filtration and washed with water to give 3-nitro-4-phenylthiobenzoic acid. This product is used in the subsequent reaction without further purification.

30 (2) To a mixture of the 3-nitro-4-phenylthiobenzoic acid obtained above, iron powder (201.0 g) and 50 % aqueous ethanol (800 ml) is added gradually with stirring a solution of conc. hydrochloric acid (20 ml) in ethanol (40 ml) under reflux. The mixture is refluxed with stirring for 15 hours, and the reaction mixture is cooled. The precipitate is separated by filtration and washed with water. To the precipitate are added sodium hydroxide (50 g) and water (1.95 liter), and the mixture is heated to dissolve them. Insoluble
35 materials are removed by filtration, and the filtrate is adjusted to pH 2-3 with diluted sulfuric acid under ice cooling. The precipitate is separated by filtration, washed with water and dried to give 3-amino-4-phenylthiobenzoic acid (218.28 g).

(3) 3-Amino-4-phenylthiobenzoic acid (110.27 g) is added to a heated solution of conc. sulfuric acid (81 ml) in water (400 ml), and the mixture is heated with stirring for 2 hours and then cooled to -5 °C with an ice-sodium chloride bath. To the mixture is added a solution of sodium nitrite (36.25 g) in water (80 ml)
40 which is previously ice-cooled over a period of one hour. The mixture is further stirred at 0-5 °C for 30 minutes. To the mixture is added urea (2 g), and the mixture is stirred for 30 minutes to decompose the unreacted nitrous acid. The resulting mixture is gradually added with stirring to a mixture of conc. sulfuric acid (121 ml), anhydrous sodium sulfate (168 g) and water (112 ml) at 100 - 110 °C over a period of one hour and 15 minutes. After the addition, the mixture is stirred at the same temperature for one hour. The
45 reaction mixture is cooled, and the resulting brown granular precipitate is separated by filtration, washed with water, and dried at 50 °C overnight. The product is added to a mixture of methanol (1.4 liter) and conc. sulfuric acid (70 ml), and the mixture is refluxed with stirring for 2 hours. After the reaction is completed, the reaction mixture is concentrated under reduced pressure, and to the residue is added water (1.5 liter), and the mixture is extracted with ethyl acetate (500 ml x 3). The combined extracts are
50 dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue is extracted with heated hexane (4.2 liter), and the extract is cooled. The resulting yellow precipitate is separated by filtration to give methyl 3-hydroxy-4-phenylthiobenzoate (49.37 g).

NMR (CDCl₃) δ: 7.13-7.71 (m, 8H), 6.47 (bs, 1H), 3.92 (s, 3H).

55 Reference Example 2

To a mixture of methyl 3-hydroxy-4-phenylthiobenzoate (49.11 g), potassium carbonate (27.33 g) and acetone (627 ml) is added dimethyl sulfate (17.85 ml), and the mixture is refluxed with stirring for 6 hours.

The reaction mixture is cooled, and the precipitate is separated by filtration and washed with acetone. The filtrate and washings are combined and concentrated under reduced pressure to give methyl 3-methoxy-4-phenylthiobenzoate.

NMR (CDCl₃) δ: 7.35-7.51 (m, 7H), 6.79 (d, J=8.57 Hz, 1H), 3.96 (s, 3H), 3.88 (s, 3H)

Reference Example 3

(1) To a solution of methyl 3-methoxy-4-phenylthiobenzoate (30.67 g) in dry diethyl ether (744 ml) is added gradually with stirring lithium aluminum hydride (4.32 g) under cooling. The mixture is stirred for one hour, and to the reaction mixture are added in order ethyl acetate, methanol and water, and the unreacted lithium aluminum hydride is decomposed. The organic layer is separated, and the aqueous layer is extracted with ethyl acetate (300 ml x 2). The filtrates are combined with above organic layer and washed with saturated aqueous sodium chloride solution (300 ml x 2), dried over anhydrous sodium sulfate and then concentrated under reduced pressure to give 1-hydroxymethyl-3-methoxy-4-phenylthiobenzene.

NMR (CDCl₃) δ: 7.20-7.37 (m, 5H), 7.04 (d, J=7.69 Hz, 1H), 6.95 (bs, 1H), 6.84 (bd, J=7.91 Hz, 1H), 4.68 (s, 2H), 3.87 (s, 3H)

(2) The 1-hydroxymethyl-3-methoxy-4-phenylthiobenzene obtained above is dissolved in methylene chloride (372 ml), and thereto is added with stirring thionyl chloride (9.12 ml) under ice cooling. The mixture is stirred for one hour, and the reaction mixture is washed with ice water (500 ml x 2), and thereto is added ethyl acetate (500 ml). The mixture is washed in order with 5 % aqueous sodium hydrogen carbonate solution (20 ml), water (200 ml) and saturated aqueous sodium chloride solution (200 ml x 2), dried over anhydrous sodium sulfate, and concentrated under reduced pressure to give 1-chloromethyl-3-methoxy-4-phenylthiobenzene.

NMR (CDCl₃) δ: 7.25-7.32 (m, 5H), 6.89-6.94 (m, 3H), 4.55 (s, 2H), 3.89 (s, 3H)

(3) The 1-chloromethyl-3-methoxy-4-phenylthiobenzene obtained above is dissolved in N,N-dimethylformamide (200 ml), and thereto is added finely divided sodium cyanide (7.34 g), and the mixture is stirred at 30 °C for 14 hours. To the reaction mixture are added saturated aqueous sodium chloride solution (300 ml) and ice water (300 ml), and the mixture is extracted with ethyl acetate (300 ml x 3). The combined extracts are washed with saturated aqueous sodium chloride solution (200 ml x 3) and dried over anhydrous sodium sulfate to give 1-cyanomethyl-3-methoxy-4-phenylthiobenzene.

NMR (CDCl₃) δ: 7.25-7.41 (m, 5H), 7.01 (d, J=7.70 Hz, 1H), 6.83 (s, 1H), 6.79 (d, J=7.47 Hz, 1H), 3.89 (s, 3H), 3.72 (s, 2H)

Reference Example 4

A solution of potassium hydroxide (20.86 g) in N,N-dimethylacetamide (70 ml) is heated to 150 °C, and thereto are added with stirring thiophenol (19.52 ml) and 4-bromobenzoic acid (25.47 g) under nitrogen atmosphere at the same temperature. The mixture is refluxed under nitrogen atmosphere for 20 hours. The reaction mixture is poured into ice water (400 ml), and the mixture is washed with benzene (400 ml), and the aqueous layer is separated. The benzene layer is further extracted with 2.5N sodium hydroxide solution (100 ml x 4). The extracts are combined with the above aqueous layer and adjusted to pH 1-2 with conc hydrochloric acid. The resulting precipitate is separated by filtration, washed with water and dried to give 4-phenylthiobenzoic acid (26.29 g).

NMR (DMSO-d₆) δ: 7.95 (d, J=8.57 Hz, 2H), 7.34-7.48 (m, 5H), 7.20 (d, J=8.57 Hz, 2H)

Reference Example 5

A mixture of 4-phenylthiobenzoic acid (26.29 g), conc. sulfuric acid (5 ml) and methanol (400 ml) is refluxed with stirring for 10 hours. After the reaction is completed, the reaction mixture is concentrated under reduced pressure, and to the residue is added ethyl acetate (400 ml). The mixture is washed with saturated aqueous sodium chloride solution (200 ml x 3), dried over anhydrous magnesium sulfate, and concentrated under reduced pressure to give methyl 4-phenylthiobenzoate (27.44 g).

NMR (CDCl₃) δ: 7.89 (d, J=8.58 Hz, 2H), 7.32-7.53 (m, 5H), 7.20 (d, J=8.79 Hz, 2H), 3.88 (s, 3H)

Reference Example 6

(1) To a solution of methyl 4-phenylthiobenzoate (27 g) in dry diethyl ether (500 ml) is added gradually with stirring lithium aluminum hydride (2.5 g) under ice cooling. The mixture is stirred for one hour, and to the reaction mixture are added in order ethyl acetate and water, and the unreacted lithium aluminum hydride is decomposed. The organic layer is separated, and the aqueous layer is extracted with ethyl acetate (100 ml x 2). The filtrates are combined with above organic layer and washed with saturated aqueous sodium chloride solution (100 ml x 2), dried over anhydrous sodium sulfate and then concentrated under reduced pressure to give 1-hydroxymethyl-4-phenylthiobenzene (25 g).

NMR (CDCl₃) δ: 7.19-7.40 (m, 9H), 4.67 (s, 2H)

(2) The 1-hydroxymethyl-4-phenylthiobenzene (3.0 g) is dissolved in methylene chloride (15 ml), and thereto is added with stirring thionyl chloride (1.5 ml) under ice cooling. The mixture is stirred for one hour, and the reaction mixture is washed with ice water (10 ml x 3), and thereto is added methylene chloride (50 ml). The mixture is washed in order with 5 % aqueous sodium hydrogen carbonate solution (5 ml x 3) and saturated aqueous sodium chloride solution (30 ml x 2), dried over anhydrous sodium sulfate, and concentrated under reduced pressure to give 1-chloromethyl-4-phenylthiobenzene (3.0 g).

NMR (CDCl₃) δ: 7.25-7.35 (m, 9H), 4.54 (s, 2H)

(3) The 1-chloromethyl-4-phenylthiobenzene (3.0 g) is dissolved in N,N-dimethylformamide (15 ml), and thereto is added finely divided sodium cyanide (1.0 g), and the mixture is stirred at room temperature for 17 hours. To the reaction mixture are added saturated aqueous sodium chloride solution (50 ml) and ice water (50 ml), and the mixture is extracted with ethyl acetate (100 ml x 3). The combined extracts are washed with saturated aqueous sodium chloride solution (50 ml x 3), dried over anhydrous sodium sulfate and concentrated under reduced pressure to give 1-cyanomethyl-4-phenylthiobenzene (2.9 g).

NMR (CDCl₃) δ: 7.29-7.38 (m, 9H), 3.71 (s, 2H)

Reference Example 7

Potassium hydroxide (1.368 g) is dissolved in N,N-dimethylacetamide (20 ml) with heating, and thereto is added thiophenol (1.16 ml) under nitrogen atmosphere. To the mixture is added 4-chloro-3-methylbenzoic acid, and the mixture is refluxed under nitrogen atmosphere for 2 days. After the reaction is completed, the reaction mixture is cooled and poured into ice water (100 ml), and the mixture is washed with benzene (50 ml) and the aqueous layer is separated. The benzene layer is further extracted with 5 % aqueous sodium hydroxide solution (50 ml), and the extract is combined with the above aqueous layer and adjusted to pH 2-3 with hydrochloric acid. The resulting precipitate is separated by filtration, washed with water, and dried to give 3-methyl-4-phenylthiobenzoic acid (1.55 g).

Reference Example 8

A mixture of 3-methyl-4-phenylthiobenzoic acid (85 g), conc. sulfuric acid (20 ml) and methanol (1.2 liter) is refluxed with stirring for 4 hours. After the reaction is completed, the reaction mixture is concentrated under reduced pressure. To the residue is added ethyl acetate (1.5 liter), and the mixture is washed with saturated aqueous sodium chloride solution (400 ml x 3), dried over anhydrous sodium sulfate and concentrated under reduced pressure to give methyl 3-methyl-4-phenylthiobenzoate (80.33 g).

NMR (CDCl₃) δ: 7.85 (bs, 1H), 7.70 (bd, J=8.13 Hz, 1H), 7.37 (bs, 5H), 7.00 (d, J=8.13 Hz, 1H)

Reference Example 9

(1) To a solution of methyl 3-methyl-4-phenylthiobenzoate (80.33 g) in dry diethyl ether (900 ml) is added gradually with stirring lithium aluminum hydride (7.08 g) under ice cooling. The mixture is stirred for one hour, and to the reaction mixture are added in order ethyl acetate, methanol and water, and the unreacted lithium aluminum hydride is decomposed. The organic layer is separated, and the aqueous layer is extracted with ethyl acetate (300 ml x 2). The extracts are combined with above organic layer and washed with saturated aqueous sodium chloride solution (300 ml x 2), dried over anhydrous sodium sulfate and then concentrated under reduced pressure to give 1-hydroxymethyl-3-methyl-4-phenylthiobenzene.

NMR (CDCl₃) δ: 7.04-7.36 (m, 8H), 4.62 (s, 2H), 2.37 (s, 3H)

(2) The 1-hydroxymethyl-3-methyl-4-phenylthiobenzene obtained above is dissolved in methylene chloride (100 ml), and thereto is added with stirring thionyl chloride (23.34 ml) under ice cooling. The mixture is stirred for one hour, and the reaction mixture is washed with ice water (100 ml x 3), and thereto is added ethyl acetate (500 ml). The mixture is washed in order with 5 % aqueous sodium hydrogen carbonate solution (50 ml x 4) and saturated aqueous sodium chloride solution (100 ml x 2), dried over anhydrous sodium sulfate and concentrated under reduced pressure to give 1-chloromethyl-3-methyl-4-phenylthiobenzene.

NMR (CDCl₃) δ: 7.16-7.25 (m, 8H), 4.53 (s, 2H), 2.37 (s, 3H)

(3) The 1-chloromethyl-3-methyl-4-phenylthiobenzene obtained above is dissolved in N,N-dimethylformamide (56 ml), and thereto is added finely divided sodium cyanide (18.16 g), and the mixture is stirred at room temperature overnight. To the reaction mixture are added saturated aqueous sodium chloride solution (300 ml) and ice water (300 ml), and the mixture is extracted with ethyl acetate (300 ml x 3). The combined extracts are washed with saturated aqueous sodium chloride solution (200 ml x 3), dried over anhydrous sodium sulfate and concentrated under reduced pressure to give 1-cyanomethyl-3-methyl-4-phenylthiobenzene (45.95 g).

NMR (CDCl₃) δ: 7.10-7.37 (m, 8H), 3.69 (s, 2H), 2.38 (s, 3H)

Reference Example 10

To a solution of 2-bromo-4-fluorotoluene (45 g) in dry diethyl ether (500 ml) is added magnesium (for Grignard reagent, 7 g), and the mixture is refluxed with stirring. To the reaction mixture is added methyl iodide (1 ml), by which the reaction initiates vigorously, and then the mixture is stirred for 30 minutes after taking off the heating bath. Thereafter, the reaction becomes mild, and then the reaction mixture is refluxed for 30 minutes. After allowing to cool, dimethyl disulfide (24 ml) is added to the reaction mixture, and the mixture is refluxed for 3 hours. After allowing to cool, water and 10 % hydrochloric acid are added to the reaction mixture, and the mixture is extracted with diethyl ether. The extract is washed with water (500 ml x 3), dried over anhydrous sodium sulfate and then the solvent is distilled off. The resulting residue is distilled under reduced pressure to give 4-fluoro-2-methylthiotoluene (30 g).

b.p. at 20 mbar (15 mmHg): 95 °C

NMR (CDCl₃) δ: 6.60-7.14 (m, 3H), 2.45 (s, 3H), 2.27 (s, 3H)

Reference Example 11

To a suspension of aluminum chloride (29 g) in carbon disulfide (300 ml) is added chloromethyl methyl ether (17 ml), and the mixture is stirred for 30 minutes. To the mixture is added 4-fluoro-2-methylthiotoluene (17.2 g), and the mixture is stirred at room temperature for 2 hours. To the reaction mixture is added water, and the mixture is extracted with diethyl ether. The extract is washed with water, dried over anhydrous sodium sulfate, and concentrated under reduced pressure to give 5-chloromethyl-4-fluoro-2-methylthiotoluene (21 g).

NMR (CDCl₃) δ: 7.30 (d, J = 9.0 Hz, 1H), 7.13 (d, J = 8.0 Hz, 1H), 6.83 (d, J = 10.5 Hz, 1H), 4.57 (s, 2H), 2.45 (s, 3H), 2.26 (s, 3H)

Reference Example 12

5-Chloromethyl-4-fluoro-2-methylthiotoluene (21 g) is dissolved in N,N-dimethylformamide (90 ml), and thereto is added finely divided sodium cyanide (6.03 g), and the mixture is stirred at room temperature for 18 hours. To the reaction mixture are added saturated aqueous sodium chloride solution (300 ml) and ice water (300 ml), and the mixture is extracted with ethyl acetate (300 ml x 3). The combined extracts are washed with saturated aqueous sodium chloride solution (200 ml x 3), dried over anhydrous sodium sulfate and concentrated under reduced pressure to give 5-cyano-methyl-4-fluoro-2-methylthiotoluene.

NMR (CDCl₃) δ: 7.30 (d, J = 9.0 Hz, 1H), 7.14 (d, J = 8.0 Hz, 1H), 6.85 (d, J = 10.5 Hz, 1H), 3.68 (s, 2H), 2.45 (s, 3H), 2.27 (s, 3H)

Reference Example 13

To a suspension of sodium methoxide (5.56 g) in benzene (200 ml) is added dropwise with stirring a mixture of ethyl formate (8.14 g) and phenylacetonitrile (11.7 g) under ice cooling. After 30 minutes, the ice bath is taken off. After reacting for 3 hours, ice water is added to the reaction mixture, and the aqueous

layer is separated. The organic layer is washed with 0.5 N sodium hydroxide solution (50 ml x 3), and the aqueous layer and the washings are combined and adjusted to pH 3-4 with conc. hydrochloric acid. The mixture is stirred under ice cooling for 20 minutes, and the resulting precipitate is separated by filtration and washed with water to give α -formylphenylacetoneitrile. The product is used in the subsequent procedure without further purification.

The α -formylphenylacetoneitrile obtained above is dissolved in methanol-water (1 : 1 - 10 : 1, 200 ml), and to the solution is added with stirring semicarbazide hydrochloride (9.95 g) under ice cooling. After taking off the ice bath, the mixture is reacted for 12 hours. The reaction mixture is neutralized with 5N sodium hydroxide solution. The mixture is stirred for 20 minutes, and the resulting precipitate is separated by filtration, washed with water and dried to give 3-amino-2-carbamoyl-4-phenylpyrazole (16.82 g). This product is used in the subsequent procedure without purification.

Reference Example 14

To a suspension of sodium methoxide (10.8 g) in benzene (300 ml) is added dropwise with stirring a mixture of ethyl formate (16.28 g) and phenylacetoneitrile (23.4 g) under ice cooling. After 30 minutes, the ice bath is taken off. After reacting for 3 hours, ice water is added to the reaction mixture, and the aqueous layer is separated. The organic layer is washed with 0.5 N sodium hydroxide solution (100 ml x 3), and the aqueous layer and the washings are combined and adjusted to pH 3-4 with conc. hydrochloric acid. The mixture is stirred under ice cooling for 20 minutes, and the resulting precipitate is separated by filtration and washed with water to give α -formylphenylacetoneitrile (21.13 g). The product is used in the subsequent procedure without further purification.

A mixture of the α -formylphenylacetoneitrile (18.85 g) obtained above, hydrazine hydrate (8.46 g), acetic acid (16.9 ml) and benzene (200 ml) is refluxed while azeotropically dehydrating. After reacting for 2 hours, the reaction mixture is cooled and washed with 6 N hydrochloric acid (28.5 ml and 12.7 ml x 2). The washing liquids are combined and are neutralized with 28 % aqueous ammonia. The mixture is stirred for 20 minutes, and the resulting precipitate is separated by filtration, washed with water and dried to give 3-amino-4-phenylpyrazole (15.16 g). This product is used in the subsequent procedure without further purification.

To a suspension of 3-amino-4-phenylpyrazole (3.97 g) in ethyl acetate (15 ml) - benzene (75 ml) is added with stirring a solution of ethoxycarbonyl isothiocyanate (3.28 g) in benzene (25 ml) under cooling at 5°C. After the cooling bath is taken off, the mixture is further stirred for 15 hours. The reaction mixture is concentrated under reduced pressure, and the residue is recrystallized from ethyl acetate to give N-carbethoxy-N'-[3-(4-phenyl)pyrazolyl]thiourea (3.34 g).

Example 1

4-Hydroxy-8-phenylpyrazolo[1,5-a]-1,3,5-triazine:

A mixture of 3-amino-2-carbamoyl-4-phenylpyrazole (4.8 g) and ethyl orthoformate (30 ml) is stirred at 100 - 110°C for 13 hours, and thereto is added methanol or ethyl acetate. The precipitate is separated by filtration, washed with methanol or ethyl acetate, and dried to give the title compound (2.08 g).

m.p. 292 - 299°C (decomp.)

NMR (DMSO- d_6) δ : 8.54 (s, 1H), 8.10 (s, 1H), 7.96-8.06 (m, 2H), 7.24-7.52 (m, 3H)

In the same manner as described in Example 1 by using appropriate starting materials, there are prepared the compounds in Examples 2 to 65.

Example 2

4-Hydroxy-8-(3-methylphenyl)pyrazolo[1,5-a]-1,3,5-triazine

m.p. 262.5 - 265.0°C

NMR (DMSO- d_6) δ : 8.55 (s, 1H), 8.12 (s, 1H), 7.85 (bs, 1H), 7.82 (d, J=8.40 Hz, 1H), 7.31 (t, J=8.40 Hz, 1H), 7.17 (d, J=9.01 Hz, 1H), 2.36 (s, 3H)

Example 3

4-Hydroxy-8-(4-methylphenyl)pyrazolo[1,5-a]-1,3,5-triazine

- 5 m.p. >300 °C
 NMR (DMSO-d₆) δ: 8.52 (s, 1H), 8.08 (s, 1H), 7.90 (d, J = 8.19 Hz, 2H), 7.22 (d, J = 8.19 Hz, 2H), 2.32 (s, 3H)

Example 4

- 10 8-(4-Ethylphenyl)-4-hydroxypyrazolo[1,5-a]-1,3,5-triazine

- m.p. >300 °C
 NMR (DMSO-d₆) δ: 8.54 (s, 1H), 8.09 (s, 1H), 7.92 (d, J = 8.4 Hz, 2H), 7.26 (d, J = 8.4 Hz, 2H), 2.56 (q, 15 J = 3.7 Hz, 2H), 1.20 (t, J = 3.7 Hz, 3H)

Example 5

- 20 8-(4-t-Butylphenyl)-4-hydroxypyrazolo[1,5-a]-1,3,5-triazine

- m.p. >300 °C
 NMR (DMSO-d₆) δ: 8.49 (s, 1H), 8.07 (s, 1H), 7.91 (d, J = 8.35 Hz, 2H), 7.42 (d, J = 8.35 Hz, 2H), 1.30 (s, 9H)

25 Example 6

8-p-Biphenyl-4-hydroxypyrazolo[1,5-a]-1,3,5-triazine

- 30 m.p. >300 °C
 NMR (DMSO-d₆) δ: 8.62 (s, 1H), 8.13 (s, 1H), 8.13 (d, J = 8.35 Hz, 2H), 7.73 (d, J = 8.35 Hz, 2H), 7.6-7.9 (m, 2H), 7.2-7.6 (m, 3H)

Example 7

- 35 4-Hydroxy-8-(3-methoxycarbonylphenyl)pyrazolo[1,5-a]-1,3,5-triazine

- m.p. 273 - 275 °C
 NMR (DMSO-d₆) δ: 8.65 (s, 2H), 8.24 (dt, J = 7.9 and 1.5 Hz, 1H), 8.18 (s, 1H), 7.86 (dt, J = 7.7 and 1.5 Hz, 1H), 7.57 (t, J = 7.7 Hz, 1H), 3.89 (s, 3H)

40

Example 8

8-(4-α,α-Ethylenedioxybenzylphenyl)-4-hydroxypyrazolo[1,5-a]-1,3,5-triazine

- 45 m.p. 291 - 291.5 °C (decomp.)
 NMR (DMSO-d₆) δ: 8.51 (s, 1H), 8.08 (s, 1H), 7.96 (d, J = 8.35 Hz, 2H), 7.26-7.51 (m, 7H), 4.00 (s, 4H)

Example 9

- 50 8-(4-Cyanophenyl)-4-hydroxypyrazolo[1,5-a]-1,3,5-triazine

- m.p. >300 °C
 NMR (DMSO-d₆) δ: 8.70 (s, 1H), 8.24 (d, J = 8.8 Hz, 2H), 8.18 (s, 1H), 7.87 (d, J = 8.8 Hz, 2H)

55

Example 10

4-Hydroxy-8-(3-nitrophenyl)pyrazolo[1,5-a]-1,3,5-triazine

5 m.p. 295 - 299 °C

NMR (DMSO-d₆) δ: 8.96 (t, J = 1.87, 1H), 8.73 (s, 1H), 8.42 (d, J = 7.91 Hz, 1H), 8.22 (s, 1H), 8.12 (dd, J = 7.03 and 2.30 Hz, 1H), 7.71 (t, J = 8.02 Hz, 1H)Example 11

10

4-Hydroxy-8-(2-methoxyphenyl)pyrazolo[1,5-a]-1,3,5-triazine

m.p. 298 - 299 °C (decomp.)

NMR (DMSO-d₆) δ: 8.44 (s, 1H), 8.03 (s, 1H), 8.0-8.1 (m, 1H), 6.91-7.37 (m, 3H)

15

Example 12

4-Hydroxy-8-(3-methoxyphenyl)pyrazolo[1,5-a]-1,3,5-triazine

20 m.p. 288 - 290 °C

NMR (DMSO-d₆) δ: 8.59 (s, 1H), 8.12 (s, 1H), 7.59-7.65 (m, 2H), 7.33 (t, J = 7.1 Hz, 1H), 6.84 (ddd, J = 7.0, 1.5 and 1.0 Hz, 1H), 3.81 (s, 3H)Example 13

25

4-Hydroxy-8-(4-methoxyphenyl)pyrazolo[1,5-a]-1,3,5-triazine

m.p. 297.5 - 305 °C

NMR (DMSO-d₆) δ: 8.48 (s, 1H), 8.06 (s, 1H), 7.92 (d, J = 9.01 Hz, 2H), 6.98 (d, J = 9.01 Hz, 2H), 3.78 (s, 3H)Example 14

35

8-(4-Benzyloxyphenyl)-4-hydroxypyrazolo[1,5-a]-1,3,5-triazine

m.p. >300 °C

NMR (DMSO-d₆) δ: 8.48 (s, 1H), 8.05 (s, 1H), 7.93 (d, J = 8.79 Hz, 2H), 7.33-7.42 (m, 5H), 7.07 (d, J = 8.79 Hz, 2H), 5.12 (s, 2H).40 Example 15

4-Hydroxy-8-(3-methylthiophenyl)pyrazolo[1,5-a]-1,3,5-triazine

m.p. 240 - 243 °C

NMR (DMSO-d₆) δ: 8.61 (s, 1H), 8.12 (s, 1H), 7.84 (t, J = 1.5 Hz, 1H), 7.80 (dt, J = 7.7 and 1.5 Hz, 1H), 7.37 (t, J = 7.7 Hz, 1H), 7.15 (dt, J = 7.7 and 1.4 Hz, 1H), 2.52 (s, 3H).Example 16

50 4-Hydroxy-8-(4-methylthiophenyl)pyrazolo[1,5-a]-1,3,5-triazine

m.p. >300 °C

NMR (DMSO-d₆) δ: 8.56 (s, 1H), 8.10 (s, 1H), 7.97 (d, J = 8.6 Hz, 2H), 7.32 (d, J = 8.6 Hz, 2H), 2.50 (s, 3H)

55

Example 17

8-(4-Ethylthiophenyl)-4-hydroxypyrazolo[1,5-a]-1,3,5-triazine

5 m.p. 288 - 289 °C

NMR (DMSO-d₆) δ: 8.56 (s, 1H), 8.11 (s, 1H), 7.98 (d, J = 8.6 Hz, 2H), 7.37 (d, J = 8.6 Hz, 2H), 3.00 (q, J = 7.4 Hz, 2H), 1.25 (t, J = 7.4 Hz, 3H)Example 18

10

8-(4-β-Chloroethylthiophenyl)-4-hydroxypyrazolo[1,5-a]-1,3,5-triazine

m.p. 249 °C (decomp.)

15 NMR (DMSO-d₆) δ: 8.58 (s, 1H), 8.11 (s, 1H), 8.00 (d, J = 8.6 Hz, 2H), 7.46 (d, J = 8.6 Hz, 2H), 3.68-3.85 (m, 2H), 3.20-3.43 (m, 2H)Example 19

4-Hydroxy-8-(4-phenylthiophenyl)pyrazolo[1,5-a]-1,3,5-triazine

20

m.p. 297 - 298 °C

NMR (DMSO-d₆) δ: 8.58 (s, 1H), 8.12 (s, 1H), 8.04 (d, J = 8.4 Hz, 2H), 7.41 (d, J = 8.5 Hz, 2H), 7.34 (s, 5H)25 Example 20

4-Hydroxy-8-[4-(2-methylphenylthio)phenyl]pyrazolo[1,5-a]-1,3,5-triazine

m.p. >300 °C

30 NMR (DMSO-d₆) δ: 8.55 (s, 1H), 8.10 (s, 1H), 8.00 (d, J = 8.35 Hz, 2H), 7.27 (d, J = 8.35 Hz, 2H), 7.20-8.29 (m, 4H)Example 21

35 4-Hydroxy-8-[4-(4-methylphenylthio)phenyl]pyrazolo[1,5-a]-1,3,5-triazine

m.p. >300 °C

40 NMR (DMSO-d₆) δ: 8.56 (s, 1H), 8.11 (s, 1H), 7.99 (d, J = 8.6 Hz, 2H), 7.32 (d, J = 8.6 Hz, 2H), 7.30 (t, J = 8.8 Hz, 2H), 7.18 (d, J = 8.8 Hz, 2H), 2.31 (s, 3H)Example 22

8-(2-Fluorophenyl)-4-hydroxypyrazolo[1,5-a]-1,3,5-triazine

45 m.p. 293 - 294 °C

NMR (DMSO-d₆) δ: 8.37 (d, J = 3.30 Hz, 1H), 8.14 (s, 1H), 8.11-8.24 (m, 1H), 7.22-7.40 (m, 3H)Example 23

50 8-(3-Fluorophenyl)-4-hydroxypyrazolo[1,5-a]-1,3,5-triazine

m.p. >300 °C

NMR (DMSO-d₆) δ: 8.64 (s, 1H), 8.15 (s, 1H), 7.82-7.94 (m, 2H), 7.33-7.58 (m, 1H), 6.95-7.18 (m, 1H)

55

Example 24

8-(4-Fluorophenyl)-4-hydroxypyrazolo[1,5-a]-1,3,5-triazine

- 5 m.p. >300 °C
 NMR (DMSO-d₆) δ: 8.56 (s, 1H), 8.11 (s, 1H), 8.05 (dd, J=5.0 and 9.01 Hz, 2H), 7.25 (dd, J=8.61 and 9.01 Hz, 2H)

Example 25

- 10 8-(2-Chlorophenyl)-4-hydroxypyrazolo[1,5-a]-1,3,5-triazine

m.p. 293 - 295 °C
 NMR (DMSO-d₆) δ: 8.38 (s, 1H), 8.08 (s, 1H), 7.33-7.75 (m, 4H)

- 15 Example 26

8-(3-Chlorophenyl)-4-hydroxypyrazolo[1,5-a]-1,3,5-triazine

- 20 m.p. >300 °C
 NMR (DMSO-d₆) δ: 8.62 (s, 1H), 8.15 (s, 2H), 7.96 (bd, J=7.21 Hz, 1H), 7.2-7.5 (m, 2H)

Example 27

- 25 8-(4-Chlorophenyl)-4-hydroxypyrazolo[1,5-a]-1,3,5-triazine

m.p. >300 °C
 NMR (DMSO-d₆) δ: 8.60 (s, 1H), 8.13 (s, 1H), 8.06 (d, J=8.6 Hz, 2H), 7.49 (d, J=8.6 Hz, 2H)

- 30 Example 28

8-(3,4-Dimethylphenyl)-4-hydroxypyrazolo[1,5-a]-1,3,5-triazine

- 35 m.p. >300 °C
 NMR (DMSO-d₆) δ: 8.52 (s, 1H), 8.09 (s, 1H), 7.78 (bs, 1H), 7.74 (dd, J=8.4 and 1.8 Hz, 1H), 7.17 (d, J=8.4 Hz, 1H), 2.27 (s, 3H), 2.24 (s, 3H)

Example 29

- 40 4-Hydroxy-8-(4-methoxy-3-methylphenyl)pyrazolo[1,5-a]-1,3,5-triazine

m.p. 279.5 - 280.5 °C (decomp.)
 NMR (DMSO-d₆) δ: 8.45 (s, 1H), 8.06 (s, 1H), 7.75-7.82 (m, 2H), 6.95 (d, J=9.23 Hz, 1H), 3.81 (s, 3H), 2.21 (s, 3H)

- 45 Example 30

4-Hydroxy-8-(3-methyl-4-methylthiophenyl)pyrazolo[1,5-a]-1,3,5-triazine

- 50 m.p. 273 - 276 °C
 NMR (DMSO-d₆) δ: 8.54 (s, 1H), 8.09 (s, 1H), 7.85 (d, J=9.0 Hz, 1H), 7.83 (s, 1H), 7.25 (d, J=9.0 Hz, 1H), 2.48 (s, 3H), 2.30 (s, 3H)

Example 31

8-(4-Ethylthio-3-methylphenyl)-4-hydroxypyrazolo[1,5-a]-1,3,5-triazine

5 m.p. 260 - 263 °C

NMR (DMSO-d₆) δ: 8.50 (s, 1H), 8.08 (s, 1H), 7.77-7.94 (m, 2H), 7.31 (d, J=9.01 Hz, 1H), 2.96 (q, J=7.26 Hz, 2H), 2.33 (s, 3H), 1.28 (t, J=7.26 Hz, 3H)Example 32

10

8-(4-Benzylthio-3-methylphenyl)-4-hydroxypyrazolo[1,5-a]-1,3,5-triazine

m.p. 234 - 236 °C

15 NMR (DMSO-d₆) δ: 8.55 (s, 1H), 8.10 (s, 1H), 7.86 (s, 1H), 7.82 (dd, J=8.0 and 1.7 Hz, 1H), 7.20-7.45 (m, 6H), 4.21 (s, 2H), 2.28 (s, 3H)Example 33

4-Hydroxy-8-(3-methyl-4-phenylthiophenyl)pyrazolo[1,5-a]-1,3,5-triazine

20

m.p. 274 - 276 °C

NMR (DMSO-d₆) δ: 8.59 (s, 1H), 8.13 (s, 1H), 8.01 (bs, 1H), 7.89 (dd, J=8.1 and 1.5 Hz, 1H), 7.36 (d, J=8.0 Hz, 1H), 7.11-7.42 (m, 5H), 2.36 (s, 3H)25 Example 34

4-Hydroxy-8-[3-methyl-4-(2-methylphenylthio)phenyl]pyrazolo[1,5-a]-1,3,5-triazine

m.p. 246 - 251 °C (decomp.)

30 NMR (DMSO-d₆) δ: 8.56 (s, 1H), 8.11 (s, 1H), 7.98 (bs, 1H), 7.84 (bd, J=8.13 Hz, 1H), 6.9-7.4 (m, 5H), 2.36 (s, 3H), 2.33 (s, 3H)Example 35

35 4-Hydroxy-8-[3-methyl-4-(3-methylphenylthio)phenyl]pyrazolo[1,5-a]-1,3,5-triazine

m.p. 270 - 273 °C

40 NMR (DMSO-d₆) δ: 8.59 (s, 1H), 8.13 (s, 1H), 7.99 (s, 1H), 7.87 (dd, J=7.9 and 1.7 Hz, 1H), 7.32 (d, J=8.0 Hz, 1H), 6.90-7.40 (m, 4H), 2.36 (s, 3H), 2.26 (s, 3H)Example 36

4-Hydroxy-8-[3-methyl-4-(4-methylphenylthio)phenyl]pyrazolo[1,5-a]-1,3,5-triazine

45 m.p. 287 - 290 °C

NMR (DMSO-d₆) δ: 8.56 (s, 1H), 8.12 (s, 1H), 7.97 (d, J=1.5 Hz, 1H), 7.82 (dd, J=9.3 and 2.0 Hz, 1H), 7.23 (d, J=9.3 Hz, 1H), 7.15 (s, 4H), 2.35 (s, 3H), 2.28 (s, 3H)Example 37

50

4-Hydroxy-8-[4-(3-methoxyphenylthio)-3-methyl]phenylpyrazolo[1,5-a]-1,3,5-triazine

m.p. 245 - 249 °C

55 NMR (DMSO-d₆) δ: 8.60 (s, 1H), 8.13 (s, 1H), 8.02 (bs, 1H), 7.91 (dd, J=7.9 and 1.6 Hz, 1H), 7.39 (d, J=8.4 Hz, 1H), 7.20 (d, J=8.1 Hz, 1H), 6.67-6.85 (m, 3H), 3.70 (s, 3H), 2.36 (s, 3H)

Example 38

4-Hydroxy-8-(4-(4-methoxyphenylthio)-3-methyl)phenylpyrazolo[1,5-a]-1,3,5-triazine

5 m.p. 283 - 287 °C

NMR (DMSO-d₆) δ: 8.53 (s, 1H), 8.10 (s, 1H), 7.92 (d, J = 1.5 Hz, 1H), 7.77 (dd, J = 8.1 and 1.7 Hz, 1H), 7.31 (d, J = 9.0 Hz, 2H), 7.03 (d, J = 8.1 Hz, 1H), 6.97 (d, J = 9.0 Hz, 2H), 3.77 (s, 3H), 2.36 (s, 3H)Example 39

10

8-(3-Ethyl-4-methylthiophenyl)-4-hydroxypyrazolo[1,5-a]-1,3,5-triazine

m.p. 289 - 294 °C (decomp.)

15 NMR (DMSO-d₆) δ: 8.46 (s, 1H), 8.05 (s, 1H), 7.77-7.87 (m, 2H), 7.25 (d, J = 9.01 Hz, 1H), 2.71 (q, J = 7.25 Hz, 2H), 2.52 (s, 3H), 1.24 (t, J = 7.25 Hz, 3H)Example 40

8-(3,4-Dimethoxyphenyl)-4-hydroxypyrazolo[1,5-a]-1,3,5-triazine

20

m.p. 250 °C (decomp.)

NMR (DMSO-d₆) δ: 8.55 (s, 1H), 8.09 (s, 1H), 7.62 (s, 1H), 7.57 (bd, J = 8.13 Hz, 1H), 6.99 (d, J = 8.13 Hz, 1H), 3.83 (s, 3H), 3.79 (s, 3H)25 Example 41

8-[(3,4-Bismethylthio)phenyl]-4-hydroxypyrazolo[1,5-a]-1,3,5-triazine

m.p. 286 - 292 °C

30 NMR (DMSO-d₆) δ: 8.63 (s, 1H), 8.12 (s, 1H), 7.91 (d, J = 1.76 Hz, 1H), 7.85 (dd, J = 8.13 and 1.76 Hz, 1H), 7.29 (d, J = 8.13 Hz, 1H), 2.53 (s, 3H), 2.48 (s, 3H)Example 42

35 8-(3,4-Difluorophenyl)-4-hydroxypyrazolo[1,5-a]-1,3,5-triazine

m.p. >300 °C

NMR (DMSO-d₆) δ: 8.61 (s, 1H), 8.15 (s, 1H), 7.2-8.2 (m, 3H)40 Example 43

8-(3-Chloro-4-methylthiophenyl)-4-hydroxypyrazolo[1,5-a]-1,3,5-triazine

m.p. 282 - 286 °C

45 NMR (DMSO-d₆) δ: 8.63 (s, 1H), 8.15 (d, J = 2.0 Hz, 1H), 8.14 (s, 1H), 7.99 (dd, J = 8.3 and 2.0 Hz, 1H), 7.36 (d, J = 8.3 Hz, 1H), 2.52 (s, 3H)Example 44

50 8-(3,4-Dichlorophenyl)-4-hydroxypyrazolo[1,5-a]-1,3,5-triazine

m.p. 296.5 - 297.5 °C

NMR (DMSO-d₆) δ: 8.63 (s, 1H), 8.31 (d, J = 1.98 Hz, 1H), 8.15 (s, 1H), 8.01 (dd, J = 8.57 and 1.98 Hz, 1H), 7.64 (d, J = 8.57 Hz, 1H)

55

Example 45

8-(2,4-Difluorophenyl)-4-hydroxypyrazolo[1,5-a]-1,3,5-triazine

- 5 m.p. >300 °C
 NMR (DMSO-d₆) δ: 8.61 (s, 1H), 8.15 (s, 1H), 7.7-8.2 (m, 2H), 7.2-7.6 (m, 1H)

Example 46

- 10 8-(2,4-Dichlorophenyl)-4-hydroxypyrazolo[1,5-a]-1,3,5-triazine

 m.p. >300 °C
 NMR (DMSO-d₆) δ: 8.39 (s, 1H), 8.09 (s, 1H), 7.75 (d, J = 8.13 Hz, 1H), 7.70 (d, J = 2.19 Hz, 1H), 7.49 (dd, J = 2.19 and 8.13 Hz, 1H)

- 15 Example 47

8-(3,5-Dimethylphenyl)-4-hydroxypyrazolo[1,5-a]-1,3,5-triazine

- 20 m.p. >300 °C
 NMR (DMSO-d₆) δ: 8.52 (s, 1H), 8.11 (s, 1H), 7.63 (s, 2H), 6.90 (s, 1H), 2.31 (s, 6H)

Example 48

- 25 8-(3,5-Dimethoxyphenyl)-4-hydroxypyrazolo[1,5-a]-1,3,5-triazine

 m.p. 280 °C (decomp.)
 NMR (DMSO-d₆) δ: 8.61 (s, 1H), 8.12 (s, 1H), 7.23 (d, J = 2.4 Hz, 2H), 6.42 (t, J = 2.4 Hz, 1H), 3.79 (s, 6H)

- 30 Example 49

8-(3,5-Dichlorophenyl)-4-hydroxypyrazolo[1,5-a]-1,3,5-triazine

- 35 m.p. >300 °C
 NMR (DMSO-d₆) δ: 8.68 (s, 1H), 8.18 (s, 1H), 8.09 d, J = 1.98 Hz, 2H), 7.39 (t, J = 1.98 Hz, 1H)

Example 50

- 40 8-(2-Fluoro-4-methylthiophenyl)-4-hydroxypyrazolo[1,5-a]-1,3,5-triazine

 m.p. 270 - 272 °C
 NMR (DMSO-d₆) δ: 8.33 (d, J = 3.5 Hz, 1H), 8.13 (s, 1H), 8.11 (t, J = 8.5 Hz, 1H), 7.21 (dd, J = 12.0 and 1.7 Hz, 1H), 7.19 (dd, J = 8.6 and 1.6 Hz, 1H), 2.53 (s, 3H)

- 45 Example 51

4-Hydroxy-8-(3,4,5-trimethoxyphenyl)pyrazolo[1,5-a]-1,3,5-triazine

- 50 m.p. 262 - 265 °C
 NMR (DMSO-d₆) δ: 8.63 (s, 1H), 8.12 (s, 1H), 7.35 (s, 2H), 3.85 (s, 6H), 3.70 (s, 3H)

Example 52

- 55 8-(4-Benzyloxy-3,5-dichlorophenyl)-4-hydroxypyrazolo[1,5-a]-1,3,5-triazine

 m.p. 273 - 273.5 °C (decomp.)
 NMR (DMSO-d₆) δ: 8.66 (s, 1H), 8.17 (s, 3H), 7.2-7.7 (m, 5H), 5.03 (s, 2H)

Example 53

4-Hydroxy-8-(3,4,5-trichlorophenyl)pyrazolo[1,5-a]-1,3,5-triazine

5 m.p. >300 °C
 NMR (DMSO-d₆) δ: 8.56 (s, 1H), 8.34 (s, 2H), 8.08 (s, 1H)

Example 54

10 8-(2-Fluoro-5-methyl-4-methylthiophenyl)-4-hydroxypyrazolo[1,5-a]-1,3,5-triazine

m.p. >300 °C
 NMR (DMSO-d₆) δ: 8.32 (d, J=3.3 Hz, 1H), 8.13 (s, 1H), 7.94 (d, J=7.9 Hz, 1H), 7.11 (d, J=12.0 Hz, 1H), 2.51 (s, 3H), 2.24 (s, 3H)

15 Example 55

4-Hydroxy-8-(3-thienyl)pyrazolo[1,5-a]-1,3,5-triazine

20 m.p. 292 - 293 °C (decomp.)
 NMR (DMSO-d₆) δ: 8.48 (s, 1H), 8.07 (s, 1H), 7.90 (dd, J=1.32 and 2.86 Hz, 1H), 7.73 (dd, J=1.32 and 5.05 Hz, 1H), 7.58 (dd, J=2.86 and 5.05 Hz, 1H)

Example 56

25 4-Hydroxy-8-(2-thienyl)pyrazolo[1,5-a]-1,3,5-triazine

m.p. 267 - 277 °C (decomp.)
 NMR (DMSO-d₆) δ: 8.44 (s, 1H), 8.10 (s, 1H), 7.47 (dd, J=5.05 and 1.10 Hz, 1H), 7.53 (dd, J=3.52 and 1.10 Hz, 1H), 7.10 (dd, J=3.52 and 5.05 Hz, 1H)

Example 57

4-Hydroxy-8-(2-pyridyl)pyrazolo[1,5-a]-1,3,5-triazine

35 m.p. 265 - 267 °C
 NMR (DMSO-d₆) δ: 8.58 (bs, 2H), 8.27 (d, J=8.13 Hz, 1H), 8.17 (s, 1H), 7.83 (dt, J=7.70 and 1.76 Hz, 1H), 7.15-7.31 (m, 1H)

40 Example 58

4-Hydroxy-8-(3-pyridyl)pyrazolo[1,5-a]-1,3,5-triazine

45 m.p. 241 - 243.5 °C
 NMR (DMSO-d₆) δ: 9.19 (d, J=2.20 Hz, 1H), 8.64 (s, 1H), 8.28-8.49 (m, 2H), 8.14 (s, 1H), 7.42 (dd, J=7.91 and 4.83 Hz, 1H)

Example 59

50 4-Hydroxy-8-(4-pyridyl)pyrazolo[1,5-a]-1,3,5-triazine

m.p. >300 °C
 NMR (DMSO-d₆) δ: 8.68 (s, 1H), 8.57 (d, J=8.57 Hz, 2H), 8.18 (s, 1H), 8.00 (d, J=8.57 Hz, 2H)

55

Example 60

8-(3-Indolyl)-4-hydroxypyrazolo[1,5-a]-1,3,5-triazine

5 m.p. >300 °C

NMR (DMSO-d₆) δ: 11.31 (s, 1H), 8.55 (s, 1H), 8.05 (s, 1H), 8.00-8.10 (m, 1H), 7.84 (d, J = 2.4 Hz, 1H), 7.40-7.50 (m, 1H), 7.05-7.25 (m, 2H)Example 61

10

8-(3-Benzo[b]thienyl)-4-hydroxypyrazolo[1,5-a]-1,3,5-triazine

m.p. 289 - 292 °C

NMR (DMSO-d₆) δ: 8.51 (s, 1H), 8.10 (s, 1H), 8.00-8.08 (m, 2H), 7.96 (s, 1H), 7.38-7.48 (m, 2H)

15

Example 62

8-(2-Benzo[b]thienyl)-4-hydroxypyrazolo[1,5-a]-1,3,5-triazine

20 m.p. >300 °C

NMR (DMSO-d₆) δ: 8.55 (s, 1H), 8.16 (s, 1H), 7.85 (s, 1H), 7.77-8.00 (m, 2H), 7.27-7.39 (m, 2H)Example 63

25 4-Hydroxy-8-(6-thiochromanyl)pyrazolo[1,5-a]-1,3,5-triazine

m.p. 260 °C (decomp.)

NMR (DMSO-d₆) δ: 8.51 (s, 1H), 8.08 (s, 1H), 7.72 (d, J = 8.8 Hz, 1H), 7.70 (s, 1H), 7.09 (d, J = 8.8 Hz, 1H), 3.05 (t, J = 5.6 Hz, 2H), 2.81 (t, J = 5.6 Hz, 2H), 1.90-2.10 (m, 2H)

30

Example 64

8-[(2,3-Dihydrobenzo[b]thiophen)-5-yl]-4-hydroxypyrazolo[1,5-a]-1,3,5-triazine

35 m.p. >300 °C

NMR (DMSO-d₆) δ: 8.53 (s, 1H), 8.08 (s, 1H), 7.91 (d, J = 1.3 Hz, 1H), 7.79 (dd, J = 8.0 and 1.5 Hz, 1H), 7.27 (d, J = 7.9 Hz, 1H), 3.35 (s, 2H), 3.26 (s, 2H)Example 65

40

4-Hydroxy-8-β-naphthylpyrazolo[1,5-a]-1,3,5-triazine

m.p. >300 °C

NMR (DMSO-d₆) δ: 8.68 (s, 1H), 8.53 (bs, 1H), 8.1-8.3 (m, 1H), 8.16 (s, 1H), 7.8-8.0 (m, 4H), 7.4-7.6 (m, 2H)

45

Example 66

8-(4-Carboxyphenyl)-4-hydroxypyrazolo[1,5-a]-1,3,5-triazine:

50

4-Hydroxy-8-(4-methylphenyl)pyrazolo[1,5-a]-1,3,5-triazine (1.13 g) is suspended in 1N sodium hydroxide solution (50 ml), and thereto is added gradually with stirring potassium permanganate (1.58 g) under cooling. After 10 minutes, the ice bath is taken off. After reacting for 5 hours, additional potassium permanganate (2.3 g) is added gradually. After reacting for 5 hours, the produced manganese dioxide is removed by filtration. The filtrate is adjusted to pH 2-3 with diluted hydrochloric acid, and the resulting precipitate is separated by filtration, washed with water and dried to give the title compound (0.56 g).

55

m.p. >300 °C

NMR (DMSO-d₆) δ: 8.65 (s, 1H), 8.16 (s, 1H), 8.16 (d, J = 8.57 Hz, 2H), 7.98 (d, J = 8.57 Hz, 2H)

Example 67

8-(3-Carboxyphenyl)-4-hydroxypyrazolo[1,5-a]-1,3,5-triazine

5 In the same manner as described in Example 66, the title compound is prepared.

m.p. >300 °C

NMR (DMSO-d₆) δ: 8.67 (bs, 1H), 8.63 (s, 1H), 8.20 (dt, J = 7.69 and 1.53 Hz, 1H), 8.17 (s, 1H), 7.85 (dt, J = 7.69 and 1.43 Hz, 1H), 7.54 (t, J = 7.69 Hz, 1H)

10 Example 68

4-Hydroxy-8-(4-methoxycarbonylphenyl)pyrazolo[1,5-a]-1,3,5-triazine

15 A mixture of 8-(4-carboxyphenyl)-4-hydroxypyrazolo[1,5-a]-1,3,5-triazine (145 mg), conc. sulfuric acid (4 ml) and methanol (4 ml) is refluxed with stirring for 24 hours. After cooling the reaction mixture, the resulting precipitate is separated by filtration, washed with methanol and dried to give the title compound (74 mg).

m.p. >300 °C (decomp.)

NMR (DMSO-d₆) δ: 8.63 (s, 1H), 8.17 (d, J = 8.24 Hz, 2H), 8.15 (s, 1H), 7.98 (d, J = 8.24 Hz, 2H)

20 Example 69

8-(4-Acetylphenyl)-4-hydroxypyrazolo[1,5-a]-1,3,5-triazine

25 To a suspension of 8-(4-ethylphenyl)-4-hydroxypyrazolo[1,5-a]-1,3,5-triazine (240 mg) in acetic acid (5 ml) are added chromium trioxide (500 mg) and water (1 ml), and the mixture is stirred at room temperature for 14 hours. To the reaction mixture is added water, and the insoluble material is separated by filtration, washed with water and dried to give the title compound (150 mg).

m.p. >300 °C

30 NMR (DMSO-d₆) δ: 8.68 (s, 1H), 8.19 (d, J = 8.6 Hz, 2H), 8.18 (s, 1H), 7.99 (d, J = 8.6 Hz, 2H), 2.58 (s, 3H)

Example 70

8-(4-Benzoylphenyl)-4-hydroxypyrazolo[1,5-a]-1,3,5-triazine

35 A mixture of 8-(4-α,α-ethylenedioxybenzylphenyl)-4-hydroxypyrazolo[1,5-a]-1,3,5-triazine (0.20 g), conc. hydrochloric acid (0.5 ml), water (1 ml), methanol (4 ml) and acetone (1 ml) is stirred at 45 - 60 °C for 2 hours. After cooling, the resulting precipitate is separated by filtration, washed with water and dried to give the title compound (0.15 g).

40 m.p. >300 °C

NMR (DMSO-d₆) δ: 8.67 (s, 1H), 8.22 (d, J = 8.35 Hz, 2H), 8.17 (s, 1H), 7.5-8.0 (m, 7H)

Example 71

45 8-[4-(4-Benzoyloxy-3,5-dibromobenzoyl)phenyl]-4-hydroxypyrazolo[1,5-a]-1,3,5-triazine

An ethylene ketal derivative of the title compound is prepared in the same manner as described in Example 1, and it is treated in the same manner as described in Example 70 to give the title compound.

m.p. 273 - 274 °C

50 NMR (DMSO-d₆) δ: 8.71 (s, 1H), 8.25 (d, J = 8.6 Hz, 2H), 8.19 (s, 1H), 7.98 (s, 2H), 7.84 (d, J = 8.6 Hz, 2H), 7.39-7.62 (m, 5H), 5.10 (s, 2H)

Example 72

55 4-Hydroxy-8-(4-nitrophenyl)pyrazolo[1,5-a]-1,3,5-triazine

To a mixture of conc. sulfuric acid (0.5 ml), conc. nitric acid (0.5 ml) and acetic acid (2 ml) is added 4-hydroxy-8-phenylpyrazolo[1,5-a]-1,3,5-triazine (310 mg), and the mixture is stirred at 50 - 60 °C. After

reacting for one hour, to the reaction mixture is added water. The insoluble material is separated by filtration, washed with water and hot methanol and dried to give the title compound (210 mg).

m.p. $>300^{\circ}\text{C}$

NMR (DMSO- d_6) δ : 8.75 (s, 1H), 8.30 (s, 4H), 8.23 (s, 1H)

- 5 In the same manner as described in Example 72 by using appropriate starting materials, there are prepared the compounds of Examples 73 to 76.

Example 73

- 10 4-Hydroxy-8-(3-methyl-4-nitrophenyl)pyrazolo[1,5-a]-1,3,5-triazine

m.p. 280°C (sublimation)

NMR (DMSO- d_6) δ : 8.73 (s, 1H), 8.22 (s, 1H), 8.12 (d, $J = 1.5$ Hz, 3H), 2.60 (s, 3H)

- 15 Example 74

4-Hydroxy-8-(3-methoxy-4-nitrophenyl)pyrazolo[1,5-a]-1,3,5-triazine

m.p. $>300^{\circ}\text{C}$

- 20 NMR (DMSO- d_6) δ : 8.79 (s, 1H), 8.22 (s, 1H), 7.99 (d, $J = 8.8$ Hz, 1H), 7.93 (d, $J = 1.7$ Hz, 1H), 7.83 (dd, $J = 8.8$ and 1.5 Hz, 1H), 4.01 (s, 3H)

Example 75

- 25 8-(3-Chloro-4-nitrophenyl)-4-hydroxypyrazolo[1,5-a]-1,3,5-triazine

m.p. 265°C (sublimation)

NMR (DMSO- d_6) δ : 8.79 (s, 1H), 8.44 (d, $J = 1.3$ Hz, 1H), 8.26 (s, 1H), 8.19 (s, 2H)

- 30 Example 76

8-(3,5-Dimethyl-4-nitrophenyl)-4-hydroxypyrazolo[1,5-a]-1,3,5-triazine

m.p. 270°C (sublimation)

- 35 NMR (DMSO- d_6) δ : 8.64 (s, 1H), 8.18 (s, 1H), 7.95 (s, 2H), 2.31 (s, 6H)

Example 77

8-(4-Aminophenyl)-4-hydroxypyrazolo[1,5-a]-1,3,5-triazine

- 40 4-Hydroxy-8-(4-nitrophenyl)pyrazolo[1,5-a]-1,3,5-triazine (660 mg) and 5 % palladium-carbon (500 mg) are suspended in 80 % aqueous methanol (100 ml), and the mixture is stirred under hydrogen atmosphere at room temperature. After reacting for 46 hours, to the reaction mixture is added conc. hydrochloric acid (5 ml), and the insoluble material is removed off by filtration. The filtrate is concentrated to dryness under
45 reduced pressure to give the title compound (450 mg).

m.p. $>300^{\circ}\text{C}$

NMR (DMSO- d_6) δ : 8.59 (s, 1H), 8.13 (s, 1H), 8.09 (d, $J = 8.6$ Hz, 2H), 7.39 (d, $J = 8.6$ Hz, 2H)

Example 78

- 50 4-Hydroxy-8-[2-(5-nitrothienyl)]pyrazolo[1,5-a]-1,3,5-triazine

- To a mixture of conc. sulfuric acid (0.2 ml), conc. nitric acid (0.2 ml) and acetic acid (3 ml) is added 4-hydroxy-8-(thienyl)pyrazolo[1,5-a]-1,3,5-triazine (440 mg) under ice cooling, and the mixture is stirred at room
55 temperature. After reacting for 3 hours, to the reaction mixture is added water. The insoluble material is separated by filtration, washed with hot methanol and dried to give the title compound (190 mg).

m.p. 250°C (sublimation)

NMR (DMSO- d_6) δ : 8.72 (s, 1H), 8.28 (s, 1H), 8.13 (d, $J = 4.4$ Hz, 1H), 7.63 (d, $J = 4.4$ Hz, 1H)

Example 79

4-Hydroxy-8-[3-(2-nitrothienyl)]pyrazolo[1,5-a]-1,3,5-triazine

- 5 In the same manner as described in Example 78 by using an appropriate starting material, the title compound is prepared.

m.p. >300 °C

NMR (DMSO-d₆) δ: 8.51 (s, 1H), 8.15 (s, 1H), 8.02 (d, J = 5.5 Hz, 1H), 7.55 (d, J = 5.5 Hz, 1H)

10 Example 80

4-Hydroxy-8-(2-hydroxyphenyl)pyrazolo[1,5-a]-1,3,5-triazine

- 15 A mixture of 4-hydroxy-8-(2-methoxyphenyl)pyrazolo[1,5-a]-1,3,5-triazine (242 mg), aluminum chloride (799 mg) and nitrobenzene (3 ml) is stirred at 80 - 90 °C for 5 hours. The reaction mixture is cooled and poured into ice water. The precipitate is separated by filtration, washed with water and dried to give the title compound (140 mg).

m.p. 293 - 297 °C (decomp.)

- 20 NMR (DMSO-d₆) δ: 9.85 (s, 1H), 8.55 (s, 1H), 8.07 (s, 1H), 7.97-8.07 (dd, J = 1.98 Hz, 1H), 6.76-7.14 (m, 3H)

In the same manner as described in Example 80 by using appropriate starting materials, there are prepared the compounds of Examples 81 to 83.

Example 81

- 25 4-Hydroxy-8-(3-hydroxyphenyl)pyrazolo[1,5-a]-1,3,5-triazine

m.p. 262 - 266 °C (decomp.)

- 30 NMR (DMSO-d₆) δ: 8.46 (s, 1H), 8.08 (s, 1H), 7.44-7.49 (m, 1H), 7.35 (bs, 1H), 7.19 (t, J = 7.58 Hz, 1H), 6.67 (dd, J = 7.69 and 1.32 Hz, 1H)

Example 82

4-Hydroxy-8-(4-hydroxyphenyl)pyrazolo[1,5-a]-1,3,5-triazine

35

m.p. >300 °C

NMR (DMSO-d₆) δ: 8.43 (s, 1H), 8.03 (s, 1H), 7.80 (d, J = 8.57 Hz, 2H), 6.81 (d, J = 8.57 Hz, 2H)

Example 83

40

8-(4-Bromo-3-hydroxyphenyl)-4-hydroxypyrazolo[1,5-a]-1,3,5-triazine

m.p. 277 - 279 °C (decomp.)

- 45 NMR (DMSO-d₆) δ: 10.23 (s, 1H), 8.45 (s, 1H), 8.10 (s, 1H), 7.69 (d, J = 1.87 Hz, 1H), 7.49 (d, J = 8.13 Hz, 1H), 7.33 (dd, J = 8.13 and 1.75 Hz, 1H)

Example 84

8-(3,5-Dichloro-4-hydroxyphenyl)-4-hydroxypyrazolo[1,5-a]-1,3,5-triazine

50

In the same manner as described in Example 80, 8-(4-benzyloxy-3,5-dichlorophenyl)-4-hydroxypyrazolo[1,5-a]-1,3,5-triazine is reacted at room temperature for one hour to give the title compound.

m.p. >300 °C

- 55 NMR (DMSO-d₆) δ: 8.60 (s, 1H), 8.14 (s, 1H), 8.04 (s, 2H)

Example 85

8-(3,5-Dibromo-4-hydroxyphenyl)-4-hydroxypyrazolo[1,5-a]-1,3,5-triazine

- 5 A benzyl derivative of the title compound is prepared in the same manner as described in Example 1, and it is treated in the same manner as described in Example 80 to give the title compound.

m.p. >300 °C

NMR (DMSO-d₆) δ: 8.63 (s, 1H), 8.24 (s, 2H), 8.15 (s, 1H)

10 Example 86

8-(3,5-Dimethoxy-4-hydroxyphenyl)-4-hydroxypyrazolo[1,5-a]-1,3,5-triazine

- 15 In the same manner as described in Example 80 by using an appropriate starting material, there is prepared the title compound.

m.p. 250 - 270 °C (decomp.)

NMR (DMSO-d₆) δ: 8.55 (s, 1H), 8.37 (bs, 1H), 8.07 (s, 1H), 7.31 (s, 2H), 3.79 (s, 6H)

Example 87

20

8-(3-Acetoxyphenyl)-4-hydroxypyrazolo[1,5-a]-1,3,5-triazine

- 25 A mixture of 4-hydroxy-8-(3-methoxyphenyl)pyrazolo[1,5-a]-1,3,5-triazine (242 mg), aluminum chloride (799 mg) and nitrobenzene (3 ml) is stirred at 80 - 90 °C for 5 hours. To the reaction mixture is added acetyl chloride (0.12 ml). After reacting for 45 minutes, the reaction mixture is cooled and poured into ice water. The resulting precipitate is separated by filtration, washed with water and dried to give the title compound (8 mg).

m.p. 244 - 249 °C (decomp.)

- 30 NMR (DMSO-d₆) δ: 8.58 (s, 1H), 8.13 (s, 1H), 7.79-7.96 (m, 2H), 7.45 (t, J=7.91 Hz, 1H), 7.01 (bd, J=7.91 Hz, 1H)

Example 88

8-[4-(3,5-Dibromo-4-hydroxybenzoyl)phenyl]-4-hydroxypyrazolo[1,5-a]-1,3,5-triazine

35

- A benzyl derivative of the title compound is prepared in the same manner as described in Example 71 and it is treated in the same manner as described in Example 80 to give the title compound.

m.p. >300 °C

- 40 NMR (DMSO-d₆) δ: 8.70 (s, 1H), 8.23 (d, J=8.0 Hz, 2H), 8.19 (s, 1H), 7.88 (s, 2H), 7.79 (d, J=8.1 Hz, 2H)

Example 89

4-Hydroxy-8-(4-methylsulfinylphenyl)pyrazolo[1,5-a]-1,3,5-triazine

45

- To a suspension of 4-hydroxy-8-(4-methylthiophenyl)pyrazolo[1,5-a]-1,3,5-triazine (258 mg) and sodium metaperiodate (430 mg) in methanol (20 ml) is added water (0.5 ml), and the mixture is stirred at room temperature for 40 hours. The insoluble material is separated by filtration, washed with water and dried to give the title compound (180 mg).

- 50 m.p. 285 - 286 °C

NMR (DMSO-d₆) δ: 8.66 (s, 1H), 8.22 (d, J=8.6 Hz, 2H), 8.16 (s, 1H), 7.73 (d, J=8.6 Hz, 2H), 2.76 (s, 3H)

55

Example 90

4-Hydroxy-8-(3-methyl-4-methylsulfinylphenyl)pyrazolo[1,5-a]-1,3,5-triazine

5 In the same manner as described in Example 89 by using an appropriate starting material, there is prepared the title compound.

m.p. 281 - 282 °C

NMR (DMSO-d₆) δ: 8.64 (s, 1H), 8.16 (s, 1H), 8.13 (dd, J=8.2 and 1.6 Hz, 1H), 7.95 (d, J=1.6 Hz, 1H), 7.83 (d, J=8.2 Hz, 1H), 2.70 (s, 3H), 2.39 (s, 3H)

10

Example 91

4-Hydroxy-8-(4-methanesulfonylphenyl)pyrazolo[1,5-a]-1,3,5-triazine

15 To a suspension of 4-hydroxy-8-(4-methylthiophenyl)pyrazolo[1,5-a]-1,3,5-triazine (260 mg) in acetic acid (5 ml) is added 35 % hydrogen peroxide (3 ml), and the mixture is stirred at 70 - 80 °C. After reacting for one hour, to the reaction mixture is added water. The insoluble material is separated by filtration, washed with water and dried to give the title compound (250 mg).

m.p. >300 °C

20 NMR (DMSO-d₆) δ: 8.71 (s, 1H), 8.30 (d, J=8.6 Hz, 2H), 8.20 (s, 1H), 7.96 (d, J=8.6 Hz, 2H), 3.27 (s, 3H)

Example 92

25 4-Hydroxy-8-[2-(5-phenylthiothienyl)]pyrazolo[1,5-a]-1,3,5-triazine

To a solution of thiophenol (130 ml) in N,N-dimethylformamide (2 ml) is added N-bromosuccinimide (160 mg), and the mixture is stirred at room temperature for 5 minutes. To the mixture is added 4-hydroxy-8-(2-thienyl)pyrazolo[1,5-a]-1,3,5-triazine (218 mg), and the mixture is stirred at room temperature for 2
30 hours. To the reaction mixture is added diethyl ether, and the resulting precipitate is separated by filtration, washed in order with ethanol, ethyl acetate and diethyl ether, and dried to give the title compound (120 mg).

m.p. 295 - 298 °C

35 NMR (DMSO-d₆) δ: 8.54 (s, 1H), 8.12 (s, 1H), 7.56 (d, J=3.7 Hz, 1H), 7.40 (d, J=3.7 Hz, 1H), 7.19-7.35 (m, 5H)

Example 93

4-Hydroxy-8-[4-(2-phenylthiothienyl)]pyrazolo[1,5-a]-1,3,5-triazine

40 In the same manner as described in Example 92 by using an appropriate starting material, there is prepared the title compound.

m.p. 278 - 281 °C

NMR (DMSO-d₆) δ: 8.45 (s, 1H), 8.12 (s, 1H), 7.91 (s, 2H), 7.04-7.36 (m, 5H)

45

Example 94

4-Hydroxy-8-(4-phenylaminosulfonylphenyl)pyrazolo[1,5-a]-1,3,5-triazine

50 A mixture of 4-hydroxy-8-phenylpyrazolo[1,5-a]-1,3,5-triazine (420 mg) and chlorosulfonic acid (3 ml) is stirred at 80 °C. After reacting for one hour, to the reaction mixture is added water. The resulting precipitate is separated by filtration, washed with water and dried. To the above precipitate is added aniline (10 ml), and the mixture is stirred at 80 °C for 2 hours. The reaction mixture is acidified by adding thereto 2N hydrochloric acid. The resulting precipitate is separated by filtration, washed with water and dried to give
55 the title compound (420 mg).

m.p. 274 - 277 °C

NMR (DMSO-d₆) δ: 10.21 (s, 1H), 8.62 (s, 1H), 8.17 (d, J=8.6 Hz, 2H), 8.16 (s, 1H), 7.78 (d, J=8.6 Hz, 2H), 6.92-7.34 (m, 5H)

In the same manner as described in Example 94 by using appropriate starting materials, there are prepared the compounds of Examples 95 to 140.

Example 95

5

4-Hydroxy-8-[4-(4-methylphenylaminosulfonyl)phenyl]pyrazolo[1,5-a]-1,3,5-triazine

m.p. 262 - 265 °C

NMR (DMSO-d₆) δ: 10.05 (s, 1H), 8.63 (s, 1H), 8.17 (d, J = 8.6 Hz, 2H), 8.16 (s, 1H), 7.76 (d, J = 8.6 Hz, 2H), 7.01 (s, 4H), 2.18 (s, 3H)

10

Example 96

15

8-[4-(4-Ethylphenylaminosulfonyl)phenyl]-4-hydroxypyrazolo[1,5-a]-1,3,5-triazine

m.p. 285 - 290 °C

NMR (DMSO-d₆) δ: 10.09 (s, 1H), 8.63 (s, 1H), 8.17 (s, 1H), 8.17 (d, J = 8.6 Hz, 2H), 7.78 (d, J = 8.6 Hz, 2H), 7.04 (s, 4H), 2.25 (q, J = 7.3 Hz, 2H), 1.17 (t, J = 7.3 Hz, 3H)

Example 97

20

8-[4-(3-Ethylphenylaminosulfonyl)phenyl]-4-hydroxypyrazolo[1,5-a]-1,3,5-triazine

m.p. 240 - 248 °C

NMR (DMSO-d₆) δ: 10.15 (s, 1H), 8.63 (s, 1H), 8.18 (d, J = 8.6 Hz, 2H), 8.16 (s, 1H), 7.79 (d, J = 8.6 Hz, 2H), 6.70-7.50 (m, 4H), 2.20-2.60 (m, 2H), 1.08 (t, J = 7.2 Hz, 3H)

25

Example 98

30 8-[4-(2-Ethylphenylaminosulfonyl)phenyl]-4-hydroxypyrazolo[1,5-a]-1,3,5-triazine

m.p. 250 - 254 °C

NMR (DMSO-d₆) δ: 9.51 (s, 1H), 8.67 (s, 1H), 8.21 (d, J = 8.6 Hz, 2H), 8.18 (s, 1H), 7.71 (d, J = 8.6 Hz, 2H), 7.07-7.25 (m, 4H), 2.46-2.57 (m, 2H), 0.97 (t, J = 7.7 Hz, 3H)

35

Example 99

4-Hydroxy-8-[4-(4-isopropylphenylaminosulfonyl)phenyl]pyrazolo[1,5-a]-1,3,5-triazine

40 m.p. 290 - 295 °C

NMR (DMSO-d₆) δ: 10.10 (s, 1H), 8.63 (s, 1H), 8.18 (d, J = 8.6 Hz, 2H), 8.16 (s, 1H), 7.78 (d, J = 8.6 Hz, 2H), 7.00-7.20 (m, 4H), 2.46-2.52 (m, 1H), 1.11 (d, J = 6.8 Hz, 6H)

40

Example 100

45

8-[4-(4-t-Butylphenylaminosulfonyl)phenyl]-4-hydroxypyrazolo[1,5-a]-1,3,5-triazine

m.p. 275 - 279 °C

NMR (DMSO-d₆) δ: 10.13 (s, 1H), 8.63 (s, 1H), 8.18 (d, J = 8.6 Hz, 2H), 8.17 (s, 1H), 7.80 (d, J = 8.6 Hz, 2H), 7.25 (d, J = 8.8 Hz, 2H), 7.02 (d, J = 8.8 Hz, 2H), 1.19 (s, 9H)

50

Example 101

4-Hydroxy-8-[4-(4-α-hydroxyethylphenylaminosulfonyl)phenyl]pyrazolo[1,5-a]-1,3,5-triazine

55

m.p. 236 - 239 °C

NMR (DMSO-d₆) δ: 8.54 (s, 1H), 8.18 (d, J = 8.6 Hz, 2H), 8.12 (s, 1H), 7.78 (d, J = 8.6 Hz, 2H), 7.21 (d, J = 8.6 Hz, 2H), 7.06 (d, J = 8.6 Hz, 2H), 4.61 (q, J = 6.6 Hz, 1H), 1.24 (d, J = 6.4 Hz, 3H)

Example 102

8-[4-(4-Acetylphenylaminosulfonyl)phenyl]-4-hydroxypyrazolo[1,5-a]-1,3,5-triazine

5 m.p. 260 - 262 °C

NMR (DMSO-d₆) δ: 10.82 (s, 1H), 8.63 (s, 1H), 8.21 (d, J = 8.8 Hz, 2H), 8.16 (s, 1H), 7.88 (d, J = 8.8 Hz, 2H), 7.84 (d, J = 8.8 Hz, 2H), 7.24 (d, J = 8.8 Hz, 2H), 3.42 (s, 3H)Example 103

10 8-[4-(4-Cyanophenylaminosulfonyl)phenyl]-4-hydroxypyrazolo[1,5-a]-1,3,5-triazine

m.p. 272 - 274 °C

15 NMR (DMSO-d₆) δ: 11.01 (s, 1H), 8.64 (s, 1H), 8.22 (d, J = 8.6 Hz, 2H), 8.18 (s, 1H), 7.88 (d, J = 8.6 Hz, 2H), 7.70 (d, J = 9.0 Hz, 2H), 7.28 (d, J = 9.0 Hz, 2H)Example 104

20 8-[4-(4-Carboxyphenylaminosulfonyl)phenyl]-4-hydroxypyrazolo[1,5-a]-1,3,5-triazine

m.p. 200 - 202 °C

NMR (DMSO-d₆) δ: 10.75 (s, 1H), 8.62 (s, 1H), 8.20 (d, J = 8.6 Hz, 2H), 8.15 (s, 1H), 7.86 (d, J = 8.6 Hz, 2H), 7.80 (d, J = 8.6 Hz, 2H), 7.22 (d, J = 8.8 Hz, 2H)25 Example 105

4-Hydroxy-8-[4-(4-methoxycarbonylphenylaminosulfonyl)phenyl]pyrazolo[1,5-a]-1,3,5-triazine

m.p. 241 - 243 °C

30 NMR (DMSO-d₆) δ: 10.81 (s, 1H), 8.63 (s, 1H), 8.21 (d, J = 8.8 Hz, 2H), 8.17 (s, 1H), 7.86 (d, J = 8.8 Hz, 2H), 7.83 (d, J = 8.8 Hz, 2H), 7.25 (d, J = 8.8 Hz, 2H), 3.78 (s, 3H)Example 106

35 4-Hydroxy-8-[4-(4-hydroxyphenylaminosulfonyl)phenyl]pyrazolo[1,5-a]-1,3,5-triazine

m.p. 175 - 177 °C

NMR (DMSO-d₆) δ: 9.69 (s, 1H), 8.63 (s, 1H), 8.17 (s, 1H), 8.16 (d, J = 8.6 Hz, 2H), 7.70 (d, J = 8.6 Hz, 2H), 6.89 (d, J = 9.0 Hz, 2H), 6.61 (d, J = 9.0 Hz, 2H)

40

Example 107

4-Hydroxy-8-[4-(3-hydroxyphenylaminosulfonyl)phenyl]pyrazolo[1,5-a]-1,3,5-triazine

45 m.p. 166 - 169 °C

NMR (DMSO-d₆) δ: 10.10 (s, 1H), 8.64 (s, 1H), 8.18 (d, J = 8.6 Hz, 2H), 8.16 (s, 1H), 7.79 (d, J = 8.6 Hz, 2H), 6.90 (t, J = 8.4 Hz, 1H), 6.37-6.61 (m, 3H)Example 108

50 4-Hydroxy-8-[4-(3,4,5-trimethoxyphenylaminosulfonyl)phenyl]pyrazolo[1,5-a]-1,3,5-triazine

m.p. 280 - 282 °C

55 NMR (DMSO-d₆) δ: 10.06 (s, 1H), 8.64 (s, 1H), 8.20 (d, J = 8.6 Hz, 2H), 8.16 (s, 1H), 7.82 (d, J = 8.6 Hz, 2H), 6.42 (s, 2H), 3.65 (s, 6H), 3.56 (s, 3H)

Example 109

8-[4-(4-Chlorophenylaminosulfonyl)phenyl]-4-hydroxypyrazolo[1,5-a]-1,3,5-triazine

5 m.p. 189 - 193 °C

NMR (DMSO- d_6) δ : 10.38 (s, 1H), 8.64 (s, 1H), 8.20 (d, J = 8.6 Hz, 2H), 8.17 (s, 1H), 7.79 (d, J = 8.6 Hz, 2H), 7.31 (d, J = 9.0 Hz, 2H), 7.12 (d, J = 9.0 Hz, 2H)Example 110

10

4-Hydroxy-8-[4-(3,4,5-trichlorophenylaminosulfonyl)phenyl]pyrazolo[1,5-a]-1,3,5-triazine

m.p. 280 - 283 °C

15 NMR (DMSO- d_6) δ : 10.91 (bs, 1H), 8.66 (s, 1H), 8.25 (d, J = 8.8 Hz, 2H), 8.19 (s, 1H), 7.87 (d, J = 8.8 Hz, 2H), 7.32 (s, 2H)EXAMPLE 111

20

8-[4-(4-Carboxy-3-hydroxyphenylaminosulfonyl)phenyl]-4-hydroxypyrazolo[1,5-a]-1,3,5-triazine

m.p. 213 - 216 °C

NMR (DMSO- d_6) δ : 10.81 (s, 1H), 8.65 (s, 1H), 8.23 (d, J = 8.6 Hz, 2H), 8.18 (s, 1H), 7.89 (d, J = 8.6 Hz, 2H), 7.65 (d, J = 9.2 Hz, 1H), 6.67-6.77 (m, 2H)25 Example 112

4-Hydroxy-8-[4-(3-hydroxy-4-methoxycarbonylphenylaminosulfonyl)phenyl]pyrazolo[1,5-a]-1,3,5-triazine

m.p. 269 - 273 °C

30 NMR (DMSO- d_6) δ : 10.84 (bs, 1H), 10.55 (bs, 1H), 8.64 (s, 1H), 8.22 (d, J = 8.6 Hz, 2H), 8.18 (s, 1H), 7.88 (d, J = 8.6 Hz, 2H), 7.64 (d, J = 9.0 Hz, 1H), 6.69-6.79 (m, 2H), 3.81 (s, 3H)Example 113

35 4-Hydroxy-8-[4-(3-methoxy-4-methoxycarbonylphenylaminosulfonyl)phenyl]pyrazolo[1,5-a]-1,3,5-triazine

m.p. 160 - 163 °C

40 NMR (DMSO- d_6) δ : 10.73 (s, 1H), 8.64 (s, 1H), 8.22 (d, J = 8.8 Hz, 2H), 8.17 (s, 1H), 7.89 (d, J = 8.8 Hz, 2H), 7.58 (d, J = 8.4 Hz, 1H), 6.90 (d, J = 1.8 Hz, 1H), 6.79 (dd, J = 8.4 and 1.8 Hz, 1H), 3.74 (s, 3H), 3.71 (s, 3H)Example 114

45

4-Hydroxy-8-[4-(3-pyridylaminosulfonyl)phenyl]pyrazolo[1,5-a]-1,3,5-triazine

m.p. >300 °C

NMR (DMSO- d_6) δ : 8.64 (s, 1H), 8.20 (d, J = 8.6 Hz, 2H), 8.17 (s, 1H), 8.14-8.33 (m, 2H), 7.30-7.50 (m, 4H)50 Example 115

4-Hydroxy-8-[4-(pyrimidin-2-ylaminosulfonyl)phenyl]pyrazolo[1,5-a]-1,3,5-triazine

m.p. 267 - 269 °C

55 NMR (DMSO- d_6) δ : 8.66 (s, 1H), 8.52 (d, J = 4.8 Hz, 2H), 8.23 (d, J = 8.8 Hz, 2H), 8.19 (s, 1H), 8.03 (d, J = 8.8 Hz, 2H), 7.05 (t, J = 4.8 Hz, 1H)

Example 116

4-Hydroxy-8-[4-(thiazol-2-ylaminosulfonyl)phenyl]pyrazolo[1,5-a]-1,3,5-triazine

5 m.p. 242 - 245 °C

NMR (DMSO-d₆) δ: 8.64 (s, 1H), 8.18 (d, J = 8.6 Hz, 2H), 8.17 (s, 1H), 7.84 (d, J = 8.6 Hz, 2H), 7.24 (d, J = 4.6 Hz, 1H), 6.82 (d, J = 4.6 Hz, 1H)Example 117

10

4-Hydroxy-8-[4-(5-methylisoxazol-3-ylaminosulfonyl)phenyl]pyrazolo[1,5-a]-1,3,5-triazine

m.p. 273 °C (decomp.)

15 NMR (DMSO-d₆) δ: 11.40 (bs, 1H), 8.67 (s, 1H), 8.24 (d, J = 8.8 Hz, 2H), 8.19 (s, 1H), 7.89 (d, J = 8.8 Hz, 2H), 6.16 (d, J = 0.9 Hz, 1H), 2.30 (d, J = 0.9 Hz, 3H)Example 118

4-Hydroxy-8-[4-(pyrazol-3-ylaminosulfonyl)phenyl]pyrazolo[1,5-a]-1,3,5-triazine

20

m.p. >300 °C

NMR (DMSO-d₆) δ: 8.63 (s, 1H), 8.18 (d, J = 8.6 Hz, 2H), 8.16 (s, 1H), 7.80 (d, J = 8.6 Hz, 2H), 7.52 (d, J = 2.4 Hz, 1H), 5.97 (d, J = 2.2 Hz, 1H)25 Example 119

8-[4-(3-aminopyrazol-2-ylsulfonyl)phenyl]-4-hydroxypyrazolo[1,5-a]-1,3,5-triazine

30 m.p. 190 - 194 °C

NMR (DMSO-d₆) δ: 8.67 (s, 1H), 8.24 (d, J = 8.4 Hz, 2H), 8.20 (s, 1H), 8.00 (d, J = 2.8 Hz, 1H), 7.86 (d, J = 8.8 Hz, 2H), 5.88 (d, J = 2.8 Hz, 1H)Example 120

35 8-[4-(3-Acetylaminopyrazol-2-ylsulfonyl)phenyl]-4-hydroxypyrazolo[1,5-a]-1,3,5-triazine

m.p. 239 - 242 °C

40 NMR (DMSO-d₆) δ: 10.89 (s, 1H), 8.69 (s, 1H), 8.53 (d, J = 2.9 Hz, 1H), 8.29 (d, J = 8.6 Hz, 2H), 8.21 (s, 1H), 7.95 (d, J = 8.6 Hz, 2H), 6.86 (d, J = 2.9 Hz, 1H), 1.98 (s, 3H)Example 121

4-Hydroxy-8-(4-N-methyl-phenylaminosulfonylphenyl)pyrazolo[1,5-a]-1,3,5-triazine

45 m.p. 252 - 255 °C

NMR (DMSO-d₆) δ: 8.68 (s, 1H), 8.22 (d, J = 8.6 Hz, 2H), 8.19 (s, 1H), 7.54 (d, J = 8.6 Hz, 2H), 7.10-7.40 (m, 5H), 3.17 (s, 3H)Example 122

50

8-(4-Dimethylaminosulfonylphenyl)-4-hydroxypyrazolo[1,5-a]-1,3,5-triazine

m.p. 283 - 284 °C

55 NMR (DMSO-d₆) δ: 8.70 (s, 1H), 8.29 (d, J = 8.6 Hz, 2H), 8.20 (s, 1H), 7.79 (d, J = 8.6 Hz, 2H), 2.64 (s, 6H)

Example 123

8-(4-Di-n-butylaminosulfonylphenyl)-4-hydroxypyrazolo[1,5-a]-1,3,5-triazine

- 5 m.p. 136 - 140 °C
 NMR (DMSO-d₆) δ: 8.51 (s, 1H), 8.26 (d, J = 8.6 Hz, 2H), 8.08 (s, 1H), 7.77 (d, J = 8.6 Hz, 2H), 2.80-3.10 (m, 4H), 0.95-1.61 (m, 8H), 0.78-0.95 (m, 6H)

Example 124

- 10 4-Hydroxy-8-(4-piperidinosulfonylphenyl)pyrazolo[1,5-a]-1,3,5-triazine

- m.p. >300 °C
 NMR (DMSO-d₆) δ: 8.61 (s, 1H), 8.28 (d, J = 8.6 Hz, 2H), 8.14 (s, 1H), 7.74 (d, J = 8.6 Hz, 2H), 2.50-3.10 (m, 4H), 1.00-1.80 (m, 6H)

Example 125

- 20 4-Hydroxy-8-(4-pyrrolidinosulfonylphenyl)pyrazolo[1,5-a]-1,3,5-triazine

- m.p. >300 °C
 NMR (DMSO-d₆) δ: 8.69 (s, 1H), 8.27 (d, J = 8.6 Hz, 2H), 8.19 (s, 1H), 7.84 (d, J = 8.6 Hz, 2H), 3.10-3.24 (m, 4H), 1.59-1.73 (m, 4H)

Example 126

- 25 4-Hydroxy-8-(4-morpholinosulfonylphenyl)pyrazolo[1,5-a]-1,3,5-triazine

- 30 m.p. >300 °C
 NMR (DMSO-d₆) δ: 8.71 (s, 1H), 8.31 (d, J = 8.6 Hz, 2H), 8.20 (s, 1H), 7.78 (d, J = 8.6 Hz, 2H), 3.59-3.64 (m, 4H), 2.90-3.00 (m, 4H)

Example 127

- 35 4-Hydroxy-8-(4-methylaminosulfonylphenyl)pyrazolo[1,5-a]-1,3,5-triazine

- m.p. 296 - 298 °C
 NMR (DMSO-d₆) δ: 8.68 (s, 1H), 8.24 (d, J = 8.4 Hz, 2H), 8.19 (s, 1H), 7.82 (d, J = 8.4 Hz, 2H), 7.39 (q, J = 5.1 Hz, 1H), 2.44 (d, J = 4.8 Hz, 3H)

40

Example 128

- 8-(4-Aminosulfonylphenyl)-4-hydroxypyrazolo[1,5-a]-1,3,5-triazine

- 45 m.p. 297 - 300 °C
 NMR (DMSO-d₆) δ: 8.67 (s, 1H), 8.22 (d, J = 8.6 Hz, 2H), 8.17 (s, 1H), 7.86 (d, J = 8.6 Hz, 2H), 7.31 (s, 2H)

Example 129

- 50 8-(4-Cyclohexylaminosulfonylphenyl)-4-hydroxypyrazolo[1,5-a]-1,3,5-triazine

- m.p. >300 °C
 NMR (DMSO-d₆) δ: 8.68 (s, 1H), 8.23 (d, J = 8.6 Hz, 2H), 8.18 (s, 1H), 7.86 (d, J = 8.6 Hz, 2H), 7.59 (d, J = 7.0 Hz, 1H), 2.70-3.00 (m, 1H), 1.00-1.62 (m, 10H)

55

Example 130

4-Hydroxy-8-(4-tetrahydrofurfurylamino-sulfonylphenyl)pyrazolo[1,5-a]-1,3,5-triazine

- 5 m.p. 258 - 262 °C
 NMR (DMSO-d₆) δ: 8.68 (s, 1H), 8.24 (d, J = 8.6 Hz, 2H), 8.19 (s, 1H), 7.84 (d, J = 8.6 Hz, 2H), 7.80-8.06 (m, 1H), 3.60-3.80 (m, 3H), 2.51 (t, J = 2.0 Hz, 2H), 1.68-1.82 (m, 4H)

Example 131

- 10 4-Hydroxy-8-(4-β-hydroxyethylamino-sulfonylphenyl)pyrazolo[1,5-a]-1,3,5-triazine

- m.p. 268 - 270 °C
 NMR (DMSO-d₆) δ: 8.68 (s, 1H), 8.24 (d, J = 8.6 Hz, 2H), 8.19 (s, 1H), 7.84 (d, J = 8.6 Hz, 2H), 7.54 (t, J = 6.1 Hz, 1H), 3.38 (t, J = 6.8 Hz, 2H), 2.70-3.00 (m, 2H)
- 15

Example 132

- 20 8-(4-Benzylamino-sulfonylphenyl)-4-hydroxypyrazolo[1,5-a]-1,3,5-triazine

- m.p. 283 - 286 °C
 NMR (DMSO-d₆) δ: 8.68 (s, 1H), 8.23 (d, J = 8.6 Hz, 2H), 8.19 (s, 1H), 8.10 (t, J = 6.4 Hz, 1H), 7.85 (d, J = 8.6 Hz, 2H), 7.26 (s, 5H), 4.02 (d, J = 6.4 Hz, 2H)

25 Example 133

8-(4-Furfurylamino-sulfonylphenyl)-4-hydroxypyrazolo[1,5-a]-1,3,5-triazine

- m.p. 214 °C (decomp.)
 NMR (DMSO-d₆) δ: 8.68 (s, 1H), 8.22 (d, J = 8.6 Hz, 2H), 8.19 (s, 1H), 8.12 (t, J = 5.9 Hz, 1H), 7.82 (d, J = 8.6 Hz, 2H), 7.48 (dd, J = 2.0 and 0.9 Hz, 1H), 6.31 (dd, J = 3.3 and 2.0 Hz, 1H), 6.19 (dd, J = 3.1 and 0.7 Hz, 1H), 4.04 (d, J = 5.9 Hz, 2H)
- 30

Example 134

- 35 4-Hydroxy-8-[4-(2-thienylmethylamino-sulfonyl)phenyl]pyrazolo[1,5-a]-1,3,5-triazine

- m.p. 240 - 245 °C
 NMR (DMSO-d₆) δ: 8.69 (s, 1H), 8.24 (d, J = 8.6 Hz, 2H), 8.23 (t, J = 5.9 Hz, 1H), 8.19 (s, 1H), 7.84 (d, J = 8.6 Hz, 2H), 7.38 (dd, J = 4.0 and 2.4 Hz, 1H), 6.92 (d, J = 4.2 Hz, 1H), 6.90 (t, J = 2.4 Hz, 1H), 4.21 (d, J = 5.9 Hz, 2H)
- 40

Example 135

- 45 8-(2-Dimethylamino-sulfonyl-5-methoxyphenyl)-4-hydroxypyrazolo[1,5-a]-1,3,5-triazine

- m.p. 246 - 248 °C
 NMR (DMSO-d₆) δ: 8.15 (s, 1H), 8.02 (s, 1H), 7.89 (d, J = 8.8 Hz, 1H), 7.14 (dd, J = 8.8 and 2.6 Hz, 1H), 7.04 (d, J = 2.6 Hz, 1H), 3.85 (s, 3H), 2.40 (s, 6H)
- 50

Example 136

8-(3-Chloro-4-dimethylamino-sulfonylphenyl)-4-hydroxypyrazolo[1,5-a]-1,3,5-triazine

- 55 m.p. 291 - 294 °C
 NMR (DMSO-d₆) δ: 8.76 (s, 1H), 8.38 (d, J = 1.5 Hz, 1H), 8.24 (s, 1H), 8.19 (dd, J = 8.4 and 1.5 Hz, 1H), 7.97 (d, J = 8.4 Hz, 1H), 2.82 (s, 6H)

Example 137

8-(4-Aminosulfonyl-3-chlorophenyl)-4-hydroxypyrazolo[1,5-a]-1,3,5-triazine

6 m.p. >300 °C

NMR (DMSO-d₆) δ: 8.74 (s, 1H), 8.34 (d, J = 1.3 Hz, 1H), 8.23 (s, 1H), 8.06 (dd, J = 8.4 and 1.3 Hz, 1H), 7.99 (d, J = 8.4 Hz, 1H), 7.55 (s, 2H)Example 138

10

8-(4-Dimethylaminosulfonyl-3-methylphenyl)-4-hydroxypyrazolo[1,5-a]-1,3,5-triazine

m.p. 256 - 258 °C

15 NMR (DMSO-d₆) δ: 8.68 (s, 1H), 8.19 (s, 1H), 8.05-8.13 (m, 2H), 7.80 (d, J = 8.8 Hz, 1H), 2.74 (s, 6H), 2.50 (s, 3H)Example 139

20

4-Hydroxy-8-[4-(4-t-butylphenylaminosulfonyl)-3-methylphenyl]pyrazolo[1,5-a]-1,3,5-triazine

m.p. 258 - 260 °C

NMR (DMSO-d₆) δ: 10.24 (s, 1H), 8.63 (s, 1H), 8.17 (s, 1H), 7.99 (bs, 3H), 7.23 (d, J = 8.8 Hz, 2H), 7.00 (d, J = 8.8 Hz, 2H), 2.50 (s, 3H), 1.18 (s, 9H)25 Example 140

8-(4-Chloro-3-dimethylaminosulfonylphenyl)-4-hydroxypyrazolo[1,5-a]-1,3,5-triazine

m.p. 294 - 299 °C

30 NMR (DMSO-d₆) δ: 8.70 (s, 2H), 8.23 (s, 1H), 8.20 (dd, J = 8.6 and 2.2 Hz, 1H), 7.75 (d, J = 8.6 Hz, 1H), 2.87 (s, 6H)Example 141

35 8-(4-Bromophenyl)-4-hydroxypyrazolo[1,5-a]-1,3,5-triazine

To a suspension of 4-hydroxy-8-phenylpyrazolo[1,5-a]-1,3,5-triazine (420 mg) and aluminum chloride (1.6 g) in nitrobenzene (2 ml) is added bromine (0.5 ml), and the mixture is stirred at 60 °C. After reacting for 15 hours, to the reaction mixture is added water. The resulting precipitate is separated by filtration,
40 washed with hot methanol to give the title compound (340 mg).

m.p. >300 °C

NMR (DMSO-d₆) δ: 8.60 (s, 1H), 8.13 (s, 1H), 8.00 (d, J = 8.6 Hz, 2H), 7.61 (d, J = 8.6 Hz, 2H)

In the same manner as described in Example 141 by using appropriate starting materials, there are prepared the compounds of Examples 142 to 147.

45

Example 142

8-(4-Bromo-3-methylphenyl)-4-hydroxypyrazolo[1,5-a]-1,3,5-triazine

50 m.p. >300 °C

NMR (DMSO-d₆) δ: 8.59 (s, 1H), 8.14 (s, 1H), 8.00 (d, J = 1.5 Hz, 1H), 7.77 (dd, J = 8.3 and 1.5 Hz, 1H), 7.61 (d, J = 8.3 Hz, 1H), 2.39 (s, 3H)

55

Example 143

8-(4-Bromo-3-chlorophenyl)-4-hydroxypyrazolo[1,5-a]-1,3,5-triazine

5 m.p. >300 °C

NMR (DMSO-d₆) δ: 8.68 (s, 1H), 8.32 (d, J = 1.8 Hz, 1H), 8.18 (s, 1H), 7.95 (dd, J = 8.6 and 2.0 Hz, 1H), 7.79 (d, J = 8.6 Hz, 1H)Example 144

10

8-(4-Bromo-3,5-dimethylphenyl)-4-hydroxypyrazolo[1,5-a]-1,3,5-triazine

m.p. >300 °C

NMR (DMSO-d₆) δ: 8.57 (s, 1H), 8.14 (s, 1H), 7.84 (s, 2H), 2.41 (s, 6H)

15

Example 145

8-(4-Bromo-3-methoxyphenyl)-4-hydroxypyrazolo[1,5-a]-1,3,5-triazine

20 m.p. 288 - 291 °C (decomp.)

NMR (DMSO-d₆) δ: 8.65 (s, 1H), 8.13 (s, 1H), 7.70 (s, 1H), 7.59 (s, 2H), 3.92 (s, 3H)Example 146

25

8-(3-Bromo-4-methylthiophenyl)-4-hydroxypyrazolo[1,5-a]-1,3,5-triazine

m.p. 292 - 293 °C

NMR (DMSO-d₆) δ: 8.63 (s, 1H), 8.31 (d, J = 1.8 Hz, 1H), 8.15 (s, 1H), 8.02 (dd, J = 8.4 and 2.0 Hz, 1H), 7.31 (d, J = 8.4 Hz, 1H), 2.51 (s, 3H)

30

Example 147

8-[4-(4-Bromophenylthio)-3-methylphenyl]-4-hydroxypyrazolo[1,5-a]-1,3,5-triazine

35

m.p. >300 °C

NMR (DMSO-d₆) δ: 8.61 (s, 1H), 8.14 (s, 1H), 8.03 (d, J = 2.0 Hz, 1H), 7.93 (dd, J = 8.1 and 2.0 Hz, 1H), 7.50 (d, J = 8.8 Hz, 2H), 7.43 (d, J = 8.1 Hz, 1H), 7.10 (d, J = 8.6 Hz, 2H), 2.36 (s, 3H)Example 148

40

8-[2-(5-Bromothieryl)]-4-hydroxypyrazolo[1,5-a]-1,3,5-triazine

To a suspension of 4-hydroxy-8-(2-thienyl)pyrazolo[1,5-a]-1,3,5-triazine (440 mg) in nitrobenzene (4 ml) is added bromine (0.11 ml) under ice cooling, and the mixture is stirred at room temperature for 30 minutes.

45 To the reaction mixture is added diethyl ether, and the resulting precipitate is separated by filtration and recrystallized from N,N-dimethylformamide-methanol to give the title compound (280 mg).

m.p. 286 °C (decomp.)

NMR (DMSO-d₆) δ: 8.50 (s, 1H), 8.14 (s, 1H), 7.36 (d, J = 3.8 Hz, 1H), 7.21 (d, J = 3.8 Hz, 1H)

In the same manner as described in Example 148 by using appropriate starting materials, there are

50 prepared the compounds of Examples 149 to 151.

Example 149

8-[2-(4,5-Dibromothieryl)]-4-hydroxypyrazolo[1,5-a]-1,3,5-triazine

55

m.p. >300 °C

NMR (DMSO-d₆) δ: 8.66 (s, 1H), 8.18 (s, 1H), 7.35 (s, 1H)

Example 150

8-[3-(2-Bromothieryl)]-4-hydroxypyrazolo[1,5-a]-1,3,5-triazine

5 m.p. >300 °C
 NMR (DMSO-d₆) δ: 8.57 (s, 1H), 8.11 (s, 1H), 7.69 (d, J = 5.7 Hz, 1H), 7.54 (d, J = 5.7 Hz, 1H)

Example 151

10 8-[3-(2,5-Dibromothieryl)]-4-hydroxypyrazolo[1,5-a]-1,3,5-triazine

m.p. >300 °C
 NMR (DMSO-d₆) δ: 8.57 (s, 1H), 8.14 (s, 1H), 7.68 (s, 1H)

15 Example 152

4-Acetoxy-8-(3-methyl-4-methylthiophenyl)pyrazolo[1,5-a]-1,3,5-triazine

20 To a mixture of 4-hydroxy-8-(3-methyl-4-methylthiophenyl)pyrazolo[1,5-a]-1,3,5-triazine (0.100 g), triethylamine (0.1 ml) and methylene chloride (10 ml) is added dropwise acetyl chloride (0.1 ml) at room temperature. After reacting for 10 minutes, to the reaction mixture is added methylene chloride (90 ml). The mixture is washed with water (20 ml x 3), dried over anhydrous sodium sulfate, and concentrated under reduced pressure to give the title compound (0.110 g).

25 m.p. 213 °C
 NMR (CDCl₃) δ: 8.63 (s, 1H), 8.30 (s, 1H), 7.70 (bd, J = 8.36 Hz, 1H), 7.65 (bs, 1H), 7.21 (d, J = 8.79 Hz, 1H), 2.92 (s, 3H), 2.49 (s, 3H), 2.39 (s, 3H)

In the same manner as described in Example 1 by using appropriate starting materials, there are prepared the compounds of Examples 153 to 159

30 Example 153

4-Hydroxy-8-(4-phenylthiomethylphenyl)pyrazolo[1,5-a]-1,3,5-triazine

35 m.p. >300 °C
 NMR (DMSO-d₆) δ: 8.54 (s, 1H), 8.10 (s, 1H), 7.68 (d, J = 8.3 Hz, 2H), 7.39 (d, J = 8.3 Hz, 2H), 7.14-7.34 (m, 5H), 4.24 (s, 2H)

Example 154

40 4-Hydroxy-8-(3-phenoxyphenyl)pyrazolo[1,5-a]-1,3,5-triazine

m.p. 292 - 293 °C
 NMR (DMSO-d₆) δ: 8.59 (s, 1H), 8.10 (s, 1H), 7.7-7.8 (m, 2H), 7.3-7.5 (m, 3H), 6.8-7.2 (m, 4H)

45 Example 155

4-Hydroxy-8-[3-methyl-4-(pyridin-2-ylthio)phenyl]pyrazolo[1,5-a]-1,3,5-triazine

50 m.p. >300 °C
 NMR (DMSO-d₆) δ: 8.64 (s, 1H), 8.38 (ddd, J = 4.8, 2.0 and 1.0 Hz, 1H), 8.16 (s, 1H), 8.08 (d, J = 1.7 Hz, 1H), 7.97 (dd, J = 8.0 and 1.7 Hz, 1H), 7.61 (d, J = 8.0 Hz, 1H), 7.61 (ddd, J = 8.5, 8.1 and 2.0 Hz, 1H), 7.11 (ddd, J = 8.5, 4.8 and 1.0 Hz, 1H), 6.84 (dt, J = 8.1 and 1.0 Hz, 1H), 2.37 (s, 3H)

55

Example 156

4-Hydroxy-8-(3-methoxy-4-methylthiophenyl)pyrazolo[1,5-a]-1,3,5-triazine

- 5 m.p. 284 - 285 °C
 NMR (DMSO-d₆) δ: 8.61 (s, 1H), 8.11 (s, 1H), 7.66 (dd, J = 8.13 and 1.54 Hz, 1H), 7.61 (bs, 1H), 7.18 (d, J = 8.13 Hz, 1H), 3.89 (s, 3H), 2.40 (s, 3H)

Example 157

- 10 4-Hydroxy-8-(3-methoxy-4-phenylthiophenyl)pyrazolo[1,5-a]-1,3,5-triazine

- m.p. 247 - 248 °C
 NMR (DMSO-d₆) δ: 8.64 (s, 1H), 8.13 (s, 1H), 7.74 (d, J = 1.75 Hz, 1H), 7.63 (dd, J = 7.91 and 1.75 Hz, 1H), 7.22-7.35 (m, 5H), 7.15 (d, J = 7.91 Hz, 1H)

Example 158

- 20 8-(3-Chloro-4-phenylthiophenyl)-4-hydroxypyrazolo[1,5-a]-1,3,5-triazine

- m.p. 290 - 293 °C
 NMR (DMSO-d₆) δ: 8.62 (s, 1H), 8.27 (d, J = 2.0 Hz, 1H), 8.15 (s, 1H), 7.92 (dd, J = 8.4 and 2.0 Hz, 1H), 7.41 (s, 5H), 7.16 (d, J = 8.4 Hz, 1H)

Example 159

- 25 8-(2-Fluoro-3-methyl-4-methylthiophenyl)-4-hydroxypyrazolo[1,5-a]-1,3,5-triazine

- 30 m.p. >300 °C
 NMR (DMSO-d₆) δ: 8.33 (d, J = 3.5 Hz, 1H), 8.12 (s, 1H), 7.99 (t, J = 8.3 Hz, 1H), 7.14 (d, J = 8.1 Hz, 1H), 2.51 (s, 3H), 2.23 (s, 3H)
 In the same manner as described in Example 89 by using appropriate starting materials, there are prepared the compounds of Examples 160 to 164

Example 160

- 35 8-(2-Fluoro-5-methyl-4-methylsulfinylphenyl)-4-hydroxypyrazolo[1,5-a]-1,3,5-triazine

- 40 m.p. >300 °C
 NMR (DMSO-d₆) δ: 8.41 (d, J = 3.5 Hz, 1H), 8.19 (s, 1H), 8.08 (d, J = 7.5 Hz, 1H), 7.62 (d, J = 10.5 Hz, 1H), 2.74 (s, 3H), 2.35 (s, 3H)

Example 161

- 45 4-Hydroxy-8-(4-phenylsulfinylphenyl)pyrazolo[1,5-a]-1,3,5-triazine

- m.p. 290 - 291 °C (decomp.) NMR (DMSO-d₆) δ: 8.60 (s, 1H), 8.17 (d, J = 8.57 Hz, 2H), 8.13 (s, 1H), 7.75 (d, J = 8.57 Hz, 2H), 7.64-7.74 (m, 2H), 7.47-7.60 (m, 3H)

Example 162

- 50 4-Hydroxy-8-(3-methyl-4-phenylsulfinylphenyl)pyrazolo[1,5-a]-1,3,5-triazine

- 55 m.p. 243 - 245.5 °C
 NMR (DMSO-d₆) δ: 8.60 (s, 1H), 8.14 (s, 1H), 8.11 (bd, J = 8.35 Hz, 1H), 7.93 (bs, 1H), 7.84 (d, J = 8.35 Hz, 1H), 7.47-7.67 (m, 5H)

Example 163

4-Hydroxy-8-(3-methoxy-4-methylsulfinylphenyl)pyrazolo[1,5-a]-1,3,5-triazine

m.p. 259 - 260 °C

NMR (DMSO-d₆) δ: 8.70 (s, 1H), 8.16 (s, 1H), 7.92 (bd, J = 7.91 Hz, 1H), 7.75 (bs, 1H), 7.66 (d, J = 8.13 Hz, 1H), 3.95 (s, 3H), 2.73 (s, 3H)

Example 164

4-Hydroxy-8-(3-methoxy-4-phenylsulfinylphenyl)pyrazolo[1,5-a]-1,3,5-triazine monohydrate

m.p. 173 - 175 °C

NMR (DMSO-d₆) δ: 8.66 (s, 1H), 8.15 (s, 1H), 7.45-7.95 (m, 8H), 3.88 (s, 3H)

The above monohydrate compound is dried at 80 °C for 12 hours to give the corresponding anhydrous compound, m.p. 258 - 266 °C (decomp.)

In the same manner as described in Example 91 by using an appropriate starting material, there is prepared the compound of Example 165.

Example 165

8-(2-Fluoro-5-methyl-4-methylsulfonylphenyl)-4-hydroxypyrazolo[1,5-a]-1,3,5-triazine

m.p. >300 °C

NMR (DMSO-d₆) δ: 8.44 (d, J = 3.7 Hz, 1H), 8.27 (d, J = 7.0 Hz, 1H), 8.24 (s, 1H), 7.75 (D, J = 10.0 Hz, 1H), 3.28 (s, 3H), 2.54 (s, 3H)

In the same manner as described in Example 141 by using appropriate starting materials, there are prepared the compounds of Examples 160 to 167.

Example 166

8-[4-(3-Bromo-4-methoxyphenylthio)-3-methylphenyl]-4-hydroxypyrazolo[1,5-a]-1,3,5-triazine

m.p. 280 - 285 °C

NMR (DMSO-d₆) δ: 8.56 (s, 1H), 8.12 (s, 1H), 7.87 (d, J = 1.6 Hz, 1H), 7.83 (dd, J = 7.9 and 1.6 Hz, 1H), 7.48 (d, J = 2.0 Hz, 1H), 7.32 (dd, J = 8.4 and 2.2 Hz, 1H), 7.19 (d, J = 8.1 Hz, 1H), 7.13 (d, J = 8.5 Hz, 1H), 3.85 (s, 3H), 2.37 (s, 3H)

Example 167

8-[4-(2,4-Dibromo-5-methoxyphenylthio)-3-methylphenyl]-4-hydroxypyrazolo[1,5-a]-1,3,5-triazine

m.p. >300 °C

NMR (DMSO-d₆) δ: 8.64 (s, 1H), 8.15 (s, 1H), 8.12 (d, J = 1.5 Hz, 1H), 8.00 (dd, J = 8.1 and 1.5 Hz, 1H), 7.87 (s, 1H), 7.46 (d, J = 7.9 Hz, 1H), 6.47 (s, 1H), 3.53 (s, 3H), 2.38 (s, 3H)

Example 168

4-Hydroxy-8-(3-methoxy-4-phenylsulfinylphenyl)pyrazolo[1,5-a]-1,3,5-triazine monohydrate

To a suspension of 4-hydroxy-8-(3-methoxy-4-phenylthiophenyl)pyrazolo[1,5-a]-1,3,5-triazine (11.21 g) in acetic acid (384 ml) is added 30 % hydrogen peroxide (10.24 ml) over a period of about 3.5 hours. The mixture is stirred at room temperature for 28 hours, and to the reaction mixture is added water (400 ml). The resulting precipitate is separated by filtration, washed with water and dried to give the title compound (11.31 g).

NMR (DMSO-d₆) δ: 8.66 (s, 1H), 8.15 (s, 1H), 7.45-7.95 (m, 8H), 3.88 (s, 3H)

The above monohydrate compound is dried at 80 °C under reduced pressure for 12 hours to give the corresponding anhydrous compound, m.p. 258 - 266 °C (decomp.)

In the same manner as described in Example 1 by using an appropriate starting material, there is prepared the compound of Example 169.

Example 169

8-(Dibenzothiophen-2-yl)-4-hydroxypyrazolo[1,5-a]-1,3,5-triazine

m.p. >300 °C

NMR (DMSO-d₆) δ: 8.94 (d, J = 1.1 Hz, 1H), 8.80 (s, 1H), 7.98-8.46 (m, 4H), 8.18 (s, 1H), 7.49-7.59 (m,

2H)

In the same manner as described in Example 162 by using an appropriate starting material, there is prepared the compound of Example 170.

Example 170

4-Hydroxy-8-[3-methyl-4-(pyridin-2-ylsulfinyl)phenyl]pyrazolo[1,5-a]-1,3,5-triazine

m.p. 172 - 174 °C

NMR (DMSO-d₆) δ: 8.58 (s, 1H), 8.55 (dt, J = 4.83 and 1.10 Hz, 1H), 8.13 (s, 1H), 7.93-8.10 (m, 4H),

7.71 (d, J = 8.13 Hz, 1H), 7.47 (ddd, J = 6.59, 4.56 and 2.20 Hz, 1H), 2.61 (s, 3H)

In the same manner as described in Example 91 by using appropriate starting materials, there are prepared the compounds of Examples 171 to 174.

Example 171

4-Hydroxy-8-(4-phenylsulfonylphenyl)pyrazolo[1,5-a]-1,3,5-triazine

m.p. >300 °C

NMR (DMSO-d₆) δ: 8.66 (s, 1H), 8.26 (d, J = 8.79 Hz, 2H), 8.18 (s, 1H), 7.99 (d, 2H), 7.92-8.01 (m, 2H),

7.59-7.71 (m, 3H)

Example 172

4-Hydroxy-8-(3-methyl-4-phenylsulfonylphenyl)pyrazolo[1,5-a]-1,3,5-triazine

m.p. 297 - 298 °C (decomp.)

NMR (DMSO-d₆) δ: 8.66 (s, 1H), 8.18 (s, 1H), 8.17 (s, 1H), 8.16 (s, 1H), 8.02 (bs, 1H), 7.82-7.93 (m, 2H),

7.60-7.73 (m, 3H)

Example 173

4-Hydroxy-8-(3-methoxy-4-phenylsulfonylphenyl)pyrazolo[1,5-a]-1,3,5-triazine

m.p. 286 - 287 °C

NMR (DMSO-d₆) δ: 8.71 (s, 1H), 8.18 (s, 1H), 8.04 (d, J = 8.35 Hz, 1H), 7.56-7.96 (m, 7H)

Example 174

4-Hydroxy-8-[3-methyl-4-(3-methylphenylsulfonyl)phenyl]pyrazolo[1,5-a]-1,3,5-triazine

m.p. 278 - 280 °C (decomp.)

NMR (DMSO-d₆) δ: 8.65 (s, 1H), 8.18 (s, 1H), 8.15 (s, 2H), 8.02 (bs, 1H), 7.46-7.66 (m, 4H), 2.42 (s, 3H),

2.39 (s, 3H)

Example 175

4-Hydroxy-8-(3-methoxy-4-phenylsulfinylphenyl)pyrazolo[1,5-a]-1,3,5-triazine dihydrate

- 5 4-Hydroxy-8-(3-methoxy-4-phenylsulfinylphenyl)pyrazolo[1,5-a]-1,3,5-triazine monohydrate (80 g) is dissolved in N,N-dimethylformamide (600 ml), and the insoluble material is filtered off. To the filtrate is added water (3 liters), and the resulting precipitate is separated by filtration and refluxed in acetone (1.6 liter) for 2 hours. After cooling, the precipitate is separated by filtration and refluxed in chloroform-methanol (1 : 1, 800 ml) for 2 hours. After cooling, the precipitate is again separated by filtration and refluxed in 50 % ethanol
 10 (1.5 liter) for 3 hours. After cooling, the precipitate is separated by filtration and dried under reduced pressure at 80 °C for 10 hours to give the title compound (60.5 g).

m.p. 226 - 235 °C

NMR (DMSO-d₆) (90 MHz) δ : 8.66 (s, 1H), 8.15 (s, 1H), 7.46-7.94 (m, 8H), 3.88 (s, 3H)

15

Elementary analysis:			
Calcd. (%):	C,53.72;	H,4.51;	N,13.92
Found (%):	C,54.10;	H,4.70;	N,13.96

20

Example 176

4-Hydroxy-8-(3-methoxy-4-phenylsulfinylphenyl)pyrazolo[1,5-a]-1,3,5-triazine semihydrate

- 25 4-Hydroxy-8-(3-methoxy-4-phenylsulfinylphenyl)pyrazolo[1,5-a]-1,3,5-triazine dihydrate (3 g) is suspended in ethanol (70 ml), and the mixture is refluxed for 3 hours. After cooling, the precipitate is separated by filtration and is again suspended in ethanol (70 ml), and the mixture is refluxed for 3 hours. After cooling, the precipitate is separated by filtration and dried under reduced pressure at 110 °C for 20 hours to give the title compound (2.8 g).

30

m.p. 245 - 246 °C (decomp.)

NMR (DMSO-d₆) (270 MHz) δ : 8.69 (s, 1H), 8.18 (s, 1H), 7.90 (d, J=8.1 Hz, 1H), 7.76 (d, J=8.2 Hz, 1H), 7.50-7.71 (m, 6H), 3.89 (s, 3H)

35

Elementary analysis:			
Calcd. (%):	C,57.59;	H,4.03;	N,14.93
Found (%):	C,57.46;	H,4.06;	N,14.81

40

Example 177

4-Hydroxy-8-(3-methoxy-4-phenylsulfinylphenyl)pyrazolo[1,5-a]-1,3,5-triazine

- 45 4-Hydroxy-8-(3-methoxy-4-phenylsulfinylphenyl)pyrazolo[1,5-a]-1,3,5-triazine dihydrate (15 g) is suspended in ethyl acetate (450 ml), and the mixture refluxed for 3 hours. After cooling, the precipitate is separated by filtration and is again suspended in ethyl acetate (400 ml), and the mixture is refluxed for 3 hours. After cooling, the precipitate is separated by filtration and dried under reduced pressure at 120 °C for 50 hours to give the title compound (13.7 g).

50

NMR (DMSO-d₆) (270 MHz) δ : 8.69 (s, 1H), 8.18 (s, 1H), 7.90 (d, J=8.1 Hz, 1H), 7.77 (d, J=8.2 Hz, 1H), 7.50-7.70 (m, 6H), 3.89 (s, 3H)

55

Elementary analysis:			
Calcd. (%):	C,59.01;	H,3.85;	N,15.29
Found (%):	C,59.07;	H,3.85;	N,15.09

Preparations of this invention are illustrated below.

Preparation

Film coated tablets are prepared from the following components.

Components	Amount
4-Hydroxy-8-[4-(4-methylphenylthio)phenyl]pyrazolo[1,5-a]-1,3,5-triazine	100 g
Avicel® (tradename of microcrystalline cellulose, manufactured by Asahi Chemical, Japan)	40 g
Corn starch	30 g
Magnesium stearate	2 g
TC-5 (tradename of hydroxypropyl methylcellulose manufactured by Shinetsh Kagaku Kogyo, Japan)	10 g
Polyethylene glycol 6000	3 g
Castor oil	40 g
Ethanol	40 g

4-Hydroxy-8-[4-(4-methylphenylthio)phenyl]pyrazolo[1,5-a]-1,3,5-triazine, Avicel®, corn starch and magnesium stearate are mixed and kneaded and the mixture is tabletted using a conventional pounder (R 10 mm) for sugar coating. The tablets thus obtained are coated with film coating agent consisting of TC-5, polyethylene glycol 6000, castor oil and ethanol to give film coated tablets.

The pharmacological properties of the compounds were tested as shown in the following Experiments.

Experiment 1 (In vitro)

(1) Preparation of xanthine oxidase solution:

ICR strain mice were decapitated and the small intestine of each mouse was rapidly perfused with cooled physiological saline solution and removed. The small intestine was homogenized in 4-fold volume of cooled phosphate buffered saline solution (PBS) and then centrifuged at 105,000 g for 60 minutes. The supernatant fluid was dialyzed overnight against PBS. The dialyzed solution thus prepared was stored at -20 °C until used.

(2) Preparation of the solution containing the present compound:

The compound of this invention was dissolved in DMSO (200 μ l) and 2N NaOH (100 μ l), and then PBS was added to prepare a solution (25 ml) containing 10^{-3} M of the compound of this invention. This solution was diluted with PBS to prepare solutions containing the compound in the concentration of 10^{-4} , 10^{-5} , 10^{-6} , 10^{-7} , 10^{-8} , 10^{-9} , 10^{-10} , and 10^{-11} M, respectively.

(3) Method for the measurement:

The assay mixture, consisted of the composition mentioned below, was incubated at 37 °C for 5 minutes. The reaction was stopped by heating in boiling water for one minute. Twenty microliters of the supernatant was analyzed by high performance liquid chromatography (HPLC) under the conditions mentioned below.

Composition of solution

Xanthine oxidase solution (diluted in 4-folds with PBS)	200 μ l
Xanthine (1 mM)	100 μ l
Solution containing the present compound	200 μ l
PBS	500 μ l

Conditions of HPLC

Column: Cosmosil packed column (ϕ 4.6 mm x 150 mm, 5C₁₈-300)

Eluting solution: 10 mM phosphate buffer (pH 6.0)

Flow rate: 1.0 ml/minute

Detector: UV 292 nm

Sample volume: 20 μ l

Retention time: 2.4 minutes (uric acid)

(4) Percent inhibition of the compound against xanthine oxidase:

The percent inhibition was calculated by the following equation.

Percent inhibition (%) =

$$\frac{[\text{Amount of uric acid in control solution}] - [\text{Amount of uric acid in the solution treated with the present compound}]}{\text{Amount of uric acid in control solution}^*} \times 100$$

*) Control solution means a mixture of DMSO and 2N NaOH used for the preparation of the solution containing the present compound.

As to each of the solutions containing the present compound as prepared in the above (2), the present inhibition was calculated, and IC₅₀ values were obtained from a plot of the percent inhibition against the log of the concentration of the compound of this invention.

As a positive control, a commercially available xanthine oxidase inhibitor, allopurinol (= 4-hydroxypyrazolo[3,4-d]pyrimidine) was used.

The experimental results are shown in the table hereinafter.

Experiment 2 (In vivo: oral administration)

(1) Animals, method of administration and sampling of serum:

5 Normal male ICR mice (weighting about 30 g), were provided normal diet and tap water *ad libitum*. A test compound suspended in 0.5 % CMC-Na was administered orally to the mice (each group: 6 mice) in a dose of 5 mg/kg. Four hours after the administration of the test compound, blood (about 0.6 ml) was collected from the vena cave inferior of mice under ether anesthesia, and the serum was separated from the blood in a usual manner.

10

(2) Measurement of amount of uric acid in serum:

To the serum (200 μ l) was added 10 % perchloric acid (100 μ l), and the mixture was centrifuged. To the supernatant fluid (100 μ l) was added 0.2 M Na_2HPO_4 (200 μ l), and the mixture (20 μ l) was analyzed by HPLC to measure the amount of uric acid. The HPLC was carried out under the following conditions.

15

Column: Cosmosil packed column (ϕ 4.6 mm x 150 mm,
5C₁₈-300)

20

Eluting solution: 10 mM phosphate buffer (pH 6.0)

Flow rate: 1.0 ml/minute

25

Detector: UV 292 nm

Sample volume: 20 μ l

Retention time: 2.4 minutes (uric acid)

30

(3) Lowering effect of test compound on the level of uric acid in serum:

35 The lowering rate of uric acid in serum was calculated by the following equation.

Lowering rate of uric acid in serum (%) =

40

$$\frac{\left[\begin{array}{l} \text{Amount of uric} \\ \text{acid in control} \\ \text{animal} \end{array} \right] - \left[\begin{array}{l} \text{Amount of uric acid in} \\ \text{the animal treated with} \\ \text{the present compound} \end{array} \right]}{\text{Amount of uric acid in control animal}} \times 100$$

45

As a positive control, a commercially available xanthine oxidase inhibitor, allopurinol was used.

50

55

The experimental results are shown in the table hereinafter.

5	Example No. of Test compound	in vitro Xanthine oxidase inhibition (IC ₅₀)	in vivo Lowering rate (%) of uric acid in serum (in 4 hours)
	17	3.0×10^{-8}	Not tested
10	19	1.6×10^{-7}	Not tested
	21	3.1×10^{-7}	Not tested
15	30	7.1×10^{-8}	47 %
	31	1.0×10^{-8}	63.5 %
	33	1.8×10^{-8}	62 %
20	39	4.5×10^{-8}	Not tested
	41	2.4×10^{-8}	60.1 %
25	43	1.0×10^{-8}	60.6 %
	52	5.3×10^{-8}	Not tested
	53	1.5×10^{-8}	Not tested
30	54	5.5×10^{-7}	65.2 %
	70	5.2×10^{-9}	Not tested
35	73	4.0×10^{-8}	Not tested
	74	5.0×10^{-8}	Not tested
	95	3.6×10^{-9}	Not tested
40	96	1.0×10^{-10}	Not tested
	97	4.5×10^{-10}	Not tested
45	99	1.4×10^{-10}	Not tested
	100	7.5×10^{-10}	Not tested
	101	5.4×10^{-8}	Not tested
50	105	2.2×10^{-9}	Not tested

- to be continued -

5

10

15

20

25

30

35


Example No. of Test compound	in vitro Xanthine oxidase inhibition (IC ₅₀)	in vivo Lowering rate (%) of uric acid in serum (in 4 hours)
107	6.4×10^{-8}	Not tested
109	3.6×10^{-9}	Not tested
112	6.5×10^{-9}	Not tested
113	3.4×10^{-8}	Not tested
134	7.6×10^{-8}	Not tested
136	3.2×10^{-8}	Not tested
138	3.9×10^{-8}	Not tested
142	5.2×10^{-8}	Not tested
143	3.6×10^{-8}	Not tested
146	2.7×10^{-9}	47.0 %
158	5.0×10^{-9}	Not tested
161	8.0×10^{-9}	57.2 %
162	2.4×10^{-9}	73.6 %
177	2.5×10^{-8}	63.9 %
Reference Allopurinol	2.0×10^{-6}	34 %

40 Claims

Claims for the following Contracting States : CH, DE, FR, GB, IT, LI, NL, SE

1. A pyrazolotriazine compound of the formula:

45



(1)

50

wherein

55

R¹ is hydroxy or an C₁₋₆ alkanoyloxy,


R² is hydrogen atom,

R³ is (1) an unsaturated heterocyclic group


selected from pyrrolyl, pyridyl, thienyl, thiopyranyl, indolyl, benzothienyl, 2,3-dihydrobenzothienyl,

thiochromanyl, dibenzothieryl, which


may optionally have one or two substituents selected from a halogen atom, nitro, and phenylthio, (2) naphthyl, and (3) a phenyl which may optionally have one to three substituents selected from the group consisting of (i) an C₁₋₆ alkyl, (ii) phenyl, (iii) an C₁₋₆ alkoxy, (iv) cyano, (v) nitro, (vi) an C₁₋₆ alkoxy, (vii) a phenyl-C₁₋₆ alkoxy, (viii) a phenylthio-C₁₋₆ alkyl, (ix) phenoxy, (x) a group of the formula:



wherein R is an C₁₋₆ alkyl, a halogen-substituted C₁₋₆ alkyl, a phenyl which may optionally have one to three substituents selected from a halogen atom, an C₁₋₆ alkyl and an C₁₋₆ alkoxy, or pyridyl, and t is an integer of 0, 1 or 2, (xi) a halogen atom, (xii) a phenyl-C₁₋₆ alkyl, (xiii) carboxy, (xiv) an C₁₋₆ alkanoyl, (xv) a benzoyl which may optionally have one to three substituents selected from a halogen atom, a phenyl-C₁₋₆ alkoxy and hydroxy on the phenyl ring, (xvi) amino, (xvii) hydroxy, (xviii) an C₁₋₆ alkanoyloxy, (xix) a group of the formula:




wherein R⁴ and R⁵ are the same or different and are each hydrogen atom, a C₃₋₈ cycloalkyl, an C₁₋₆ alkyl which may optionally have a substituent selected from hydroxy, furyl, thienyl, tetrahydrofuranyl and phenyl, a phenyl which may optionally have one to three substituents selected from an C₁₋₆ alkyl, a hydroxy-substituted C₁₋₆ alkyl, an C₁₋₆ alkanoyl, cyano, carboxy, an C₁₋₆ alkoxy, and a halogen atom, or a heterocyclic group selected from pyridyl, pyrimidinyl, thiazolyl, isoxazolyl, and pyrazolyl, said heterocyclic group being optionally substituted by an C₁₋₆ alkyl, amino, or an C₁₋₆ alkanoylamino, or R⁴ and R⁵ may join together with the adjacent nitrogen atom to form a saturated 5- or 6-membered heterocyclic group which may optionally be intervened with oxygen atom, or (xx) a group of the formula:




wherein A is an C₁₋₆ alkylene.

2. The compound according to claim 1, wherein


R³ is (1) an unsaturated heterocyclic group selected from pyrrolyl, pyridyl, thienyl, thiopyranyl, indolyl, benzothieryl, 2,3-dihydrobenzothieryl, thiochromanyl, or dibenzothieryl, which may optionally have one or two substituents selected from a halogen atom, nitro, and phenylthio, (2) naphthyl, and (3) a phenyl which may optionally have one to three substituents selected from the group consisting of (i) a C₁₋₆ alkyl, (ii) phenyl, (iii) a C₁₋₆ alkoxy, (iv) cyano, (v) nitro, (vi) a C₁₋₆ alkoxy, (vii) a phenyl-C₁₋₆ alkoxy, (viii) a phenylthio-C₁₋₆ alkyl, (ix) phenoxy, (x) a group of the formula:



wherein R is a C₁₋₆ alkyl, a halogen-substituted C₁₋₆ alkyl, a phenyl which may optionally have one to three substituents selected from a halogen atom, a C₁₋₆ alkyl and a C₁₋₆ alkoxy, or pyridyl, and l is an integer of 0, 1 or 2, (xi) a halogen atom, (xii) a phenyl(C₁₋₆)alkyl, (xiii) carboxy, (xiv) a C₁₋₆ alkanoyl, (xv) a benzoyl which may optionally have one to three substituents selected from a halogen atom, a phenyl(C₁₋₆)alkoxy and hydroxy on the phenyl ring, (xvi) amino, (xvii) hydroxy, (xviii) a C₁₋₆ alkanoyloxy, (xix) a group of the formula:




wherein R⁴ and R⁵ are the same or different and are each hydrogen atom, a cycloalkyl, a C₁₋₆ alkyl which may optionally have a substituent selected from hydroxy, furyl, thienyl, tetrahydrofuranyl and phenyl, a phenyl which may optionally have one to three substituents selected from a C₁₋₆ alkyl, a hydroxy-substituted C₁₋₆ alkyl, a C₁₋₆ alkanoyl, cyano, carboxy, a C₁₋₆ alkoxycarbonyl, hydroxy, a C₁₋₆ alkoxy, and a halogen atom, or a heterocyclic group selected from pyridyl, pyrimidinyl, thiazolyl, isoxazolyl, and pyrazolyl, said heterocyclic group being optionally substituted by a C₁₋₆ alkyl, amino, or a C₁₋₆ alkanoylamino, or R⁴ and R⁵ may join together with the adjacent nitrogen atom to form a heterocyclic group selected from the group consisting of pyrrolidinyl, piperidinyl, tetrahydro-1,2-oxazinyl, tetrahydro-1,3-oxazinyl, and morpholino, or (xx) a group of the formula:




wherein A is a C₁₋₄ alkylene.


3. The compound according to claim 2, wherein R¹ is hydroxy.
4. The compound according to claim 2, wherein R¹ is a C₁₋₆ alkanoyloxy.
5. The compound according to claim 3, wherein R³ is a phenyl which has at least one substituent of a group of the formula:



(wherein R is a C₁₋₆ alkyl, a halogen-substituted C₁₋₆ alkyl, a phenyl which may optionally have one to three substituents selected from a halogen atom, a C₁₋₆ alkyl and a C₁₋₆ alkoxy, or pyridyl, and l is an integer of 0, 1 or 2) and may optionally have further one or two substituents selected from the group consisting of (i) a C₁₋₆ alkyl, (ii) phenyl, (iii) a C₁₋₆ alkoxycarbonyl, (iv) cyano, (v) nitro, (vi) a C₁₋₆ alkoxy, (vii) a phenyl(C₁₋₆)alkoxy, (viii) a phenylthio(C₁₋₆)alkyl, (ix) phenoxy, (x) a halogen atom, (xi) a phenyl(C₁₋₆)alkyl, (xii) carboxy, (xiii) a C₁₋₆ alkanoyl, (xiv) a benzoyl which may optionally have one to three substituents selected from a halogen atom, a phenyl(C₁₋₆)alkoxy and hydroxy on the phenyl ring, (xv) amino, (xvi) hydroxy, (xvii) a C₁₋₆ alkanoyloxy, (xviii) a group of the formula:




wherein R⁴ and R⁵ are the same or different and are each hydrogen atom, a cycloalkyl, a C₁₋₆ alkyl which may optionally have a substituent selected from hydroxy, furyl, thienyl, tetrahydrofuranyl and phenyl, a phenyl which may optionally have one to three substituents selected from a C₁₋₆ alkyl, a hydroxy-substituted C₁₋₆ alkyl, a C₁₋₆ alkanoyl, cyano, carboxy, a C₁₋₆ alkoxycarbonyl, hydroxy, a C₁₋₆ alkoxy, and a halogen atom, or a heterocyclic group selected from pyridyl, pyrimidinyl, thiazolyl, isoxazolyl, and pyrazolyl, said heterocyclic group being optionally substituted by a C₁₋₆ alkyl, amino, or a C₁₋₆ alkanoylamino, or R⁴ and R⁵ may join together with the adjacent nitrogen atom to form a heterocyclic group selected from the group consisting of pyrrolidinyl, piperidinyl, tetrahydro-1,2-oxazinyl, tetrahydro-1,3-oxazinyl, and morpholino, or (xx) a group of the formula:




wherein A is a C₁₋₄ alkylene.


6. The compound according to claim 3, wherein R³ is a phenyl which has at least one substituent of the formula



(wherein R⁴ and R⁵ are the same or different and are each hydrogen atom, a cycloalkyl, a C₁₋₆ alkyl which may optionally have a substituent selected from hydroxy, furyl, thienyl, tetrahydrofuranyl and phenyl, a phenyl which may optionally have one to three substituents selected from a C₁₋₆ alkyl, a hydroxy-substituted C₁₋₆ alkyl, a C₁₋₆ alkanoyl, cyano, carboxy, a C₁₋₆ alkoxycarbonyl, hydroxy, a C₁₋₆ alkoxy, and a halogen atom, or a heterocyclic group selected from pyridyl, pyrimidinyl, thiazolyl, isoxazolyl, and pyrazolyl, said heterocyclic group being optionally substituted by a C₁₋₆ alkyl, amino, or a C₁₋₆ alkanoylamino, or R⁴ and R⁵ may join together with the adjacent nitrogen atom to form a heterocyclic group selected from the group consisting of pyrrolidinyl, piperidinyl, tetrahydro-1,2-oxazinyl, tetrahydro-1,3-oxazinyl, and morpholino) and may optionally have further one or two substituents selected from the group consisting of (i) a C₁₋₆ alkyl, (ii) phenyl, (iii) a C₁₋₆ alkoxycarbonyl, (iv) cyano, (v) nitro, (vi) a C₁₋₆ alkoxy, (vii) a phenyl(C₁₋₆)alkoxy, (viii) a phenylthio(C₁₋₆)alkyl, (ix) phenoxy, (x) a group of the formula:




wherein R is a C₁₋₆ alkyl, a halogen-substituted C₁₋₆ alkyl, a phenyl which may optionally have one to three substituents selected from a halogen atom, a C₁₋₆ alkyl and a C₁₋₆ alkoxy, or pyridyl, and l is an integer of 0, 1 or 2, (xi) a halogen atom, (xii) a phenyl(C₁₋₆)alkyl, (xiii) carboxy, (xiv) a C₁₋₆ alkanoyl, (xv) a benzoyl which may optionally have one to three substituents selected from a halogen atom, a phenyl(C₁₋₆)alkoxy and hydroxy on the phenyl ring, (xvi) amino, (xvii) hydroxy, (xviii) a C₁₋₆ alkanoyloxy, and (xix) a group of the formula:



wherein A is a C₁₋₄ alkylene.


7. The compound according to claim 3, wherein R³ is a phenyl which has any one of substituents selected from the group consisting of (i) a C₁₋₆ alkyl, (ii) phenyl, (iii) a C₁₋₆ alkoxy, (iv) cyano, (v) nitro, (vi) a C₁₋₆ alkoxy, (vii) a phenyl(C₁₋₆)alkoxy, (viii) a phenylthio(C₁₋₆)alkyl, (ix) phenoxy, (x) a halogen atom, (xi) a phenyl(C₁₋₆)alkyl, (xii) carboxy, (xiii) a C₁₋₆ alkanoyl, (xiv) a benzoyl which may optionally have one to three substituents selected from a halogen atom, a phenyl(C₁₋₆)alkoxy and hydroxy on the phenyl ring, (xv) amino, (xvi) hydroxy, (xvii) a C₁₋₆ alkanoyloxy, and (xviii) a group of the formula:



wherein A is a C₁₋₄ alkylene, and may optionally have further one or two substituents selected from a group the formula:




wherein R is a C₁₋₆ alkyl, a halogen-substituted C₁₋₆ alkyl, a phenyl which may optionally have one to three substituents selected from a halogen atom, a C₁₋₆ alkyl and a C₁₋₆ alkoxy, or pyridyl, and l is an integer of 0, 1 or 2, and a group of the formula:



wherein R⁴ and R⁵ are the same or different and are each hydrogen atom, a cycloalkyl, a C₁₋₆ alkyl which may optionally have a substituent selected from hydroxy, furyl, thienyl, tetrahydrofuranyl and phenyl, a phenyl which may optionally have one to three substituents selected from a C₁₋₆ alkyl, a hydroxy-substituted C₁₋₆ alkyl, a C₁₋₆ alkanoyl, cyano, carboxy, a C₁₋₆ alkoxy, a C₁₋₆ alkoxy, and a halogen atom, or a heterocyclic group selected from pyridyl, pyrimidinyl, thiazolyl, isoxazolyl, and pyrazolyl, said heterocyclic group being optionally substituted by a C₁₋₆ alkyl, amino, or a C₁₋₆ alkanoylamino, or R⁴ and R⁵ may join together with the adjacent nitrogen atom to form a heterocyclic group selected from the group consisting of pyrrolidinyl, piperidinyl, tetrahydro-1,2-oxazinyl-tetrahydro-1,3-oxazinyl, and morpholino.

8. The compound according to claim 5, wherein R³ is a phenyl which is substituted by a group of the formula:



5

wherein R is a C₁₋₆ alkyl, a halogen-substituted C₁₋₆ alkyl, a phenyl which may optionally have one to three substituents selected from a halogen atom, a C₁₋₆ alkyl and a C₁₋₆ alkoxy, or pyridyl, and l is an integer of 0, 1 or 2 and may optionally have other one or two substituents selected from the group consisting of a C₁₋₆ alkyl, a C₁₋₆ alkoxy, a halogen atom, and a C₁₋₆ alkylthio.


10

9. The compound according to claim 6, wherein R³ is a phenyl having one to three substituents selected from the group consisting of a C₁₋₆ alkyl, a C₁₋₆ alkoxy, nitro, a halogen atom, a phenyl(C₁₋₆)alkoxy, and a benzoyl having optionally one to three substituents selected from a halogen atom, a phenyl-(C₁₋₆)alkoxy and hydroxy.

15

10. The compound according to claim 7, wherein R³ is a phenyl which is substituted by a group of the formula:

20




25

(wherein R⁴ is hydrogen atom and R⁵ is a thienyl(C₁₋₆)alkyl, or a phenyl which may optionally have one to three substituents selected from a C₁₋₆ alkyl, a hydroxy-substituted C₁₋₆ alkyl, a C₁₋₆ alkoxycarbonyl, hydroxy, a C₁₋₆ alkoxy, and a halogen atom; or R⁴ and R⁵ are the same and are each a C₁₋₆ alkyl) and has optionally further a substituent selected from a C₁₋₆ alkyl or a halogen atom.

30

11. The compound according to claim 8, wherein R³ is a phenyl which is substituted by a group of the formula:

35




wherein R is a C₁₋₆ alkyl or phenyl, and l is an integer of 0, 1 or 2.

40

12. The compound according to claim 8, wherein R³ is a phenyl which is substituted by a group of the formula:

45




50

wherein R is a halogen-substituted C₁₋₆ alkyl, a phenyl which may optionally have one to three substituents selected from a halogen atom, a C₁₋₆ alkyl and a C₁₋₆ alkoxy, or pyridyl, and l is an integer of 0, 1 or 2.


55

13. The compound according to claim 8, wherein R³ is a phenyl having one to three substituents selected from the group consisting of a C₁₋₆ alkyl, a C₁₋₆ alkoxy, a halogen atom, and a C₁₋₆ alkylthio.
14. A process for preparing a pyrazolotriazine compound of the formula (1) as set forth in claim 1, which comprises

(a) reacting a compound of the formula:




wherein R³ is as defined in claim 1 with an alkyl orthoformate to give a compound of the formula:




(1-a)

wherein R³ is as defined in claim 1, or
(b) acylating a compound of the formula:



wherein R² and R³ are as defined in claim 1 to give a compound of the formula:



(1-e)


wherein R² and R³ are as defined in claim 1 and R^{1a} is a C₁₋₆ alkanoyl.

15. A pharmaceutical composition for the prophylaxis and treatment of gout, which comprises an active ingredient a prophylactically and therapeutically effective amount of a pyrazolotriazine compound of the formula (1) as set forth in claim 1 in admixture with a pharmaceutically acceptable carrier or diluent.

16. Use of a prophylactically and therapeutically effective amount of a pyrazolotriazine compound of the formula (1) as set forth in claim 1 for the preparation of a medicament for the prophylaxis and treatment of gout.


5 **Claims for the following Contracting State : ES**

1. A process for preparing a pyrazolotriazine compound of the formula (1):




wherein


- 20 R¹ is hydroxy or an C₁₋₆ alkanoyloxy,
 R² is hydrogen atom,
 R³ is (1) an unsaturated heterocyclic group
 selected from pyrrolyl, pyridyl, thienyl, thiopyranyl, indolyl, benzothienyl, 2,3-dihydrobenzothienyl,
 thiochromanyl, dibenzothienyl, which
 25 may optionally have one or two substituents selected from a halogen atom, nitro, and phenylthio, (2)
 naphthyl, and (3) a phenyl which may optionally have one to three substituents selected from the group
 consisting of (i) an C₁₋₆ alkyl, (ii) phenyl, (iii) an C₁₋₆ alkoxycarbonyl, (iv) cyano, (v) nitro, (vi) an C₁₋₆
 alkoxy, (vii) a phenyl-C₁₋₆ alkoxy, (viii) a phenylthio-C₁₋₆ alkyl, (ix) phenoxy, (x) a group of the formula:




- 35 wherein R is an C₁₋₆ alkyl, a halogen-substituted C₁₋₆ alkyl, a phenyl which may optionally have one
 to three substituents selected from a halogen atom, an C₁₋₆ alkyl and an C₁₋₆ alkoxy, or pyridyl, and l
 is an integer of 0, 1 or 2, (xi) a halogen atom, (xii) a phenyl-C₁₋₆ alkyl, (xiii) carboxy, (xiv) an C₁₋₆
 alkanoyl, (xv) a benzoyl which may optionally have one to three substituents selected from a halogen
 atom, a phenyl-C₁₋₆ alkoxy and hydroxy on the phenyl ring, (xvi) amino, (xvii) hydroxy, (xviii) an C₁₋₆
 40 alkanoyloxy, (xix) a group of the formula:




- wherein R⁴ and R⁵ are the same or different and are each hydrogen atom, a C₃₋₈ cycloalkyl, an C₁₋₆
 alkyl which may optionally have a substituent selected from hydroxy, furyl, thienyl, tetrahydrofuranly
 and phenyl, a phenyl which may optionally have one to three substituents selected from an C₁₋₆ alkyl,
 50 a hydroxy-substituted C₁₋₆ alkyl, an C₁₋₆ alkanoyl, cyano, carboxy, an C₁₋₆ alkoxycarbonyl, hydroxy,
 an C₁₋₆ alkoxy, and a halogen atom, or a heterocyclic group selected from pyridyl, pyrimidinyl,
 thiazolyl, isoxazolyl, and pyrazolyl, said heterocyclic group being optionally substituted by an C₁₋₆
 alkyl, amino, or an C₁₋₆ alkanoylamino, or R⁴ and R⁵ may join together with the adjacent nitrogen atom
 to form a saturated 5- or 6-membered heterocyclic group which may optionally be intervened with
 55 oxygen atom, or (xx) a group of the formula:



wherein A is an C_{1-6} alkylene, which comprises
(a) reacting a compound of the formula:




wherein R^3 is as defined above with an alkyl orthoformate to give a compound of the formula:




(1-a)

wherein R^3 is as defined above, or
(b) acylating a compound of the formula:




wherein R^2 and R^3 are as defined above to give a compound of the formula:




(1-e)

wherein R² and R³ are as defined above and R^{1a} is a C₁₋₆ alkanoyl.


2. The process according to claim 1, wherein R³ is (1) an unsaturated heterocyclic group selected from pyrrolyl, pyridyl, thienyl, thiopyranyl, indolyl, benzothienyl, 2,3-dihydrobenzothienyl, thiochromanyl, or dibenzothienyl, which may optionally have one or two substituents selected from a halogen atom, nitro, and phenylthio, (2) naphthyl, and (3) a phenyl which may optionally have one to three substituents selected from the group consisting of (i) a C₁₋₆ alkyl, (ii) phenyl, (iii) a C₁₋₆ alkoxy, (iv) cyano, (v) nitro, (vi) a C₁₋₆ alkoxy, (vii) a phenyl(C₁₋₆)alkoxy, (viii) a phenylthio(C₁₋₆)alkyl, (ix) phenoxy, (x) a group of the formula:



wherein R is a C₁₋₆ alkyl, a halogen-substituted C₁₋₆ alkyl, a phenyl which may optionally have one to three substituents selected from a halogen atom, a C₁₋₆ alkyl and a C₁₋₆ alkoxy, or pyridyl, and l is an integer of 0, 1 or 2, (xi) a halogen atom, (xii) a phenyl(C₁₋₆)alkyl, (xiii) carboxy, (xiv) a C₁₋₆ alkanoyl, (xv) a benzoyl which may optionally have one to three substituents selected from a halogen atom, a phenyl(C₁₋₆)alkoxy and hydroxy on the phenyl ring, (xvi) amino, (xvii) hydroxy, (xviii) a C₁₋₆ alkanoyloxy, (xix) a group of the formula:




wherein R⁴ and R⁵ are the same or different and are each hydrogen atom, a cycloalkyl, a C₁₋₆ alkyl which may optionally have a substituent selected from hydroxy, furyl, thienyl, tetrahydrofuranyl and phenyl, a phenyl which may optionally have one to three substituents selected from a C₁₋₆ alkyl, a hydroxy-substituted C₁₋₆ alkyl, a C₁₋₆ alkanoyl, cyano, carboxy, a C₁₋₆ alkoxy, a C₁₋₆ alkoxy, and a halogen atom, or a heterocyclic group selected from pyridyl, pyrimidinyl, thiazolyl, isoxazolyl, and pyrazolyl, said heterocyclic group being optionally substituted by a C₁₋₆ alkyl, amino, or a C₁₋₆ alkanoylamino, or R⁴ and R⁵ may join together with the adjacent nitrogen atom to form a heterocyclic group selected from the group consisting of pyrrolidinyl, piperidinyl, tetrahydro-1,2-oxazinyl, tetrahydro-1,3-oxazinyl, and morpholino, or (xx) a group of the formula:




wherein A is a C₁₋₄ alkylene.


3. The process according to claim 2, wherein R¹ is hydroxy.
4. The process according to claim 2, wherein R¹ is a C₁₋₆ alkanoyloxy.
5. The process according to claim 3, wherein R³ is a phenyl which has at least one substituent of a group of the formula:



(wherein R is a C₁₋₆ alkyl, a halogen-substituted C₁₋₆ alkyl, a phenyl which may optionally have one to three substituents selected from a halogen atom, a C₁₋₆ alkyl and a C₁₋₆ alkoxy, or pyridyl, and l is an integer of 0, 1 or 2) and may optionally have further one or two substituents selected from the group consisting of (i) a C₁₋₆ alkyl, (ii) phenyl, (iii) a C₁₋₆ alkoxy, (iv) cyano, (v) nitro, (vi) a C₁₋₆ alkoxy, (vii) a phenyl(C₁₋₆)alkoxy, (viii) a phenylthio(C₁₋₆)alkyl, (ix) phenoxy, (x) a halogen atom, (xi) a phenyl(C₁₋₆)alkyl, (xii) carboxy, (xiii) a C₁₋₆ alkanoyl, (xiv) a benzoyl which may optionally have one to three substituents selected from a halogen atom, a phenyl(C₁₋₆)alkoxy and hydroxy on the phenyl ring, (xv) amino, (xvi) hydroxy, (xvii) a C₁₋₆ alkanoyloxy, (xviii) a group of the formula:




wherein R⁴ and R⁵ are the same or different and are each hydrogen atom, a cycloalkyl, a C₁₋₆ alkyl which may optionally have a substituent selected from hydroxy, furyl, thienyl, tetrahydrofuranyl and phenyl, a phenyl which may optionally have one to three substituents selected from a C₁₋₆ alkyl, a hydroxy-substituted C₁₋₆ alkyl, a C₁₋₆ alkanoyl, cyano, carboxy, a C₁₋₆ alkoxy, and a halogen atom, or a heterocyclic group selected from pyridyl, pyrimidinyl, thiazolyl, isoxazolyl, and pyrazolyl, said heterocyclic group being optionally substituted by a C₁₋₆ alkyl, amino, or a C₁₋₆ alkanoylamino, or R⁴ and R⁵ may join together with the adjacent nitrogen atom to form a heterocyclic group selected from the group consisting of pyrrolidinyl, piperidinyl, tetrahydro-1,2-oxazinyl, tetrahydro-1,3-oxazinyl, and morpholino, or (xx) a group of the formula:




wherein A is a C₁₋₄ alkylene.

6. The process according to claim 3, wherein R³ is a phenyl which has at least one substituent of the formula




(wherein R⁴ and R⁵ are the same or different and are each hydrogen atom, a cycloalkyl, a C₁₋₆ alkyl which may optionally have a substituent selected from hydroxy, furyl, thienyl, tetrahydrofuranyl and phenyl, a phenyl which may optionally have one to three substituents selected from a C₁₋₆ alkyl, a hydroxy-substituted C₁₋₆ alkyl, a C₁₋₆ alkanoyl, cyano, carboxy, a C₁₋₆ alkoxy, and a halogen atom, or a heterocyclic group selected from pyridyl, pyrimidinyl, thiazolyl, isoxazolyl, and pyrazolyl, said heterocyclic group being optionally substituted by a C₁₋₆ alkyl, amino, or a C₁₋₆ alkanoylamino, or R⁴ and R⁵ may join together with the adjacent nitrogen atom to form a heterocyclic group selected from the group consisting of pyrrolidinyl, piperidinyl, tetrahydro-1,2-oxazinyl, tetrahydro-1,3-oxazinyl, and morpholino, or (xx) a group of the formula:

C₁₋₆ alkoxy, and a halogen atom, or a heterocyclic group selected from pyridyl, pyrimidinyl, thiazolyl, isoxazolyl, and pyrazolyl, said heterocyclic group being optionally substituted by a C₁₋₆ alkyl, amino, or a C₁₋₆ alkanoylamino, or R⁴ and R⁵ may join together with the adjacent nitrogen atom to form a heterocyclic group selected from the group consisting of pyrrolidinyl, piperidinyl, tetrahyro-1,2-oxazinyl, tetrahydro-1,3-oxazinyl, and morpholino) and may optionally have further one or two substituents selected from the group consisting of (i) a C₁₋₆ alkyl, (ii) phenyl, (iii) a C₁₋₆ alkoxy, (iv) cyano, (v) nitro, (vi) a C₁₋₆ alkoxy, (vii) a phenyl(C₁₋₆)alkoxy, (viii) a phenylthio(C₁₋₆)alkyl, (ix) phenoxy, (x) a group of the formula:




wherein R is a C₁₋₆ alkyl, a halogen-substituted C₁₋₆ alkyl, a phenyl which may optionally have one to three substituents selected from a halogen atom, a C₁₋₆ alkyl and a C₁₋₆ alkoxy, or pyridyl, and *t* is an integer of 0, 1 or 2, (xi) a halogen atom, (xii) a phenyl(C₁₋₆)alkyl, (xiii) carboxy, (xiv) a C₁₋₆ alkanoyl, (xv) a benzoyl which may optionally have one to three substituents selected from a halogen atom, a phenyl(C₁₋₆)alkoxy and hydroxy on the phenyl ring, (xvi) amino, (xvii) hydroxy, (xviii) a C₁₋₆ alkanoyloxy, and (xix) a group of the formula:




wherein A is a C₁₋₄ alkylene.


7. The process according to claim 3, wherein R³ is a phenyl which has any one of substituents selected from the group consisting of (i) a C₁₋₆ alkyl, (ii) phenyl, (iii) a C₁₋₆ alkoxy, (iv) cyano, (v) nitro, (vi) a C₁₋₆ alkoxy, (vii) a phenyl(C₁₋₆)alkoxy, (viii) a phenylthio(C₁₋₆)alkyl, (ix) phenoxy, (x) a halogen atom, (xi) a phenyl(C₁₋₆)alkyl, (xii) carboxy, (xiii) a C₁₋₆ alkanoyl, (xiv) a benzoyl which may optionally have one to three substituents selected from a halogen atom, a phenyl(C₁₋₆)alkoxy and hydroxy on the phenyl ring, (xv) amino, (xvi) hydroxy, (xvii) a C₁₋₆ alkanoyloxy, and (xviii) a group of the formula:



wherein A is a C₁₋₄ alkylene, and may optionally have further one or two substituents selected from a group the formula:




wherein R is a C₁₋₆ alkyl, a halogen-substituted C₁₋₆ alkyl, a phenyl which may optionally have one to three substituents selected from a halogen atom, a C₁₋₆ alkyl and a C₁₋₆ alkoxy, or pyridyl, and *t* is an integer of 0, 1 or 2, and a group of the formula:



wherein R^4 and R^5 are the same or different and are each hydrogen atom, a cycloalkyl, a C_{1-6} alkyl which may optionally have a substituent selected from hydroxy, furyl, thienyl, tetrahydrofuranyl and phenyl, a phenyl which may optionally have one to three substituents selected from a C_{1-6} alkyl, a hydroxy-substituted C_{1-6} alkyl, a C_{1-6} alkanoyl, cyano, carboxy, a C_{1-6} alkoxycarbonyl, hydroxy, a C_{1-6} alkoxy, and a halogen atom, or a heterocyclic group selected from pyridyl, pyrimidinyl, thiazolyl, isoxazolyl, and pyrazolyl, said heterocyclic group being optionally substituted by a C_{1-6} alkyl, amino, or a C_{1-6} alkanoylamino, or R^4 and R^5 may join together with the adjacent nitrogen atom to form a heterocyclic group selected from the group consisting of pyrrolidinyl, piperidinyl, tetrahydro-1,2-oxazinyl, tetrahydro-1,3-oxazinyl, and morpholino.


8. The process according to claim 5, wherein R^3 is a phenyl which is substituted by a group of the formula:



wherein R is a C_{1-6} alkyl, a halogen-substituted C_{1-6} alkyl, a phenyl which may optionally have one to three substituents selected from a halogen atom, a C_{1-6} alkyl and a C_{1-6} alkoxy, or pyridyl, and l is an integer of 0, 1 or 2 and may optionally have other one or two substituents selected from the group consisting of a C_{1-6} alkyl, a C_{1-6} alkoxy, a halogen atom, and a C_{1-6} alkylthio.


9. The process according to claim 6, wherein R^3 is a phenyl having one to three substituents selected from the group consisting of a C_{1-6} alkyl, a C_{1-6} alkoxy, nitro, a halogen atom, a phenyl(C_{1-6})alkoxy, and a benzoyl having optionally one to three substituents selected from a halogen atom, a phenyl(C_{1-6})alkoxy and hydroxy.

10. The process according to claim 7, wherein R^3 is a phenyl which is substituted by a group of the formula:




(wherein R^4 is hydrogen atom and R^5 is a thienyl(C_{1-6})alkyl, or a phenyl which may optionally have one to three substituents selected from a C_{1-6} alkyl, a hydroxy-substituted C_{1-6} alkyl, a C_{1-6} alkoxycarbonyl, hydroxy, a C_{1-6} alkoxy, and a halogen atom; or R^4 and R^5 are the same and are each a C_{1-6} alkyl) and has optionally further a substituent selected from a C_{1-6} alkyl or a halogen atom.

11. The process according to claim 8, wherein R^3 is a phenyl which is substituted by a group of the formula:



wherein R is a C_{1-6} alkyl or phenyl, and l is an integer of 0, 1 or 2.

12. The process according to claim 8, wherein R³ is a phenyl which is substituted by a group of the formula:



wherein R is a halogen-substituted C₁₋₆ alkyl, a phenyl which may optionally have one to three substituents selected from a halogen atom, a C₁₋₆ alkyl and a C₁₋₆ alkoxy, or pyridyl, and t is an integer of 0, 1 or 2.

13. The process according to claim 8, wherein R³ is a phenyl having one to three substituents selected from the group consisting of a C₁₋₆ alkyl, a C₁₋₆ alkoxy, a halogen atom, and a C₁₋₆ alkylthio.


14. A process for preparing a pharmaceutical composition for the prophylaxis and treatment of gout, which comprises admixing an active ingredient a prophylactically and therapeutically effective amount of a pyrazolotriazine compound of the formula (1) prepared as set forth in any of claims 1 to 13 with a pharmaceutically acceptable carrier or diluent.

15. Use of a prophylactically and therapeutically effective amount of a pyrazolotriazine compound of the formula (1) as set forth in any of claims 1 to 13 for the preparation of a medicament for the prophylaxis and treatment of gout.

Patentansprüche

Patentansprüche für folgende Vertragsstaaten : CH, DE, FR, GB, IT, LI, NL, SE

1. Pyrazolotriazin-Verbindung der Formel:




worin

R¹ Hydroxy oder C₁₋₆-Alkanoyloxy ist,


R² ein Wasserstoffatom ist,

R³ (1) eine ungesättigte, aus Pyrrolyl, Pyridyl, Thienyl, Thiopyranyl, Indolyl, Benzothienyl, 2,3-Dihydrobenzothienyl, Thiochromanyl, Dibenzothienyl ausgewählte heterocyclische Gruppe, welche gegebenenfalls einen oder zwei Substituenten besitzen kann, die aus einem Halogenatom, Nitro und Phenylthio ausgewählt sind, (2) Naphthyl und (3) Phenyl ist, welches gegebenenfalls einen bis drei Substituenten besitzen kann, welche aus der aus (i) C₁₋₆-Alkyl, (ii) Phenyl, (iii) C₁₋₆-Alkoxycarbonyl, (iv) Cyano, (v) Nitro, (vi) C₁₋₆-Alkoxy, (vii) Phenyl-C₁₋₆-alkoxy, (viii) Phenylthio-C₁₋₆-alkyl, (ix) Phenoxy, (x) einer Gruppe der Formel:




worin R C₁₋₆ Alkyl, halogensubstituiertes C₁₋₆-Alkyl, Phenyl, welches gegebenenfalls einen bis drei aus einem Halogenatom, C₁₋₆-Alkyl und C₁₋₆-Alkoxy ausgewählte Substituenten besitzen kann, oder

Pyridyl ist und I eine ganze Zahl 0, 1 oder 2 ist, (xi) einem Halogenatom, (xii) Phenyl-C₁₋₆-alkyl, (xiii) Carboxy, (xiv) C₁₋₆-Alkanoyl, (xv) Benzoyl, welches gegebenenfalls einen bis drei aus einem Halogenatom, Phenyl-C₁₋₆-alkoxy und Hydroxy ausgewählte Substituenten am Phenylring besitzen kann, (xvi) Amino, (xvii) Hydroxy, (xviii) C₁₋₆-Alkanoyloxy, (xix) eine Gruppe der Formel:




worin R⁴ und R⁵ gleich oder verschieden sind und jeweils ein Wasserstoffatom, C₃₋₈-Cycloalkyl, C₁₋₆-Alkyl, welches gegebenenfalls einen aus Hydroxy, Furyl, Thienyl, Tetrahydrofuranyl und Phenyl ausgewählten Substituenten besitzen kann, Phenyl, welches gegebenenfalls einen bis drei aus C₁₋₆-Alkyl, hydroxysubstituiertem C₁₋₆-Alkyl, C₁₋₆-Alkanoyl, Cyano, Carboxy, C₁₋₆-Alkoxycarbonyl, Hydroxy, C₁₋₆-Alkoxy und einem Halogenatom ausgewählte Substituenten besitzen kann, oder eine heterocyclische Gruppe sind, welche aus Pyridyl, Pyrimidinyl, Thiazolyl, Isoxazolyl und Pyrazolyl ausgewählt ist, wobei die heterocyclische Gruppe gegebenenfalls durch C₁₋₆-Alkyl, Amino oder C₁₋₆-Alkanoylamino substituiert ist, oder R⁴ und R⁵ sich zusammen mit dem benachbarten Stickstoffatom unter Bilden einer gesättigten 5- oder 6-gliedrigen heterocyclischen Gruppe, die gegebenenfalls durch ein Sauerstoffatom unterbrochen sein kann, verbinden können, oder (xx) einer Gruppe der Formel




worin A C₁₋₆-Alkylen ist, bestehenden Gruppe ausgewählt sind.

2. Verbindung gemäß Anspruch 1, worin R³ (1) eine aus Pyrrolyl, Pyridyl, Thienyl, Thiopyranyl, Indolyl, Benzothienyl, 2,3-Dihydrobenzothienyl, Thiochromanyl oder Dibenzothienyl ausgewählte ungesättigte heterocyclische Gruppe, welche gegebenenfalls einen oder zwei aus einem Halogenatom, Nitro und Phenylthio ausgewählte Substituenten besitzen kann, (2) Naphthyl und (3) Phenyl ist, welches gegebenenfalls einen bis drei Substituenten besitzen kann, welche aus der aus (i) C₁₋₆-Alkyl, (ii) Phenyl, (iii) C₁₋₆-Alkoxycarbonyl, (iv) Cyano, (v) Nitro, (vi) C₁₋₆-Alkoxy, (vii) Phenyl-C₁₋₆-alkoxy, (viii) Phenylthio-C₁₋₆-alkyl, (ix) Phenoxy, (x) einer Gruppe der Formel:




worin R C₁₋₆-Alkyl, halogensubstituiertes C₁₋₆-Alkyl, Phenyl, welches gegebenenfalls einen bis drei aus einem Halogenatom, C₁₋₆-Alkyl und C₁₋₆-Alkoxy ausgewählte Substituenten besitzen kann, oder Pyridyl ist und I eine ganze Zahl 0, 1 oder 2 ist, (xi) einem Halogenatom, (xii) Phenyl-C₁₋₆-alkyl, (xiii) Carboxy, (xiv) C₁₋₆-Alkanoyl, (xv) Benzoyl, welches gegebenenfalls einen bis drei aus einem Halogenatom, Phenyl-C₁₋₆-alkoxy und Hydroxy ausgewählte Substituenten am Phenylring besitzen kann, (xvi) Amino, (xvii) Hydroxy, (xviii) C₁₋₆-Alkanoyloxy, (xix) einer Gruppe der Formel:




worin R⁴ und R⁵ gleich oder verschieden sind und jeweils ein Wasserstoffatom, Cycloalkyl, C₁₋₆-Alkyl, welches gegebenenfalls einen aus Hydroxy, Furyl, Thienyl, Tetrahydrofuranyl und Phenyl ausgewählten

Substituenten besitzen kann, Phenyl, welches gegebenenfalls einen bis drei aus C₁₋₆-Alkyl, hydroxysubstituiertem C₁₋₆-Alkyl, C₁₋₆-Alkanoyl, Cyano, Carboxy, C₁₋₆-Alkoxy und einem Halogenatom ausgewählte Substituenten besitzen kann, oder eine heterocyclische Gruppe sind, welche aus Pyridyl, Pyrimidinyl, Thiazolyl, Isoxazolyl und Pyrazolyl ausgewählt ist, wobei die heterocyclische Gruppe gegebenenfalls durch C₁₋₆-Alkyl, Amino oder C₁₋₆-Alkanoylamino substituiert ist, oder R⁴ und R⁵ sich zusammen mit dem benachbarten Stickstoffatom unter Bilden einer heterocyclischen Gruppe, die aus der Gruppe ausgewählt ist, die aus Pyrrolidinyl, Piperidinyl, Tetrahydro-1,2-oxazinyl, Tetrahydro-1,3-oxazinyl und Morpholino besteht, verbinden können, oder (xx) einer Gruppe der Formel




worin A C₁₋₄-Alkylen ist, bestehenden Gruppe ausgewählt sind.


3. Verbindung gemäß Anspruch 2, worin R¹ Hydroxy ist.
4. Verbindung gemäß Anspruch 2, worin R¹ C₁₋₆-Alkanoyloxy ist.
5. Verbindung gemäß Anspruch 3, worin R³ Phenyl ist, welches wenigstens einen Substituenten einer Gruppe der Formel



besitzt (worin R C₁₋₆-Alkyl, halogensubstituiertes C₁₋₆-Alkyl, Phenyl, das gegebenenfalls einen bis drei Substituenten besitzen kann, die aus einem Halogenatom, C₁₋₆-Alkyl und C₁₋₆-Alkoxy ausgewählt sind, oder Pyridyl ist und l eine ganze Zahl 0, 1 oder 2 ist) und gegebenenfalls einen oder zwei weitere Substituenten besitzen kann, die aus der Gruppe ausgewählt sind, die aus (i) C₁₋₆-Alkyl, (ii) Phenyl, (iii) C₁₋₆-Alkoxy, (iv) Cyano, (v) Nitro, (vi) C₁₋₆-Alkoxy, (vii) Phenyl-C₁₋₆-alkoxy, (viii) Phenylthio-C₁₋₆-alkyl, (ix) Phenoxo, (x) einem Halogenatom, (xi) Phenyl-C₁₋₆-alkyl, (xii) Carboxy, (xiii) C₁₋₆-Alkanoyl, (xiv) Benzoyl, das gegebenenfalls einen bis drei Substituenten besitzen kann, die aus einem Halogenatom, Phenyl-C₁₋₆-alkoxy und Hydroxy am Phenylring ausgewählt sind, (xv) Amino, (xvi) Hydroxy, (xvii) C₁₋₆-Alkanoyloxy, (xviii) einer Gruppe der Formel:




worin R⁴ und R⁵ gleich oder verschieden sind und jeweils ein Wasserstoffatom, Cycloalkyl, C₁₋₆-Alkyl, das gegebenenfalls einen Substituenten besitzen kann, der aus Hydroxy, Furyl, Thienyl, Tetrahydrofuran und Phenyl ausgewählt ist, Phenyl, das gegebenenfalls einen bis drei Substituenten besitzen kann, die aus C₁₋₆-Alkyl, hydroxysubstituiertem C₁₋₆-Alkyl, C₁₋₆-Alkanoyl, Cyano, Carboxy, C₁₋₆-Alkoxy und einem Halogenatom ausgewählt sind, oder eine heterocyclische Gruppe sind, die aus Pyridyl, Pyrimidinyl, Thiazolyl, Isoxazolyl und Pyrazolyl ausgewählt ist, wobei die heterocyclische Gruppe gegebenenfalls durch C₁₋₆-Alkyl, Amino oder C₁₋₆-Alkanoylamino substituiert ist, oder R⁴ und R⁵ sich mit dem benachbarten Stickstoffatom unter Bilden einer heterocyclischen Gruppe verbinden können, die aus der Gruppe ausgewählt ist, die aus Pyrrolidinyl, Piperidinyl, Tetrahydro-1,2-oxazinyl, Tetrahydro-1,3-oxazinyl und Morpholino besteht, oder (xx) einer Gruppe der Formel




besteht, worin A C₁₋₄-Alkylen ist.


6. Verbindung gemäß Anspruch 3, worin R³ Phenyl ist, das wenigstens einen Substituenten der Formel



besitzt (worin R⁴ und R⁵ gleich oder verschieden sind und jeweils ein Wasserstoffatom, Cycloalkyl, C₁₋₆-Alkyl, das gegebenenfalls einen Substituenten besitzen kann, der aus Hydroxy, Furyl, Thienyl, Tetrahydrofuryl und Phenyl ausgewählt ist, Phenyl, das gegebenenfalls einen bis drei Substituenten besitzen kann, die aus C₁₋₆-Alkyl, hydroxysubstituiertem C₁₋₆-Alkyl, C₁₋₆-Alkanoyl, Cyano, Carboxy, C₁₋₆-Alkoxycarbonyl, Hydroxy, C₁₋₆-Alkoxy und einem Halogenatom ausgewählt sind, oder eine heterocyclische Gruppe sind, die aus Pyridyl, Pyrimidinyl, Thiazolyl, Isoxazolyl und Pyrazolyl ausgewählt ist, wobei die heterocyclische Gruppe gegebenenfalls durch C₁₋₆-Alkyl, Amino oder C₁₋₆-Alkanoylamino substituiert ist, oder R⁴ und R⁵ sich mit dem benachbarten Stickstoffatom unter Bilden einer heterocyclischen Gruppe verbinden können, die aus der Gruppe ausgewählt ist, die aus Pyrrolidinyl, Piperidinyl, Tetrahydro-1,2-oxazinyl, Tetrahydro-1,3-oxazinyl und Morpholino besteht) und gegebenenfalls einen oder zwei weitere Substituenten besitzen kann, die aus der Gruppe ausgewählt sind, die aus (i) C₁₋₆-Alkyl, (ii) Phenyl, (iii) C₁₋₆-Alkoxycarbonyl, (iv) Cyano, (v) Nitro, (vi) C₁₋₆-Alkoxy, (vii) Phenyl-C₁₋₆-alkoxy, (viii) Phenylthio-C₁₋₆-alkyl, (ix) Phenoxy, (x) einer Gruppe der Formel




worin R C₁₋₆-Alkyl, halogensubstituiertes C₁₋₆-Alkyl, Phenyl, das gegebenenfalls einen bis drei Substituenten besitzen kann, die aus einem Halogenatom, C₁₋₆-Alkyl und C₁₋₆-Alkoxy ausgewählt sind, und l eine ganze Zahl 0, 1 oder 2 ist, (xi) einem Halogenatom, (xii) Phenyl-C₁₋₆-Alkyl, (xiii) Carboxy, (xiv) C₁₋₆-Alkanoyl, (xv) Benzoyl, das gegebenenfalls einen bis drei Substituenten besitzen kann, die aus einem Halogenatom, Phenyl-C₁₋₆-alkoxy und Hydroxy am Phenylring ausgewählt sind, (xvi) Amino, (xvii) Hydroxy, (xviii) C₁₋₆-Alkanoyloxy und (xix) einer Gruppe der Formel




besteht, worin A C₁₋₄-Alkylen ist.

7. Verbindung gemäß Anspruch 3, worin R³ Phenyl ist, das irgendeinen Substituenten besitzt, der aus der Gruppe ausgewählt ist, die aus (i) C₁₋₆-Alkyl, (ii) Phenyl, (iii) C₁₋₆-Alkoxycarbonyl, (iv) Cyano, (v) Nitro, (vi) C₁₋₆-Alkoxy, (vii) Phenyl-C₁₋₆-alkoxy, (viii) Phenylthio-C₁₋₆-alkyl, (ix) Phenoxy, (x) einem Halogenatom, (xi) Phenyl-C₁₋₆-alkyl, (xii) Carboxy, (xiii) C₁₋₆-Alkanoyl, (xiv) Benzoyl, das gegebenenfalls inen


bis drei Substituenten besitzen kann, die aus einem Halogenatom, Phenyl-C₁₋₆-alkoxy und Hydroxy am Phenylring ausgewählt sind, (xv) Amino, (xvi) Hydroxy, (xvii) C₁₋₆-Alkanoyloxy und (xviii) einer Gruppe der Formel



besteht, worin A C₁₋₄-Alkylen ist, und das gegebenenfalls einen oder zwei weitere Substituenten besitzen kann, die aus einer Gruppe der Formel




worin R C₁₋₆-Alkyl, halogensubstituiertes C₁₋₆-Alkyl, Phenyl, welches gegebenenfalls einen bis drei Substituenten besitzen kann, die aus einem Halogenatom, C₁₋₆-Alkyl und C₁₋₆-Alkoxy ausgewählt sind, oder Pyridyl ist und l eine ganze Zahl 0, 1 oder 2 ist, und einer Gruppe der Formel



ausgewählt sind, worin R⁴ und R⁵ gleich oder verschieden sind und jeweils ein Wasserstoffatom, Cycloalkyl, C₁₋₆-Alkyl, das gegebenenfalls einen Substituenten besitzen kann, der aus Hydroxy, Furyl, Thienyl, Tetrahydrofuranyl und Phenyl ausgewählt ist, Phenyl, das gegebenenfalls einen bis drei Substituenten besitzen kann, die aus C₁₋₆-Alkyl, hydroxysubstituiertem C₁₋₆-Alkyl, C₁₋₆-Alkanoyl, Cyano, Carboxy, C₁₋₆-Alkoxycarbonyl, Hydroxy, C₁₋₆-Alkoxy und einem Halogenatom ausgewählt sind, oder eine heterocyclische Gruppe sind, die aus Pyridyl, Pyrimidinyl, Thiazolyl, Isoxazolyl und Pyrazolyl ausgewählt ist, wobei die heterocyclische Gruppe gegebenenfalls durch C₁₋₆-Alkyl, Amino oder C₁₋₆-Alkanoylamino substituiert ist, oder R⁴ und R⁵ sich mit dem benachbarten Stickstoffatom unter Bilden einer heterocyclischen Gruppe verbinden können, die aus der Gruppe ausgewählt ist, die aus Pyrrolidinyl, Piperidinyl, Tetrahydro-1,2-oxazinyl, Tetrahydro-1,3-oxazinyl und Morpholino besteht.


8. Verbindung gemäß Anspruch 5, worin R³ Phenyl ist, das durch eine Gruppe der Formel



substituiert ist, worin R C₁₋₆-Alkyl, halogensubstituiertes C₁₋₆-Alkyl, Phenyl, welches gegebenenfalls einen bis drei Substituenten besitzen kann, die aus einem Halogenatom, C₁₋₆-Alkyl und C₁₋₆-Alkoxy ausgewählt sind, oder Pyridyl ist und l eine ganze Zahl 0, 1 oder 2 ist, und gegebenenfalls einen oder zwei Substituenten besitzen kann, die aus der Gruppe ausgewählt sind, die aus C₁₋₆-Alkyl, C₁₋₆-Alkoxy, einem Halogenatom und C₁₋₆-Alkylthio besteht.


9. Verbindung gemäß Anspruch 6, worin R³ Phenyl mit einem bis drei Substituenten ist, die aus der Gruppe ausgewählt sind, die aus C₁₋₆-Alkyl, C₁₋₆-Alkoxy, Nitro, einem Halogenatom, Phenyl-C₁₋₆-alkoxy und Benzoyl mit gegebenenfalls einem bis drei Substituenten besteht, die aus einem Halogenatom, Phenyl-C₁₋₆-alkoxy und Hydroxy ausgewählt sind.

10. Verbindung gemäß Anspruch 7, worin R³ Phenyl ist, welches durch eine Gruppe der Formel




substituiert ist (worin R⁴ ein Wasserstoffatom ist und R⁵ Thienyl-C₁₋₆-alkyl oder Phenyl ist, das gegebenenfalls einen bis drei Substituenten besitzen kann, die aus C₁₋₆-Alkyl, hydroxysubstituiertem C₁₋₆-Alkyl, C₁₋₆-Alkoxycarbonyl, Hydroxy, C₁₋₆-Alkoxy und einem Halogenatom ausgewählt sind; oder R⁴ und R⁵ gleich sind und jeweils C₁₋₆-Alkyl sind) und gegebenenfalls einen weiteren Substituenten besitzt, der aus C₁₋₆-Alkyl oder einem Halogenatom ausgewählt ist.

11. Verbindung gemäß Anspruch 8, worin R³ Phenyl ist, welches durch eine Gruppe der Formel



substituiert ist, worin R C₁₋₆-Alkyl oder Phenyl ist und I eine ganze Zahl 0, 1 oder 2 ist.

12. Verbindung gemäß Anspruch 8, worin R³ Phenyl ist, welches durch eine Gruppe der Formel




substituiert ist, worin R halogensubstituiertes C₁₋₆-Alkyl, Phenyl, welches gegebenenfalls einen bis drei Substituenten besitzen kann, die aus einem Halogenatom, C₁₋₆-Alkyl und C₁₋₆-Alkoxy ausgewählt sind, oder Pyridyl ist und I eine ganze Zahl 0, 1 oder 2 ist.


13. Verbindung gemäß Anspruch 8, worin R³ Phenyl mit einem bis drei Substituenten ist, welche aus der Gruppe ausgewählt sind, die aus C₁₋₆-Alkyl, C₁₋₆-Alkoxy, einem Halogenatom und C₁₋₆-Alkylthio besteht.

14. Verfahren zum Herstellen einer in Anspruch 1 angegebenen Pyrazolotriazin-Verbindung der Formel (1), welches

(a) das Umsetzen einer Verbindung der Formel




worin R³ wie in Anspruch 1 definiert ist, mit einem Orthoameisensäurealkylester unter Ergeben einer Verbindung der Formel




(1-a)

worin R³ wie in Anspruch 1 definiert ist, oder
(b) das Acylieren einer Verbindung der Formel



worin R² und R³ wie in Anspruch 1 definiert sind, unter Ergeben einer Verbindung der Formel




(1-e)

worin R² und R³ wie in Anspruch 1 definiert sind, und R¹ᵃ C₁-₆-Alkanoyl ist, umfaßt.

15. Pharmazeutische Zusammensetzung zur Prophylaxe und Behandlung von Gicht, welche einen wirksamen Bestandteil eine prophylaktisch und therapeutisch wirksame Menge einer in Anspruch 1 angegebenen Pyrazolotriazinverbindung der Formel (1) im Gemisch mit einem pharmazeutisch annehmbaren Träger oder Verdünnungsmittel umfaßt.
16. Verwendung einer prophylaktisch und therapeutisch wirksamen Menge einer in Anspruch 1 angegebenen Pyrazolotriazinverbindung der Formel (1) zur Herstellung eines Arzneimittels zur Prophylaxe und Behandlung von Gicht.

Patentansprüche für folgenden Vertragsstaat : ES

1. Verfahren zum Herstellen einer Pyrazolotriazin-Verbindung der Formel (1):




15 worin


R¹ Hydroxy oder C₁₋₆-Alkanoyloxy ist,

R² ein Wasserstoffatom ist,


R³ (1) eine ungesättigte, aus Pyrrolyl, Pyridyl, Thienyl, Thiopyranyl, Indolyl, Benzothienyl, 2,3-Dihydrobenzothienyl, Thiochromanyl, Dibenzothienyl ausgewählte heterocyclische Gruppe, welche gegebenenfalls einen oder zwei Substituenten besitzen kann, die aus einem Halogenatom, Nitro und Phenylthio ausgewählt sind, (2) Naphthyl und (3) Phenyl ist, welches gegebenenfalls einen bis drei Substituenten besitzen kann, welche aus der aus (i) C₁₋₆-Alkyl, (ii) Phenyl, (iii) C₁₋₆-Alkoxycarbonyl, (iv) Cyano, (v) Nitro, (vi) C₁₋₆-Alkoxy, (vii) Phenyl-C₁₋₆-alkoxy, (viii) Phenylthio-C₁₋₆-alkyl, (ix) Phenoxy, (x) einer Gruppe der Formel:




35 worin R C₁₋₆ Alkyl, halogensubstituiertes C₁₋₆-Alkyl, Phenyl, welches gegebenenfalls einen bis drei aus einem Halogenatom, C₁₋₆-Alkyl und C₁₋₆-Alkoxy ausgewählte Substituenten besitzen kann, oder Pyridyl ist und l eine ganze Zahl 0, 1 oder 2 ist, (xi) einem Halogenatom, (xii) Phenyl-C₁₋₆-alkyl, (xiii) Carboxy, (xiv) C₁₋₆-Alkanoyl, (xv) Benzoyl, welches gegebenenfalls einen bis drei aus einem Halogenatom, Phenyl-C₁₋₆-alkoxy und Hydroxy ausgewählte Substituenten am Phenylring besitzen kann, (xvi) Amino, (xvii) Hydroxy, (xviii) C₁₋₆-Alkanoyloxy, (xix) eine Gruppe der Formel:




45 worin R⁴ und R⁵ gleich oder verschieden sind und jeweils ein Wasserstoffatom, C₃₋₈-Cycloalkyl, C₁₋₆-Alkyl, welches gegebenenfalls einen aus Hydroxy, Furyl, Thienyl, Tetrahydrofuranyl und Phenyl ausgewählten Substituenten besitzen kann, Phenyl, welches gegebenenfalls einen bis drei aus C₁₋₆-Alkyl, hydroxysubstituiertem C₁₋₆-Alkyl, C₁₋₆-Alkanoyl, Cyano, Carboxy, C₁₋₆-Alkoxycarbonyl, Hydroxy, C₁₋₆-Alkoxy und einem Halogenatom ausgewählte Substituenten besitzen kann, oder eine heterocyclische Gruppe sind, welche aus Pyridyl, Pyrimidinyl, Thiazolyl, Isoxazolyl und Pyrazolyl ausgewählt ist, wobei die heterocyclische Gruppe gegebenenfalls durch C₁₋₆-Alkyl, Amino oder C₁₋₆-Alkanoylamino substituiert ist, oder R⁴ und R⁵ sich zusammen mit dem benachbarten Stickstoffatom unter Bilden einer gesättigten 5- oder 6-gliedrigen heterocyclischen Gruppe, die gegebenenfalls durch ein Sauerstoffatom unterbrochen sein kann, verbinden können, oder (xx) einer Gruppe der Formel



worin A C₁₋₆-Alkylen ist, bestehenden Gruppe ausgewählt sind, welches
(a) das Umsetzen einer Verbindung der Formel




worin R³ wie in Anspruch 1 definiert ist, mit einem Orthoameisensäurealkylester unter Ergeben einer
Verbindung der Formel




(1-a)

worin R³ wie in Anspruch 1 definiert ist, oder
(b) das Acylieren einer Verbindung der Formel




worin R² und R³ wie in Anspruch 1 definiert sind, unter Ergeben einer Verbindung der Formel




(1-e)

worin R^2 und R^3 wie in Anspruch 1 definiert sind, und R^1a C_{1-6} -Alkanoyl ist, umfaßt.


2. Verfahren gemäß Anspruch 1, worin R^3 (1) eine aus Pyrrolyl, Pyridyl, Thienyl, Thiopyranyl, Indolyl, Benzothienyl, 2,3-Dihydrobenzothienyl, Thiochromanyl oder Dibenzothienyl ausgewählte ungesättigte heterocyclische Gruppe, welche gegebenenfalls einen oder zwei aus einem Halogenatom, Nitro und Phenylthio ausgewählte Substituenten besitzen kann, (2) Naphthyl und (3) Phenyl ist, welches gegebenenfalls einen bis drei Substituenten besitzen kann, welche aus der aus (i) C_{1-6} -Alkyl, (ii) Phenyl, (iii) C_{1-6} -Alkoxycarbonyl, (iv) Cyano, (v) Nitro, (vi) C_{1-6} -Alkoxy, (vii) Phenyl- C_{1-6} -alkoxy, (viii) Phenylthio- C_{1-6} -alkyl, (ix) Phenoxy, (x) einer Gruppe der Formel:



worin R C_{1-6} -Alkyl, halogensubstituiertes C_{1-6} -Alkyl, Phenyl, welches gegebenenfalls einen bis drei aus einem Halogenatom, C_{1-6} -Alkyl und C_{1-6} -Alkoxy ausgewählte Substituenten besitzen kann, oder Pyridyl ist und 1 eine ganze Zahl 0, 1 oder 2 ist, (xi) einem Halogenatom, (xii) Phenyl- C_{1-6} -alkyl, (xiii) Carboxy, (xiv) C_{1-6} -Alkanoyl, (xv) Benzoyl, welches gegebenenfalls einen bis drei aus einem Halogenatom, Phenyl- C_{1-6} -alkoxy und Hydroxy ausgewählte Substituenten am Phenylring besitzen kann, (xvi) Amino, (xvii) Hydroxy, (xviii) C_{1-6} -Alkanoyloxy, (xix) einer Gruppe der Formel:




worin R^4 und R^5 gleich oder verschieden sind und jeweils ein Wasserstoffatom, Cycloalkyl, C_{1-6} -Alkyl, welches gegebenenfalls einen aus Hydroxy, Furyl, Thienyl, Tetrahydrofuryl und Phenyl ausgewählten Substituenten besitzen kann, Phenyl, welches gegebenenfalls einen bis drei aus C_{1-6} -Alkyl, hydroxysubstituiertem C_{1-6} -Alkyl, C_{1-6} -Alkanoyl, Cyano, Carboxy, C_{1-6} -Alkoxycarbonyl, Hydroxy, C_{1-6} -Alkoxy und einem Halogenatom ausgewählte Substituenten besitzen kann, oder eine heterocyclische Gruppe sind, welche aus Pyridyl, Pyrimidinyl, Thiazolyl, Isoxazolyl und Pyrazolyl ausgewählt ist, wobei die heterocyclische Gruppe gegebenenfalls durch C_{1-6} -Alkyl, Amino oder C_{1-6} -Alkanoylamino substituiert ist, oder R^4 und R^5 sich zusammen mit dem benachbarten Stickstoffatom unter Bilden einer heterocyclischen Gruppe, die aus der Gruppe ausgewählt ist, die aus Pyrrolidinyl, Piperidinyl, Tetrahydro-1,2-oxazinyl, Tetrahydro-1,3-oxazinyl und Morpholino besteht, verbinden können, oder (xx) einer Gruppe der Formel




worin A C₁₋₄-Alkylen ist, bestehenden Gruppe ausgewählt sind.


3. Verfahren gemäß Anspruch 2, worin R¹ Hydroxy ist.
4. Verfahren gemäß Anspruch 2, worin R¹ C₁₋₆-Alkanoyloxy ist.
5. Verfahren gemäß Anspruch 3, worin R³ Phenyl ist, welches wenigstens einen Substituenten einer Gruppe der Formel



besitzt (worin R C₁₋₆-Alkyl, halogensubstituiertes C₁₋₆-Alkyl, Phenyl, das gegebenenfalls einen bis drei Substituenten besitzen kann, die aus einem Halogenatom, C₁₋₆-Alkyl und C₁₋₆-Alkoxy ausgewählt sind, oder Pyridyl ist und I eine ganze Zahl 0, 1 oder 2 ist) und gegebenenfalls einen oder zwei weitere Substituenten besitzen kann, die aus der Gruppe ausgewählt sind, die aus (i) C₁₋₆-Alkyl, (ii) Phenyl, (iii) C₁₋₆-Alkoxycarbonyl, (iv) Cyano, (v) Nitro, (vi) C₁₋₆-Alkoxy, (vii) Phenyl-C₁₋₆-alkoxy, (viii) Phenylthio-C₁₋₆-alkyl, (ix) Phenoxy, (x) einem Halogenatom, (xi) Phenyl-C₁₋₆-alkyl, (xii) Carboxy, (xiii) C₁₋₆-Alkanoyl, (xiv) Benzoyl, das gegebenenfalls einen bis drei Substituenten besitzen kann, die aus einem Halogenatom, Phenyl-C₁₋₆-alkoxy und Hydroxy am Phenylring ausgewählt sind, (xv) Amino, (xvi) Hydroxy, (xvii) C₁₋₆-Alkanoyloxy, (xviii) einer Gruppe der Formel:




worin R⁴ und R⁵ gleich oder verschieden sind und jeweils ein Wasserstoffatom, Cycloalkyl, C₁₋₆-Alkyl, das gegebenenfalls einen Substituenten besitzen kann, der aus Hydroxy, Furyl, Thienyl, Tetrahydrofuran und Phenyl ausgewählt ist, Phenyl, das gegebenenfalls einen bis drei Substituenten besitzen kann, die aus C₁₋₆-Alkyl, hydroxysubstituiertem C₁₋₆-Alkyl, C₁₋₆-Alkanoyl, Cyano, Carboxy, C₁₋₆-Alkoxycarbonyl, Hydroxy, C₁₋₆-Alkoxy und einem Halogenatom ausgewählt sind, oder eine heterocyclische Gruppe sind, die aus Pyridyl, Pyrimidinyl, Thiazolyl, Isoxazolyl und Pyrazolyl ausgewählt ist, wobei die heterocyclische Gruppe gegebenenfalls durch C₁₋₆-Alkyl, Amino oder C₁₋₆-Alkanoylamino substituiert ist, oder R⁴ und R⁵ sich mit dem benachbarten Stickstoffatom unter Bilden einer heterocyclischen Gruppe verbinden können, die aus der Gruppe ausgewählt ist, die aus Pyrrolidinyl, Piperidinyl, Tetrahydro-1,2-oxazinyl, Tetrahydro-1,3-oxazinyl und Morpholino besteht, oder (xx) einer Gruppe der Formel




besteht, worin A C₁₋₄-Alkylen ist.


6. Verfahren gemäß Anspruch 3, worin R³ Phenyl ist, das wenigstens einen Substituenten der Formel



besitzt (worin R⁴ und R⁵ gleich oder verschieden sind und jeweils ein Wasserstoffatom, Cycloalkyl, C₁₋₆-Alkyl, das gegebenenfalls einen Substituenten besitzen kann, der aus Hydroxy, Furyl, Thienyl, Tetrahydrofuranyl und Phenyl ausgewählt ist, Phenyl, das gegebenenfalls einen bis drei Substituenten besitzen kann, die aus C₁₋₆-Alkyl, hydroxysubstituiertem C₁₋₆-Alkyl, C₁₋₆-Alkanoyl, Cyano, Carboxy, C₁₋₆-Alkoxycarbonyl, Hydroxy, C₁₋₆-Alkoxy und einem Halogenatom ausgewählt sind, oder eine heterocyclische Gruppe sind, die aus Pyridyl, Pyrimidinyl, Thiazolyl, Isoxazolyl und Pyrazolyl ausgewählt ist, wobei die heterocyclische Gruppe gegebenenfalls durch C₁₋₆-Alkyl, Amino oder C₁₋₆-Alkanoylamino substituiert ist, oder R⁴ und R⁵ sich mit dem benachbarten Stickstoffatom unter Bilden einer heterocyclischen Gruppe verbinden können, die aus der Gruppe ausgewählt ist, die aus Pyrrolidinyl, Piperidinyl, Tetrahydro-1,2-oxazinyl, Tetrahydro-1,3-oxazinyl und Morpholino besteht) und gegebenenfalls einen oder zwei weitere Substituenten besitzen kann, die aus der Gruppe ausgewählt sind, die aus (i) C₁₋₆-Alkyl, (ii) Phenyl, (iii) C₁₋₆-Alkoxycarbonyl, (iv) Cyano, (v) Nitro, (vi) C₁₋₆-Alkoxy, (vii) Phenyl-C₁₋₆-alkoxy, (viii) Phenylthio-C₁₋₆-alkyl, (ix) Phenoxy, (x) einer Gruppe der Formel




worin R C₁₋₆-Alkyl, halogensubstituiertes C₁₋₆-Alkyl, Phenyl, das gegebenenfalls einen bis drei Substituenten besitzen kann, die aus einem Halogenatom, C₁₋₆-Alkyl und C₁₋₆-Alkoxy ausgewählt sind, und I eine ganze Zahl 0, 1 oder 2 ist, (xi) einem Halogenatom, (xii) Phenyl-C₁₋₆-Alkyl, (xiii) Carboxy, (xiv) C₁₋₆-Alkanoyl, (xv) Benzoyl, das gegebenenfalls einen bis drei Substituenten besitzen kann, die aus einem Halogenatom, Phenyl-C₁₋₆-alkoxy und Hydroxy am Phenylring ausgewählt sind, (xvi) Amino, (xvii) Hydroxy, (xviii) C₁₋₆-Alkanoyloxy und (xix) einer Gruppe der Formel



besteht, worin A C₁₋₄-Alkylen ist.

7. Verfahren gemäß Anspruch 3, worin R³ Phenyl ist, das irgendeinen Substituenten besitzt, der aus der Gruppe ausgewählt ist, die aus (i) C₁₋₆-Alkyl, (ii) Phenyl, (iii) C₁₋₆-Alkoxycarbonyl, (iv) Cyano, (v) Nitro, (vi) C₁₋₆-Alkoxy, (vii) Phenyl-C₁₋₆-alkoxy, (viii) Phenylthio-C₁₋₆-alkyl, (ix) Phenoxy, (x) einem Halogenatom, (xi) Phenyl-C₁₋₆-alkyl, (xii) Carboxy, (xiii) C₁₋₆-Alkanoyl, (xiv) Benzoyl, das gegebenenfalls einen bis drei Substituenten besitzen kann, die aus einem Halogenatom, Phenyl-C₁₋₆-alkoxy und Hydroxy am Phenylring ausgewählt sind, (xv) Amino, (xvi) Hydroxy, (xvii) C₁₋₆-Alkanoyloxy und (xviii) einer Gruppe der Formel



besteht, worin A C₁₋₄-Alkylen ist, und das gegebenenfalls einen oder zwei weitere Substituenten besitzen kann, die aus einer Gruppe der Formel



10 worin R C₁₋₆-Alkyl, halogensubstituiertes C₁₋₆-Alkyl, Phenyl, welches gegebenenfalls einen bis drei Substituenten besitzen kann, die aus einem Halogenatom, C₁₋₆-Alkyl und C₁₋₆-Alkoxy ausgewählt sind, oder Pyridyl ist und I eine ganze Zahl 0, 1 oder 2 ist, und einer Gruppe der Formel



20 ausgewählt sind, worin R⁴ und R⁵ gleich oder verschieden sind und jeweils ein Wasserstoffatom, Cycloalkyl, C₁₋₆-Alkyl, das gegebenenfalls einen Substituenten besitzen kann, der aus Hydroxy, Furyl, Thienyl, Tetrahydrofuranyl und Phenyl ausgewählt ist, Phenyl, das gegebenenfalls einen bis drei Substituenten besitzen kann, die aus C₁₋₆-Alkyl, hydroxysubstituiertem C₁₋₆-Alkyl, C₁₋₆-Alkanoyl, Cyano, Carboxy, C₁₋₆-Alkoxycarbonyl, Hydroxy, C₁₋₆-Alkoxy und einem Halogenatom ausgewählt sind, oder eine heterocyclische Gruppe sind, die aus Pyridyl, Pyrimidinyl, Thiazolyl, Isoxazolyl und Pyrazolyl ausgewählt ist, wobei die heterocyclische Gruppe gegebenenfalls durch C₁₋₆-Alkyl, Amino oder C₁₋₆-Alkanoylamino substituiert ist, oder R⁴ und R⁵ sich mit dem benachbarten Stickstoffatom unter Bilden einer heterocyclischen Gruppe verbinden können, die aus der Gruppe ausgewählt ist, die aus Pyrrolidinyl, Piperidinyl, Tetrahydro-1,2-oxazinyl, Tetrahydro-1,3-oxazinyl und Morpholino besteht.

30


8. Verfahren gemäß Anspruch 5, worin R³ Phenyl ist, das durch eine Gruppe der Formel



40 substituiert ist, worin R C₁₋₆-Alkyl, halogensubstituiertes C₁₋₆-Alkyl, Phenyl, welches gegebenenfalls einen bis drei Substituenten besitzen kann, die aus einem Halogenatom, C₁₋₆-Alkyl und C₁₋₆-Alkoxy ausgewählt sind, oder Pyridyl ist und I eine ganze Zahl 0, 1 oder 2 ist, und gegebenenfalls einen oder zwei Substituenten besitzen kann, die aus der Gruppe ausgewählt sind, die aus C₁₋₆-Alkyl, C₁₋₆-Alkoxy, einem Halogenatom und C₁₋₆-Alkylthio besteht.

45 9. Verfahren gemäß Anspruch 6, worin R³ Phenyl mit einem bis drei Substituenten ist, die aus der Gruppe ausgewählt sind, die aus C₁₋₆-Alkyl, C₁₋₆-Alkoxy, Nitro, einem Halogenatom, Phenyl-C₁₋₆-alkoxy und Benzoyl mit gegebenenfalls einem bis drei Substituenten besteht, die aus einem Halogenatom, Phenyl-C₁₋₆-alkoxy und Hydroxy ausgewählt sind.


50 10. Verfahren gemäß Anspruch 7, worin R³ Phenyl ist, welches durch eine Gruppe der Formel



substituiert ist (worin R⁴ ein Wasserstoffatom ist und R⁵ Thienyl-C₁₋₆-alkyl oder Phenyl ist, das


gegebenenfalls einen bis drei Substituenten besitzen kann, die aus C₁₋₆-Alkyl, hydroxysubstituiertem C₁₋₆-Alkyl, C₁₋₆-Alkoxycarbonyl, Hydroxy, C₁₋₆-Alkoxy und einem Halogenatom ausgewählt sind; oder R⁴ und R⁵ gleich sind und jeweils C₁₋₆-Alkyl sind) und gegebenenfalls einen weiteren Substituenten besitzt, der aus C₁₋₆-Alkyl oder einem Halogenatom ausgewählt ist.

11. Verfahren gemäß Anspruch 8, worin R³ Phenyl ist, welches durch eine Gruppe der Formel



substituiert ist, worin R C₁₋₆-Alkyl oder Phenyl ist und l eine ganze Zahl 0, 1 oder 2 ist.

12. Verfahren gemäß Anspruch 8, worin R³ Phenyl ist, welches durch eine Gruppe der Formel



substituiert ist, worin R halogensubstituiertes C₁₋₆-Alkyl, Phenyl, welches gegebenenfalls einen bis drei Substituenten besitzen kann, die aus einem Halogenatom, C₁₋₆-Alkyl und C₁₋₆-Alkoxy ausgewählt sind, oder Pyridyl ist und l eine ganze Zahl 0, 1 oder 2 ist.

13. Verfahren gemäß Anspruch 8, worin R³ Phenyl mit einem bis drei Substituenten ist, welche aus der Gruppe ausgewählt sind, die aus C₁₋₆-Alkyl, C₁₋₆-Alkoxy, einem Halogenatom und C₁₋₆-Alkylthio besteht.


14. Verfahren zum Herstellen einer pharmazeutischen Zusammensetzung zur Prophylaxe und Behandlung von Gicht, welches das Vermischen eines wirksamen Bestandteils eine prophylaktisch und therapeutisch wirksame Menge einer Pyrazolotriazinverbindung der Formel (1), die wie in einem der Ansprüche 1 bis 13 hergestellt wurde, mit einem pharmazeutisch annehmbaren Träger oder Verdünnungsmittel umfaßt.

15. Verwendung einer prophylaktisch und therapeutisch wirksamen Menge einer in einem der Ansprüche 1 bis 13 angegebenen Pyrazolotriazinverbindung der Formel (1) zur Herstellung eines Arzneimittels zur Prophylaxe und Behandlung von Gicht.

Revendications

Revendications pour les Etats contractants suivants : CH, DE, FR, GB, IT, LI, NL, SE

1. Pyrazolo-triazines, composés de formule :




dans laquelle

R¹ représente un groupe hydroxyle ou un groupe alcanoyloxy en C_{1-C6} ;


R² représente un atome d'hydrogène,

R³ représente (1) un groupe hétérocyclique insaturé, choisi parmi un groupe pyrrolyle, pyridyle,


thiényle, thiopyrannyle, indolyle, benzothiényne, 2,3-dihydrobenzothiényl, thiochromanyle, dibenzothiényne, qui peuvent éventuellement comporter un ou deux substituants choisis parmi un atome d'halogène, un groupe nitro et un groupe phénylthio ; (2) un groupe naphthyle, et (3) un groupe phényle qui peut éventuellement comporter un à trois substituants choisis dans l'ensemble consistant en (i) un reste alkyle en C₁-C₆, (ii) un reste phényle, (iii) un reste alcoxycarbonyle en C₁-C₆, (iv) un reste cyano, (v) un groupe nitro, (vi) un reste alcoxy en C₁-C₆, (vii) un reste phényl-alcoxy en C₁-C₆, (viii) un reste phénylthio-alkyle en C₁-C₆, (ix) un reste phénoxy, (x) un groupe de formule



dans laquelle R représente un groupe alkyle en C₁-C₆, halogéno-alkyle en C₁-C₆, qui est substitué, un groupe phényle qui peut éventuellement comporter un à trois substituants choisis parmi un atome d'halogène, un groupe alkyle en C₁-C₆ et un groupe alcoxy en C₁-C₆, ou un groupe pyridyle et (l) est un nombre entier valant 0,1 ou 2, (xi) un atome d'halogène, (xii) un reste phényl-alkyle en C₁-C₆, (xiii) un reste carboxy, (xiv) un reste alcanoyle en C₁-C₆, (xv) un reste benzoyle qui peut éventuellement comporter un à trois substituants choisis parmi un atome d'halogène, un groupe phényl-alcoxy en C₁-C₆ et un groupe hydroxyle fixé sur le noyau phényle, (xvi) un reste amino, (xvii) un reste hydroxy, (xviii) un reste alcanoyloxy en C₁-C₆, (xix) un groupe de formule




dans laquelle R⁴ et R⁵ sont identiques ou différents et représentent chacun un atome d'hydrogène, un reste cycloalkyle en C₃-C₈, un reste alkyle en C₁-C₆ qui peut éventuellement comporter un substituant choisi parmi un reste hydroxy, furyle, thiényle, tétrahydrofurannyle et phényle, un reste phényle qui peut éventuellement comporter un à trois substituants choisis parmi un reste alkyle en C₁-C₆, un reste hydroxy-alkyle en C₁-C₆ qui est substitué, un reste alcanoyle en C₁-C₆, cyano, carboxy, un reste alcoxycarbonyle en C₁-C₆, hydroxyle, un reste alcoxy en C₁-C₆ et un atome d'halogène, ou un groupe hétérocyclique choisi parmi un groupe pyridyle, pyrimidinyle, thiazolyle, isoxazolyle et pyrazolyle, ce groupe hétérocyclique étant éventuellement substitué par un reste alkyle en C₁-C₆, amino, ou un reste alcanoylamino en C₁-C₆, ou bien R⁵ et R⁶ peuvent être reliés pour former avec l'atome d'azote adjacent un groupe hétérocyclique pentagonal ou hexagonal saturé, qui peut éventuellement être interrompu par un atome d'oxygène, ou (xx) un groupe de formule :




dans laquelle A représente un reste alkylène en C₁-C₆.

2. Composé selon la revendication 1, dans lequel R³ représente (1) un groupe hétérocyclique insaturé choisi parmi un groupe pyrrolyle, pyridyle, thiényle, thiopyrannyle, indolyle, benzothiényne, 2,3-dihydrobenzothiényne, thiochromanyle ou dibenzothiényne, qui peut éventuellement comporter un ou deux substituants choisis parmi un atome d'halogène, un groupe nitro et un groupe phénylthio, (2) un groupe naphthyle, et (3) un groupe phényle qui peut éventuellement comporter un à trois substituants choisis dans l'ensemble consistant en (i) un reste alkyle en C₁-C₆, (ii) un reste phényle, (iii) un reste alcoxy en C₁-C₆, (iv) un reste cyano, (v) un reste nitro, (vi) un reste alcoxy en C₁-C₆, (vii) un reste phényl-alcoxy en C₁-C₆, (viii) un reste phénylthio-alkyle en C₁-C₆, (ix) un reste phénoxy, (x) un groupe


de formule



dans laquelle R représente un reste alkyle en C₁-C₆, un reste halogéno-alkyle en C₁-C₆ qui est substitué, un reste phényle qui peut éventuellement comporter un à trois substituants choisis parmi un atome d'halogène, un reste alkyle en C₁-C₆ et un reste alcoxy en C₁-C₆, ou un reste pyridyle, et l est un nombre entier valant 0,1 ou 2 ; (xi) un atome d'halogène, (xii) un reste phényl-alkyle en C₁-C₆, (xiii) un reste carboxy, (xiv) un reste alcanoyloxy en C₁-C₆, (xv) un reste benzoyloxy qui peut éventuellement comporter un à trois substituants choisis parmi un atome d'halogène, un reste phényl-alcoxy en C₁-C₆ et un reste hydroxy fixé sur le noyau phényle, (xvi) un reste amino, (xvii) un reste hydroxyle, (xviii) un reste alcanoyloxy en C₁-C₆, (xix) un groupe de formule




dans laquelle R⁴ et R⁵ sont identiques ou différents et représentent chacun un atome d'hydrogène, un reste cycloalkyle, un reste alkyle en C₁-C₆ qui peut éventuellement comporter un substituant choisi parmi un reste hydroxyle, furyle, thiényle, tétrahydrofurannyle et phényle, un reste phényle qui peut éventuellement comporter un à trois substituants choisis parmi un reste alkyle en C₁-C₆, un reste hydroxy-alkyle substitué en C₁-C₆, un reste alcanoyloxy en C₁-C₆, cyano, carboxy, un reste alcoxy en C₁-C₆, carbonyloxy, un reste hydroxyle, un reste alcoxy en C₁-C₆ et un atome d'halogène, ou un groupe hétérocyclique choisi parmi un groupe pyridyle, pyrimidinyle, thiazolyle, isoxazolyle et pyrazolyle, ledit groupe hétérocyclique étant éventuellement substitué par un reste alkyle en C₁-C₆, amino, ou un reste alcanoylamino en C₁-C₆, ou bien R⁴ et R⁵ peuvent être reliés pour former avec l'atome d'azote adjacent un groupe hétérocyclique choisi dans l'ensemble consistant en un groupe pyrrolidinyle, pipéridinyle, tétrahydro-1,2-oxazinyle, tétrahydro-1,3-oxazinyle et morpholino, ou bien (xx) un groupe de formule




dans laquelle A représente un reste alkylène en C₁-C₄.

3. Composé selon la revendication 2, dans lequel R¹ est hydroxyle.
4. Composé selon la revendication 2, dans lequel R¹ est alcanoyloxy en C₁-C₆.
5. Composé selon la revendication 3, dans lequel R³ représente un reste phényle comportant au moins un substituant choisi dans l'ensemble formé par un reste de formule




(dans laquelle R représente un reste alkyle en C₁-C₆, un reste halogéno-alkyle substitué en C₁-C₆, un

reste phényle qui peut éventuellement comporter un à trois substituants choisis parmi un atome d'halogène, un reste alkyle en C₁-C₆, et un reste alcoxy en C₁-C₆, ou bien un reste pyridiyle, et t est un nombre entier valant 0, 1 ou 2) t qui peut éventuellement comporter un ou deux autres substituants choisis dans l'ensemble consistant en (i) un reste alkyle en C₁-C₆, (ii) un reste phényle, (iii) un reste alcoxy en C₁-C₆, (iv) un reste cyano, (v) un reste nitro, (vi) un reste alcoxy en C₁-C₆, (vii) un reste phényl-alcoxy en C₁-C₆, (viii) un reste phénylthio-alkyle en C₁-C₆, (ix) un reste phénoxy, (x) un atome d'halogène, (xi) un reste phényl-alkyle en C₁-C₆, (xii) un reste carboxy, (xiii) un reste alcanoyloxy en C₁-C₆, (xiv) un reste benzoyloxy qui peut éventuellement comporter un à trois substituants choisis parmi un atome d'halogène, un reste phényl-alcoxy en C₁-C₆, et un reste hydroxyle fixé sur le noyau phényle, (xv) un reste amino, (xvi) un reste hydroxyle, (xvii) un reste alcanoyloxy en C₁-C₆, (xviii) un groupe de formule




dans laquelle R⁴ et R⁵ sont identiques ou différents et représentent chacun un atome d'hydrogène, un reste cycloalkyle, un reste alkyle en C₁-C₆, qui peut éventuellement comporter un substituant choisi parmi un reste hydroxyle, furyle, thiényle, tétrahydrofurannyle et phényle, un reste phényle qui peut éventuellement comporter un à trois substituants choisis parmi un reste alkyle en C₁-C₆, un reste hydroxy-alkyle substitué en C₁-C₆, un reste alcanoyloxy en C₁-C₆, un reste cyano, carboxy, un reste alcoxy en C₁-C₆, un reste carbonyl, un reste hydroxyle, un reste alcoxy en C₁-C₆, et un atome d'halogène, ou un groupe hétérocyclique choisi parmi un groupe pyridiyle, pyrimidinyle, thiazolyle, isoxazolyle et pyrazolyle, ledit groupe hétérocyclique étant éventuellement substitué par un reste alkyle en C₁-C₆, amino ou un reste alcanoylamino en C₁-C₆, ou bien R⁴ et R⁵ peuvent être reliés pour former avec l'atome d'azote adjacent un groupe hétérocyclique choisi dans l'ensemble consistant en un groupe pyrrolidinyle, pipéridinyle, tétrahydro-1,2-oxazinyle, tétrahydro-1,3-oxazinyle et morpholino, ou bien (xx) un groupe de formule




dans laquelle A représente un reste alkylène en C₁-C₄.

6. Composé selon la revendication 3, dans lequel R³ représente un reste phényle pouvant comporter au moins un substituant de formule




dans laquelle R⁴ et R⁵ sont identiques ou différents et représentent chacun un atome d'hydrogène, un reste cycloalkyle, un reste alkyle en C₁-C₆, qui peut éventuellement comporter un substituant choisi parmi un reste hydroxyle, furyle, thiényle, tétrahydrofurannyle et phényle, un reste phényle qui peut éventuellement comporter un à trois substituants choisis parmi un reste alkyle en C₁-C₆, un reste hydroxy-alkyle substitué en C₁-C₆, un reste alcanoyloxy en C₁-C₆, un reste cyano, carboxy, un reste alcoxy en C₁-C₆, un reste carbonyl, un reste hydroxyle, un reste alcoxy en C₁-C₆, et un atome d'halogène, ou bien un groupe hétérocyclique choisi parmi un groupe pyridiyle, pyrimidinyle, thiazolyle, isoxazolyle et pyrazolyle, ledit groupe hétérocyclique étant éventuellement substitué par un reste alkyle en C₁-C₆, amino ou par un

reste alcanoylamino en C₁-C₆, ou bien R⁴ et R⁵ peuvent être reliés pour former avec l'atome d'azote adjacent un groupe hétérocyclique choisi dans l'ensemble consistant en un groupe pyrrolidinyne, pipéridinyne, tétrahydro-1,2-oxazinyne, tétrahydro-1,3-oxazinyne et morpholino pouvant éventuellement comporter un ou deux autres substituants choisis dans l'ensemble consistant en (i) un reste alkyle en C₁-C₆, (ii) un reste phényle, (iii) un reste alcoxy en C₁-C₆ carbonyle, (iv) un reste cyano, (v) un reste nitro, (vi) un reste alcoxy en C₁-C₆, (vii) un reste phényl-alcoxy en C₁-C₆, (viii) un reste phénylthio-alkyle en C₁-C₆, (ix) un reste phénoxy, (x) un groupe de formule




dans laquelle R représente un reste alkyle en C₁-C₆, un reste halogéno-alkyle en C₁-C₆, un reste phényle qui peut éventuellement comporter un à trois substituants choisis parmi un atome d'halogène, un reste alkyle en C₁-C₆, ou un reste hydroxy en C₁-C₆, ou bien un reste pyridyle, et l est un nombre entier valant 0, 1 ou 2; (xi) un atome d'halogène, (xii) un reste phényl-alkyle en C₁-C₆, (xiii) un reste carboxy, (xiv) un reste alcanoyne en C₁-C₆, (xv) un reste benzoyne qui peut éventuellement comporter un à trois substituants, choisis parmi un atome d'halogène, un reste phényl-alcoxy en C₁-C₆ et un reste hydroxyle fixé sur le noyau phényle, (xvi) un reste amino, (xvii) un reste hydroxyle, (xviii) un reste alcanoyloxy en C₁-C₆ et (xix) un groupe de formule




dans laquelle A représente un reste alkylène en C₁-C₄.


7. Composé selon la revendication 3, dans lequel R³ est un groupe phényle comportant l'un quelconque des substituants choisis dans l'ensemble consistant en (i) un groupe alkyle en C₁-C₆, (ii) un groupe phényle, (iii) un groupe alcoxy en C₁-C₆ carbonyle, (iv) un groupe cyano, (v) un groupe nitro, (vi) un groupe alcoxy en C₁-C₆, (vii) un groupe phényl-alcoxy en C₁-C₆, (viii) un groupe phénylthio-alkyle en C₁-C₆, (ix) un groupe phénoxy, (x) un atome d'halogène, (xi) un groupe phényl-alkyle en C₁-C₆, (xii) un groupe carboxy, (xiii) un groupe alcanoyne en C₁-C₆, (xiv) un groupe benzoyne qui peut éventuellement comporter un à trois substituants choisis parmi un atome d'halogène, un reste phényl-alcoxy en C₁-C₆ et hydroxyle sur le noyau phényle, (xv) un groupe amino, (xvi) un groupe hydroxyle, (xvii) un groupe alcanoyloxy en C₁-C₆ et (xviii) un groupe de formule



dans laquelle A représente un reste alkylène en C₁-C₄, et qui peut comporter éventuellement un ou deux autres substituants choisis parmi un groupe de formule




dans laquelle R représente un reste alkyle en C₁-C₆, un reste halogéno-alkyle en C₁-C₆, un reste phényle qui peut éventuellement comporter un à trois substituants choisis parmi un atome d'halogène, un reste alkyle en C₁-C₆ et un reste alcoxy en C₁-C₆, ou un groupe pyridyle et l est un nombre entier valant 0, 1 ou 2, et un groupe de formule



dans laquelle R⁴ et R⁵ sont identiques ou différents et représentent chacun un atome d'hydrogène, un reste cycloalkyle, un reste alkyle en C₁-C₆ qui peut éventuellement avoir un substituant choisi parmi un reste hydroxyle, furyle, thiényle, tétrahydrofurannyle et phényle, un groupe phényle qui peut éventuellement comporter un à trois substituants choisis parmi un reste alkyle en C₁-C₆, un reste hydroxy-alkyle en C₁-C₆, un reste alcanoyle en C₁-C₆, un reste cyano, carboxy, un reste alcoxy en C₁-C₆, un reste carbonyle, un reste hydroxyle, un reste alcoxy en C₁-C₆ et un atome d'halogène, ou un groupe hétérocyclique choisi parmi un groupe pyridyle, pyrimidinyle, thiazolyle, isoxazolyle et pyrazolyle, ledit groupe hétérocyclique étant éventuellement substitué par un reste alkyle en C₁-C₆, amino ou par un reste alcanoylamino en C₁-C₆, ou bien R⁴ et R⁵ peuvent être reliés pour former avec l'atome d'azote adjacent un groupe hétérocyclique choisi dans l'ensemble consistant en un groupe pyrrolidinyle, pipéridinyle, tétrahydro-1,2-oxazinyle, tétrahydro-1,3-oxazinyle et morpholino.


8. Composé selon la revendication 5, dans lequel R³ est un groupe phényle qui est substitué par un groupe de formule



dans laquelle R représente un reste alkyle en C₁-C₆, un reste halogéno-alkyle en C₁-C₆, un reste phényle qui peut éventuellement comporter un à trois substituants choisis parmi un atome d'halogène, un reste alkyle en C₁-C₆ et un reste alcoxy en C₁-C₆, ou un groupe pyridyle et l est un nombre entier valant 0, 1 ou 2, et qui peut éventuellement porter un ou deux autres substituants choisis dans l'ensemble consistant en un groupe alkyle en C₁-C₆, un groupe alcoxy en C₁-C₆, un atome d'halogène et un groupe alkylthio en C₁-C₆.

9. Composé selon la revendication 6, dans lequel R³ est un groupe phényle comportant un à trois substituants choisis dans l'ensemble consistant en un reste alkyle en C₁-C₆, un reste alcoxy en C₁-C₆, un reste nitro, un atome d'halogène, un reste phényl-alcoxy en C₁-C₆, et un reste benzoyle comportant éventuellement un à trois substituants choisis parmi un atome d'halogène, un reste phényl-alcoxy en C₁-C₆ et un reste hydroxyle.


10. Composé selon la revendication 7, dans lequel R³ est un reste phényle qui est substitué par un groupe de formule



dans laquelle R⁴ représente un atome d'hydrogène et R⁵ représente un groupe phénylalkyle en C₁-C₆, ou un reste phényle qui peut éventuellement comporter un à trois substituants choisis parmi un reste alkyle en C₁-C₆, un reste hydroxyalkyle en C₁-C₆, un reste alcoxy en C₁-C₆, un reste carbonyle, un reste hydroxyle, un reste alcoxy en C₁-C₆ et un atome d'halogène ; ou bien R⁴ et R⁵ sont identiques et représentent chacun un reste alkyle en C₁-C₆ et qui comporte éventuellement encore un substituant


choisi parmi un reste alkyle en C₁-C₆ et un atome d'halogène.

11. Composé selon la revendication 8, dans lequel R³ représente un groupe phényle qui est substitué par un groupe de formule



dans laquelle R représente un reste alkyle en C₁-C₆ ou un reste phényle, et l est un nombre entier valant 0, 1 ou 2.

12. Composé selon la revendication 8, dans lequel R³ représente un groupe phényle qui est substitué par un groupe de formule




dans laquelle R représente un reste alkyle en C₁-C₆, substitué par de l'halogène (un reste halogéno-alkyle), un reste phényle qui peut éventuellement comporter un à trois substituants choisis parmi un atome d'halogène, un reste alkyle en C₁-C₆ et un reste alcoxy en C₁-C₆ ou un groupe pyridyle, et l est un nombre entier valant 0, 1 ou 2.


13. Composé selon la revendication 8, dans lequel R³ est un groupe phényle comportant un à trois substituants choisis dans l'ensemble consistant en un reste alkyle en C₁-C₆, un reste alcoxy en C₁-C₆, un atome d'halogène et un reste alkylthio en C₁-C₆.

14. Procédé pour préparer une pyrazolotriazine, composé de formule (1) selon la revendication 1, ce composé comprenant :

a) la réaction d'un composé de formule :




dans laquelle R³ est tel que défini dans la revendication 1, avec un orthoformiate d'alkyle, ce qui donne un composé de formule :




(1-a)

dans laquelle R³ est tel que défini à la revendication 1, ou
b) l'acylation d'un composé de formule :



15 dans laquelle R² et R³ sont tels que définis à la revendication 1, ce qui donne un composé de formule :




25 (1-e)

30 dans laquelle R² et R³ sont tels que définis à la revendication 1 et R^{1a} est un reste alcanoyloxy en C₁-C₆.

- 35
15. Composition pharmaceutique pour le traitement prophylactique et le traitement curatif de la goutte, qui comprend, comme ingrédient actif, une quantité efficace, du point de vue prophylactique et thérapeutique, d'une pyrazolotriazine, composé de formule (I) selon la revendication 1, en mélange avec un excipient, véhicule ou diluant pharmaceutiquement acceptable.
- 40
16. Utilisation d'une quantité efficace, du point de vue prophylactique et thérapeutique, d'une pyrazolotriazine, composé de formule (1) tel que présenté à la revendication 1, pour la préparation d'un médicament pour le traitement prophylactique et le traitement thérapeutique de la goutte.

Revendications pour l'Etat contractant suivant : ES

- 45
1. Procédé pour préparer une pyrazolo-triazine, composé de formule (1) :



55 dans laquelle

R¹ représente un groupe hydroxyle ou un groupe alcanoyloxy en C₁-C₆ ;

R² représente un atome d'hydrogène,

R³ représente (1) un groupe hétérocyclique insaturé choisi parmi un groupe pyrrolyle, pyridyle,

thiényle, thiopyrannyle, indolyle, benzothiényne, 2,3-dihydrobenzothiényne, thiochromanyle, dibenzothiényne, qui peuvent éventuellement comporter un ou deux substituants choisis parmi un atome d'halogène, un groupe nitro et un groupe phénylthio ; (2) un groupe naphtyle, et (3) un groupe phényle qui peut éventuellement comporter un à trois substituants choisis dans l'ensemble consistant en (i) un reste alkyle en C₁-C₆, (ii) un reste phényle, (iii) un reste alcoxycarbonyle en C₁-C₆, (iv) un reste cyano, (v) un groupe nitro, (vi) un reste alcoxy en C₁-C₆, (vii) un reste phényl-alcoxy en C₁-C₆, (viii) un reste phénylthio-alkyle en C₁-C₆, (ix) un reste phénoxy, (x) un groupe de formule



dans laquelle R représente un groupe alkyle en C₁-C₆, halogéno-alkyle en C₁-C₆, qui est substitué, un groupe phényle qui peut éventuellement comporter un à trois substituants choisis parmi un atome d'halogène, un groupe alkyle en C₁-C₆ et un groupe alcoxy en C₁-C₆, ou un groupe pyridine et (l) est un nombre entier valant 0,1 ou 2, (xi) un atome d'halogène, (xii) un reste phényl-alkyle en C₁-C₆, (xiii) un reste carboxy, (xiv) un reste alcanoyle en C₁-C₆, (xv) un reste benzoyle qui peut éventuellement comporter un à trois substituants choisis parmi un atome d'halogène, un groupe phényl-alcoxy en C₁-C₆ et un groupe hydroxyle fixé sur le noyau phényle, (xvi) un reste amino, (xvii) un reste hydroxy, (xviii) un reste alcanoyloxy en C₁-C₆, (xix) un groupe de formule




dans laquelle R⁴ et R⁵ sont identiques ou différents et représentent chacun un atome d'hydrogène, un reste cycloalkyle en C₃-C₈, un reste alkyle en C₁-C₆ qui peut éventuellement comporter un substituant choisi parmi un reste hydroxy, furyle, thiényne, tétrahydrofurannyle et phényle, un reste phényle qui peut éventuellement comporter un à trois substituants choisis parmi un reste alkyle en C₁-C₆, un reste hydroxy-alkyle en C₁-C₆ qui est substitué, un reste alcanoyle en C₁-C₆, cyano, carboxy, un reste alcoxycarbonyle en C₁-C₆, hydroxyle, un reste alcoxy en C₁-C₆ et un atome d'halogène, ou un groupe hétérocyclique choisi parmi un groupe pyridyle, pyrimidinyle, thiazolyle, isoxazolyle et pyrazolyle, ce groupe hétérocyclique étant éventuellement substitué par un reste alkyle en C₁-C₆, amino, ou un reste alcanoylamino en C₁-C₆, ou bien R⁵ et R⁶ peuvent être reliés pour former avec l'atome d'azote adjacent un groupe hétérocyclique pentagonal ou hexagonal saturé, qui peut éventuellement être interrompu par un atome d'oxygène, ou (xx) un groupe de formule :




dans laquelle A représente un reste alkylène en C₁-C₆. procédé qui comprend


a) la réaction d'un composé de formule :




dans laquelle R^3 est tel que défini ci-dessus, avec un orthoformiate d'alkyle, ce qui donne un composé de formule :



dans laquelle R^3 est tel que défini ci-dessus, ou
b) l'acylation d'un composé de formule :




dans laquelle R^2 et R^3 sont tels que définis ci-dessus, ce qui donne un composé de formule :




dans laquelle R^2 et R^3 sont tels que définis ci-dessus, et R^1a est un reste alcanoylé en C_1-C_6 .

2. Procédé selon la revendication 1, dans lequel R^3 représente (1) un groupe hétérocyclique insaturé, choisi parmi un groupe pyrrole, pyridyle, thiényle, thiopyrannyle, indolyle, benzothiényle, 2,3-dihydro-benzothiényle, thiochromanyle ou dibenzothiényle, qui peut éventuellement comporter un ou deux substituants choisis parmi un atome d'halogène, un reste nitro et un reste phénylthio, (2) un reste naphthyle, et (3) un reste phényle qui peut éventuellement comporter un à trois substituants choisis


dans l'ensemble consistant en (i) un reste alkyle en C₁-C₆, (ii) un reste phényle, (iii) un reste alcoxy en C₁-C₆ carbonyle, (iv) un reste cyano, (v) un reste nitro, (vi) un reste alcoxy en C₁-C₆, (vii) un reste phényl-alcoxy en C₁-C₆, (viii) un reste phénylthio-alkyle en C₁-C₆, (ix) un reste phénoxy, (x) un groupe de formule



dans laquelle représente un reste alkyle en C₁-C₆, un reste halogéno-alkyle en C₁-C₆ qui est substitué, un reste phényle qui peut éventuellement comporter un à trois substituants choisis parmi un atome d'halogène, un reste alkyle en C₁-C₆ et un reste alcoxy en C₁-C₆, ou un groupe pyridyle, et l est un nombre entier valant 0, 1 ou 2 ; (xi) un atome d'halogène, (xii) un reste phényl-alkyle en C₁-C₆, (xiii) un reste carboxy, (xiv) un reste alcanoyloxy en C₁-C₆, (xv) un reste benzoyloxy qui peut éventuellement comporter un à trois substituants choisis parmi un atome d'halogène, un reste phényl-alcoxy en C₁-C₆ et un reste hydroxy fixé sur le noyau phényle, (xvi) un reste amino, (xvii) un reste hydroxyle, (xviii) un reste alcanoyloxy en C₁-C₆, (xix) un groupe de formule



dans laquelle R⁴ et R⁵ sont identiques ou différents et représentent chacun un atome d'hydrogène, un reste cycloalkyle, un reste alkyle en C₁-C₆ qui peut éventuellement comporter un substituant choisi parmi un reste hydroxyle, furyle, thiényl, tétrahydrofurannyle et phényle, un reste phényle qui peut éventuellement comporter un à trois substituants choisis parmi un reste alkyle en C₁-C₆, un reste hydroxy-alkyle substitué en C₁-C₆, un reste alcanoyloxy en C₁-C₆, cyano, carboxy, un reste alcoxy en C₁-C₆ carbonyle, un reste hydroxyle, un reste alcoxy en C₁-C₆ et un atome d'halogène, ou un groupe hétérocyclique choisi parmi un groupe pyridyle, pyrimidinyle, thiazolyle, isoxazolyle et pyrazolyle, ledit groupe hétérocyclique étant éventuellement substitué par un reste alkyle en C₁-C₆, amino, ou un reste alcanoylamino en C₁-C₆, ou bien R⁴ et R⁵ peuvent être reliés pour former avec l'atome d'azote adjacent un groupe hétérocyclique choisi dans l'ensemble consistant en un groupe pyrrolidinyle, pipéridinyle, tétrahydro-1,2-oxazinyle, tétrahydro-1,3-oxazinyle et morpholino, ou bien (xx) un groupe de formule




dans laquelle A représente un reste alkylène en C₁-C₄.


3. Procédé selon la revendication 2, dans lequel R¹ est hydroxyle.

4. Procédé selon la revendication 2, dans lequel R¹ est alcanoyloxy en C₁-C₆.


5. Procédé selon la revendication 3, dans lequel R³ représente un reste phényle comportant au moins un substituant qui est un groupe de formule



dans laquelle R représente un reste alkyle en C₁-C₆, un reste halogéno-alkyle substitué en C₁-C₆, un reste phényle qui peut éventuellement comporter un à trois substituants choisis parmi un atome d'halogène, un reste alkyle en C₁-C₆, et un reste alcoxy en C₁-C₆, ou bien un reste pyridiyle, et l est un nombre entier valant 0, 1 ou 2 et qui peut éventuellement comporter un ou deux autres substituants choisis dans l'ensemble consistant en (i) un reste alkyle en C₁-C₆, (ii) un reste phényle, (iii) un reste alcoxy (en C₁-C₆)carbonyle, (iv) un reste cyano, (v) un reste nitro, (vi) un reste alcoxy en C₁-C₆, (vii) un reste phényl-alcoxy en C₁-C₆, (viii) un reste phénylthio-alkyle en C₁-C₆, (ix) un reste phénoxy, (x) un atome d'halogène, (xi) un reste phényl-alkyle en C₁-C₆, (xii) un reste carboxy, (xiii) un reste alcanoyale en C₁-C₆, (xiv) un reste benzoyle qui peut éventuellement comporter un à trois substituants choisis parmi un atome d'halogène, un reste phényle-alcoxy en C₁-C₆, et un reste hydroxyle fixé sur le noyau phényle, (xv) un reste amino, (xvi) un reste hydroxyle, (xvii) un reste alcanoyloxy en C₁-C₆, (xviii) un groupe de formule




dans laquelle R⁴ et R⁵ sont identiques ou différents et représentent chacun un atome d'hydrogène, un reste cycloalkyle, un reste alkyle en C₁-C₆, qui peut éventuellement comporter un substituant choisi parmi un reste hydroxyle, furyle, thiényle, tétrahydrofurannyle et phényle, un reste phényle qui peut éventuellement comporter un à trois substituants choisis parmi un reste alkyle en C₁-C₆, un reste hydroxy-alkyle substitué en C₁-C₆, un reste alcanoyale en C₁-C₆, un reste cyano, carboxy, un reste alcoxy en C₁-C₆ carbonyle, un reste hydroxyle, un reste alcoxy en C₁-C₆, et un atome d'halogène, ou un groupe hétérocyclique choisi parmi un groupe pyridiyle, pyrimidinyle, thiazolyle, isoxazolyle et pyrazolyle, ledit groupe hétérocyclique étant éventuellement substitué par un reste alkyle en C₁-C₆, amino ou un reste alcanoylamino en C₁-C₆, ou bien R⁴ et R⁵ peuvent être reliés pour former avec l'atome d'azote adjacent un groupe hétérocyclique choisi dans l'ensemble consistant en un groupe pyrrolidinyle, pipéridinyle, tétrahydro-1,2-oxazinyle, tétrahydro-1,3-oxazinyle et morpholino, ou bien (xx) un groupe de formule




dans laquelle A représente un reste alkylène en C₁-C₄.

6. Procédé selon la revendication 3, dans lequel R³ représente un reste phényle ayant au moins un substituant de formule




dans laquelle R⁴ et R⁵ sont identiques ou différents et représentent chacun un atome d'hydrogène, un reste cycloalkyle, un reste alkyle en C₁-C₆ qui peut éventuellement comporter un substituant choisi parmi un reste hydroxyle, furyle, thiényle, tétrahydrofurannyle et phényle, un reste phényle qui peut éventuellement comporter un à trois substituants choisis parmi un reste alkyle en C₁-C₆, un reste hydroxy-alkyle substitué en C₁-C₆, un reste alcanoyale en C₁-C₆, un reste cyano, carboxy, un reste alcoxy en C₁-C₆ carbonyle, hydroxyle, un reste alcoxy en C₁-C₆, et un atome d'halogène, ou bien hétérocyclique choisi parmi un groupe pyridyle, pyrimidinyle, thiazolyle, isoxalyle et pyrazolyle, ledit groupe hétérocyclique étant éventuellement substitué par un reste alkyle en C₁-C₆, amino ou par un

reste alcanoylamino en C₁-C₆, ou bien R⁴ et R⁵ peuvent être reliés pour former avec l'atome d'azote adjacent un groupe hétérocyclique choisi dans l'ensemble consistant en un groupe pyrrolidinyle, pipéridinyle, tétrahydro-1,2-oxazinyle, tétrahydro-1,3-oxazinyle et morpholino pouvant éventuellement comporter un ou deux autres substituants choisis dans l'ensemble consistant en (i) un reste alkyle en C₁-C₆, (ii) un reste phényle, (iii) un reste alcoxy en C₁-C₆, (iv) un reste cyano, (v) un reste nitro, (vi) un reste alcoxy en C₁-C₆, (vii) un reste phényl-alcoxy en C₁-C₆, (viii) un reste phénylthio-alkyle en C₁-C₆, (ix) un reste phénoxy, (x) un groupe de formule




dans laquelle R représente un reste alkyle en C₁-C₆, un reste halogéno-alkyle en C₁-C₆, un reste phényle qui peut éventuellement comporter un à trois substituants choisis parmi un atome d'halogène, un reste alkyle en C₁-C₆ et un reste alcoxy en C₁-C₆, ou bien un reste pyridyle, et l est un nombre entier valant 0, 1 ou 2 ; (xi) un atome d'halogène, (xii) un reste phényl-alkyle en C₁-C₆, (xiii) un reste carboxy, (xiv) un reste alcanoyle en C₁-C₆, (xv) un reste benzoyle qui peut éventuellement comporter un à trois substituants, choisis parmi un atome d'halogène, un reste phényl-alcoxy en C₁-C₆ et un reste hydroxyle fixé sur le noyau phényle, (xvi) un reste amino, (xvii) un reste hydroxyle, (xviii) un reste alcanoyloxy en C₁-C₆ et (xix) un groupe de formule




dans laquelle A représente un reste alkylène en C₁-C₄.

7. Procédé selon la revendication 3, dans lequel R³ est un groupe phényle comportant l'un quelconque des substituants choisis dans l'ensemble consistant en (i) un groupe alkyle en C₁-C₆, (ii) un groupe phényle, (iii) un groupe alcoxy en C₁-C₆, (iv) un groupe cyano, (v) un groupe nitro, (vi) un groupe alcoxy en C₁-C₆, (vii) un groupe phényl-alcoxy en C₁-C₆, (viii) un groupe phénylthio-alkyle en C₁-C₆, (ix) un groupe phénoxy, (x) un atome d'halogène, (xi) un groupe phényl-alkyle en C₁-C₆, (xii) un groupe carboxy, (xiii) un groupe alcanoyle en C₁-C₆, (xiv) un groupe benzoyle qui peut éventuellement comporter un à trois substituants choisis parmi un atome d'halogène, un reste phényl-alcoxy en C₁-C₆ et hydroxyle sur le noyau phényle, (xv) un groupe amino, (xvi) un groupe hydroxyle, (xvii) un groupe alcanoyloxy en C₁-C₆ et (xviii) un groupe de formule




dans laquelle A représente un reste alkylène en C₁-C₄, et qui peut comporter éventuellement un ou deux autres substituants choisis parmi un groupe de formule




dans laquelle R représente un reste alkyle en C₁-C₆, un reste halogéno-alkyle en C₁-C₆, un reste

phényle qui peut éventuellement comporter un à trois substituants choisis parmi un atome d'halogène, un reste alkyle en C₁-C₆ et un reste alcoxy en C₁-C₆, ou un groupe pyridyle et *l* est un nombre entier valant 0, 1 ou 2, et un groupe de formule



dans laquelle R⁴ et R⁵ sont identiques ou différents et représentent chacun un atome d'hydrogène, un reste cycloalkyle, un reste alkyle en C₁-C₆ qui peut éventuellement avoir un substituant choisi parmi un reste hydroxyle, furyle, thiényle, tétrahydrofurannyle et phényle, un groupe phényle qui peut éventuellement comporter un à trois substituants choisis parmi un reste alkyle en C₁-C₆, un reste hydroxy-alkyle en C₁-C₆, un reste alcanoyle en C₁-C₆, un reste cyano, carboxy, un reste alcoxy en C₁-C₆, un reste carbonyle, un reste hydroxyle, un reste alcoxy en C₁-C₆ et un atome d'halogène, ou un groupe hétérocyclique choisi parmi un groupe pyridyle, pyrimidinyle, thiazolyle, isoxazolyle et pyrazolyle, ledit groupe hétérocyclique étant éventuellement substitué par un reste alkyle en C₁-C₆, amino ou par un reste alcanoylamino en C₁-C₆, ou bien R⁴ et R⁵ peuvent être reliés pour former avec l'atome d'azote adjacent un groupe hétérocyclique choisi dans l'ensemble consistant en un groupe pyrrolidinyle, pipéridinyle, tétrahydro-1,2-oxazinyle, tétrahydro-1,3-oxazinyle et morpholino.


8. Procédé selon la revendication 5, dans lequel R³ représente un reste phényle qui est substitué par un groupe de formule



dans laquelle R représente un reste alkyle en C₁-C₆, un reste halogéno-alkyle en C₁-C₆, un reste phényle qui peut éventuellement comporter un à trois substituants choisis parmi un atome d'halogène, un reste alkyle en C₁-C₆ et un reste alcoxy en C₁-C₆, ou un groupe pyridyle et *l* est un nombre entier valant 0, 1 ou 2 et qui peut éventuellement comporter un ou deux autres substituants choisis dans l'ensemble consistant en un groupe alkyle en C₁-C₆, un groupe alcoxy en C₁-C₆, un atome d'halogène et un groupe alkylthio en C₁-C₆.

9. Procédé selon la revendication 6, dans lequel R³ est un groupe phényle comportant un à trois substituants choisis dans l'ensemble consistant en un reste alkyle en C₁-C₆, un reste alcoxy en C₁-C₆, un reste nitro, un atome d'halogène, un reste phényl-alcoxy en C₁-C₆, et un reste benzoyle comportant éventuellement un à trois substituants choisis parmi un atome d'halogène, un reste phényl-alcoxy en C₁-C₆ et un reste hydroxyle.


10. Procédé selon la revendication 7, dans lequel R³ est un reste phényle qui est substitué par un groupe de formule



dans laquelle R⁴ représente un atome d'hydrogène et R⁵ représente un groupe thiénylalkyle en C₁-C₆, ou un reste phényle qui peut éventuellement comporter un à trois substituants choisis parmi un reste alkyle en C₁-C₆, un reste hydroxyalkyle en C₁-C₆, un reste alcoxy en C₁-C₆, un reste carbonyle, un reste hydroxyle, un reste alcoxy en C₁-C₆ et un atome d'halogène ; ou bien R⁴ et R⁵ sont identiques et représentent chacun un reste alkyle en C₁-C₆ et qui comporte éventuellement encore un substituant

choisi parmi un reste alkyle en C₁-C₆ ou un atome d'halogène.

11. Procédé selon la revendication 8, dans lequel R³ représente un groupe phényle qui est substitué par un groupe de formule




10

dans laquelle R représente un reste alkyle en C₁-C₆ ou un reste phényle, et l est un nombre entier valant 0, 1 ou 2.

15

12. Procédé selon la revendication 8, dans lequel R³ représente un groupe phényle qui est substitué par un groupe de formule



20

25

dans laquelle R représente un reste halogéno-alkyle en C₁-C₆, un reste phényle qui peut éventuellement comporter un à trois substituants choisis parmi un atome d'halogène, un reste alkyle en C₁-C₆ et un reste alcoxy en C₁-C₆ ou un groupe pyridyle, et l est un nombre entier valant 0, 1 ou 2.

30

13. Procédé selon la revendication 8, dans lequel R³ représente un groupe phényle comportant un à trois substituants choisis dans l'ensemble consistant en un reste alkyle en C₁-C₆, un reste alcoxy en C₁-C₆, un atome d'halogène et un reste alkylthio en C₁-C₆.

35

14. Procédé pour préparer une composition pharmaceutique pour le traitement prophylactique et le traitement curatif de la goutte, qui comprend le mélangeage, à titre d'ingrédient actif, d'une quantité efficace du point de vue prophylactique et thérapeutique, d'une pyrazolotriazine, composé de formule (1) préparé comme indiqué dans l'une quelconque des revendications 1 à 13, avec un excipient, véhicule ou diluant pharmaceutiquement acceptable.

40

15. Utilisation d'une quantité, efficace du point de vue prophylactique et thérapeutique, d'une pyrazolotriazine, composé de formule (1) tel que présenté dans l'une quelconque des revendications 1 à 13, pour la préparation d'un médicament pour le traitement prophylactique et le traitement thérapeutique de la goutte.

45

50

55